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APPLICATIONS OF FELINE IMMUNODEFICIENCY VIRUS  




 Feline immunodeficiency virus (FIV) is a naturally-occurring retrovirus that infects 
domestic and non-domestic feline species, and produces progressive immune depletion that 
eventually results in an acquired immunodeficiency syndrome (AIDS).  While it is accepted that 
FIV is primarily transmitted by biting, few studies have evaluated FIV oral infection kinetics and 
transmission mechanisms over the last 20 years.  Modern quantitative analyses applied to 
natural FIV oral infection could significantly further our understanding of lentiviral oral disease 
and transmission. In Chapter 1 of this dissertation, I characterized FIV salivary viral kinetics and 
antibody secretions to more fully document oral viral pathogenesis.  The results of this research 
demonstrate that (i) oral lymphoid tissues serve as a site for enhanced FIV replication, resulting 
in accumulation of FIV particles and FIV-infected cells in saliva, and (ii) failure to induce a virus-
specific oral mucosal antibody response, and/or viral capability to overcome inhibitory 
components in saliva may perpetuate chronic oral cavity infection.  Most importantly, these 
results provide a model of oral FIV pathogenesis and suggest alternative diagnostic modalities 
and translational approaches to study oral HIV infection. 
Feline immunodeficiency virus and human immunodeficiency virus (HIV) utilize parallel 
modes of receptor-mediated entry. The FIV surface glycoprotein (SU) is an important vaccine 
target for induction of virus neutralizing antibodies, and autoantibodies to the FIV binding 
receptor (CD134) block FIV infection ex vivo; highlighting the potential for immunotherapies 
which utilize anti-receptor antibodies to block viral infection.  In Chapter 2 of this dissertation, I 
immunized cats with soluble CD134, recombinant FIV-SU protein, and/or CD134+SU 
complexes prior to challenge with FIV to determine if vaccination with CD134-SU complexes 
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could induce protection against FIV infection.  Immunization induced production of anti-CD134 
and anti-SU antibodies in vaccinated cats, and purified anti-CD134 and anti-SU antibodies 
significantly inhibited FIV infection in vitro.  However, no vaccine combination protected cats 
from FIV infection in vivo, and vaccination induced high titers of antibodies directed at vaccine 
by-products relative to target antigens.  The results of this research reinforce the need to 
monitor components of vaccine preparations, and emphasize that vaccination may induce 
proliferation of susceptible target cells and enhancement of heat-labile serum components that 
counteract neutralizing antibodies. 
Feline immunodeficiency virus induces lifelong infection in cats and may result in a 
spectrum of immunodeficiency-related diseases.  Both prednisolone and cyclosporine A (CsA) 
are commonly used clinically to treat lymphoproliferative and immune-mediated diseases in 
cats, but the impact of these compounds on FIV infection has not been well documented, and 
their understanding immunomodulatory effects on FIV replication and persistence is critical to 
guide safe and effective use of these therapies in FIV infected cats.  In Chapter 3 of this 
dissertation, I administered immunosuppressive doses of prednisolone or CsA to cats 
chronically infected with FIV and monitored alterations in hematological parameters and FIV 
viral/proviral loads in response to therapy. Interestingly, both treatments caused (i) acute 
increases in CD4+ lymphocytes, (ii) increased FIV viremia, and (iii) significant alterations in 
cytokine expression that favored a shift toward a Th2 response.  The results of this research 
highlight the potential for immunosuppressive drug-induced perturbation of FIV replication and 
underscores the need for consideration of chronic viral infection status when prescribing 
immunomodulatory medications. 
Mucosal immune dysfunction, bacterial translocation, systemic immune activation, and 
chronic inflammation are well-documented features of chronic HIV infection. Despite the 
success of combinational antiretroviral therapy (cART) in diminishing HIV viral replication and 
prolonging immune function, a multitude of systemic and local manifestations of HIV infection 
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persist, including the development of chronic inflammation (periodontitis and gingivitis). 
Commonly used animal models for studying HIV pathogenesis, including SIV/SHIV infections of 
non-human primates (NHPs) or HIV infections in humanized mice, do not reliably incite oral 
lesions.  In contrast, gingivitis and periodontitis are primary clinical signs associated with 
untreated natural and experimental FIV-infection, and are principal attributes of this model that 
may be exploited to investigate pathogenic mechanisms involved in the perturbation of the oral 
immune system and microbial environment. Therefore, in Chapter 4, I present the findings of a 
pilot study in which I investigated changes in the oral microbiota and oral immune system during 
FIV infection, and further, outline the potential for the feline model of oral AIDS manifestations to 
elucidate pathogenic mechanisms of HIV-induced oral disease. By assessing FIV-associated 
changes in clinical status, oral microbiota, local and systemic viral burden, and immune profile 
under such treatment protocols, future studies implementing the feline model of lentiviral-
induced oral disease may provide a cornerstone to expand our understanding of the complex 
interactions between HIV infection, oral immune dysfunction, and the perturbations to the oral 
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Feline Immunodeficiency Virus 
 Feline immunodeficiency virus (FIV) is a naturally-occurring retrovirus that infects 
domestic and non-domestic feline species, and produces progressive immune depletion that 
eventually results in an acquired immunodeficiency syndrome (AIDS) [1-10].  A member of the 
Lentivirus genus within the Retroviridae family, much has been learned about FIV since it was 
first described in 1987, particularly in regard to its application as a model to study the closely-
related lentivirus, human immunodeficiency virus (HIV) [8-12].  The FIV virion is approximately 
100nm in diameter, spherical, and contains two identical strands of positive-sense RNA in its 
9400-base genome, which is tightly associated with the nucleocapsid protein (p7) and a t-RNAlys 
bound to each RNA molecule, serving as a primer for negative strand transcription [11-14]. This 
ribonucleoprotein complex, along with viral enzymes involved with replication and maturation 
(protease, reverse transcriptase (RT), integrase (IN), and dUTPase), are enclosed within a core 
of capsid protein (CA, p24), and surrounded by a shell of matrix protein (MA, p14) and outer 
lipid bilayer [11-13]. Viral envelope glycoproteins (gp) are embedded within the outer lipid 
bilayer, and include the surface (SU, gp95) and transmembrane (TM, gp40) subunits, which are 
cleaved from a 130-150kDa membrane-bound precursor protein, glycosylated, and non-
covalently anchored within the envelope in a trimeric form [11-13, 15].   
 The genomic structure of FIV consists of three primary open reading frames (ORFs), 
gag, pol, and env, which are flanked by two long-terminal repeats (LTR) and accompanied by 
numerous small ORFs containing regulatory and accessory genes such as vif, rev, and orfA. 
FIV gag encodes the Gag polyprotein, which is cleaved by viral protease to form the three 
mature proteins, MA, CA, and NC, and is necessary to achieve formation of mature virus 
particles [11, 16, 17].  Pol polyprotein, the primary product of the FIV pol gene, contains 4 
important enzymes involved in virus replication and maturation: protease (PR), reverse 
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transcriptase (RT), integrase (IN), and dUTPase (DU) [11].  Viral PR facilitates the cleavage of 
Gag and Pol polyproteins into functional enzymatic or structural proteins, while DU catalyzes the 
hydrolysis of dUTP to dUMP, thus minimizing misincorporation of potentially mutagenic dUTP 
into host DNA [11, 18, 19].  FIV RT is an RNA-dependent DNA polymerase involved in the 
reverse transcription of viral genomic RNA into a double-stranded copy of proviral DNA (cDNA), 
which is subsequently integrated into host cellular DNA via the mature IN enzyme, which 
contains three functional domains: an N-terminal domain, a central catalytic core, and a C-
terminal domain [20-22]. The FIV Env polyprotein, a 130-150 kDa product of the env gene, is 
proteolytically cleaved within the Golgi apparatus into two mature, glycosylated proteins, SU 
(gp95) and TM (gp40), which play a significant role in virion attachment and entry into target 
cells [11, 12].   
 The FIV genome contains one regulatory gene (rev) and two accessory genes (vif and 
orfA). FIV rev encodes Rev, a nucleolar polyprotein that binds to the Rev Response Element 
(RRE) to allow export of partially spliced and unspliced viral RNA transcripts out of the nucleus 
with the help of the nuclear export protein, exportin-1 [11, 12, 23]. The FIV Vif protein, is crucial 
to FIV replication and involved in counteraction of host defense mechanisms such as 
APOBEC3, a cellular protein that exerts an antiviral effect by deamination of cytosine to uracil 
during viral replication, resulting in degradation of synthesized minus-strand DNA [11, 12, 24].  
FIV Vif thus counteracts APOBEC3 by targeting the host protein to the E3 ubiquitin ligase 
complex, which is subsequently degraded by the proteasome [11, 12, 24].  The FIV OrfA protein 
is encoded by the accessory gene orfA, and has been shown to transactivate transcription of 
the FIV genome from the FIV LTR, localizes in the nucleus and causes cell cycle arrest at G2 in 
infected cells, and may be involved in late steps of virion formation and the early steps of virus 
infectivity, although the precise role of OrfA is still undetermined [11, 12, 25-28].  Interestingly, 
OrfA has been shown to downregulate expression of the viral receptor for FIV (CD134) on the 
surface of cells, as well as E2 ubiquitin-conjugating enzymes and a ubiquitin-protein ligase [12, 
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29, 30].  These potential functions of OrfA may have implications which aid in viral 
dissemination by preventing surface interactions with budding virions, and limit degradation of 
viral proteins by host cell ubiquitin ligase mechanisms, respectively. 
 FIV requires an initial interaction with a primary binding receptor for infection, and binds 
to host cells through a high-affinity interaction of the envelope SU protein (gp95) with the CD134 
surface molecule present in high amounts on CD4+ lymphocytes and monocytes/macrophages 
[31-35].  This interaction induces a conformational change in the SU protein, which then 
exposes a cryptic epitope in the V3 loop of Env; the binding site necessary for binding with the 
entry (co) receptor CXCR4 [34-36].  Binding of the V3 loop exposes the serpentine region of TM 
(gp40), which results in the formation of a hairpin structure that allows fusion with the cell 
membrane and subsequent cell entry  [35-37].  However, as infection progresses, the 
production of neutralizing antibodies by the host increases the need for FIV to escape selective 
pressures,  As a result, the cell tropism of FIV begins to change, as new viral variants arise 
which exhibit a decreased dependence on CD134 and increased ability to infect cells that 
express CXCR4 with limited CD134, such as naïve B cells and CD8+ T cells [2, 3, 38].  Thus, 
this expanded cell tropism results in a vast increase in the number of target cells susceptible to 
infection, which subsequently causes severe immunodepletion and clinical manifestations 
associated with AIDS-induced disease. 
FIV as a molecular analogue to HIV 
 The structural and sequence organization of FIV is very similar to HIV, which is also a 
member of the lentivirus genus [11]. HIV is morphologically characterized by a spherical virion 
that is roughly 120nm in diameter, and contains a diploid genome composed of two copies of 
single stranded, positive-sense RNA that is packaged with nucleocapsid (p7) and accessory 
proteins (protease, reverse transcriptase, integrase) [39].  Like FIV, the ribonucleoprotein 
complex at the heart of the HIV virion is contained within a dense core of Capsid protein (CA, 
	 4 
p24) and surrounded by a spherical shell of Matrix protein (MA, p17)[39].  Mature Env 
glycoproteins, SU (gp120) and TM (gp 41), are anchored within the external lipid bilayer, and 
play significant role in cell entry through binding to host cell receptors. HIV also requires an 
initial interaction with a primary binding receptor for infection, and utilizes analogous modes of 
receptor-mediated entry as FIV utilizing chemokine co-receptors [40-42].  However, in lieu of 
CD134, HIV utilizes CD4 as primary binding receptor and CCR5 as its primary co-receptor, 
although HIV is also able to utilize CXCR4 [40, 41].  Much like FIV, HIV binds to CD4+ target  
cells through a high-affinity interaction with the CD4 receptor that induces a conformational 
change in the envelope glycoprotein gp120, subsequently exposing the binding sites necessary 
for chemokine co-receptor binding (CXCR4 or CCR5) and subsequent fusion with the cell 
membrane. 
 The HIV genome encodes three primary polyproteins, Gag, Pol, and Env, as well as the 
regulatory protein, Rev, and accessory protein, Vif – all of which exhibit similar functions to FIV 
[11, 12, 39]. However, in addition to these, HIV also contains genes that encode additional 
accessory proteins involved in viral maturation, replication, and survival [39]. These include: Tat 
(p16/p14), a viral transcriptional activator, Vpr (p10-15), a promoter of nuclear localization and 
inhibitor of cell division (cell cycle arrest at G2/M), Vpu (p16), a promotor of extracellular release 
of viral particles, Nef (p27-25), a downregulator of CD4 and MHC I expression, Vpx (p12-16), a 
Vpr homolog present in HIV-2 (absent in HIV-1), and Tev (p28), a tripartite tat-env-rev protein 
[39].  FIV OrfA shares many similarities with several HIV accessory proteins, including the 
transcriptional transactivation activity of Tat, nuclear localization and cell cycle arrest functions 
of Vpr, and downregulation of cell surface receptor ability of Nef [27-29, 39].  This indicates that 
although FIV differs slightly in terms of accessory gene structure, the accessory proteins 
expressed during FIV infection exhibit many of the same functions as observed during HIV 
infection, highlighting the potential for FIV to provide insight into molecular mechanisms of 
lentiviral infection. 
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Clinical disease syndromes of FIV 
FIV is associated with a variety of clinical syndromes that predominately occur 
secondary to immunodepletion, including cachexia, anterior uveitis, chronic rhinitis, 
gingivostomatitis and periodontitis, encephalitis and neurologic dysfunction, and lymphoma [1, 
4, 9, 43-53].  The acute phase of FIV infection, lasting approximately 4-8 weeks, is 
characterized by a sharp increase in CD4+ T lymphocytes that are accompanied by high levels 
of FIV viral RNA and proviral DNA in circulation [4, 8, 54]. These hematologic changes are 
typically accompanied by mild to moderate clinical sings which include pyrexia, lethargy, and 
peripheral lymphadenopathy [4, 54, 55]. Following a prolonged asymptomatic phase, during 
which the levels of circulating virus remains stable and integrated provirus establishes a 
reservoir of latently infected target cells, there is progressive decline of CD4+ T lymphocytes 
and other immunocytes, resulting in functional immunodeficiency and susceptibility to 
opportunistic infections [6, 13, 36, 56].   
During FIV infection, loss of CD4+ T lymphocytes is directly attributable to a viral-
induced cytopathic effect, in addition to an increase in FIV-specific CD8-mediated programed 
cell death, lack of thymic regeneration, and spontaneous apoptosis in response to decreased 
cytokine support [10, 13, 57, 58]. As a result, the most frequent clinical disease syndromes 
associated with FIV infection manifest as a direct consequence of immune depletion and 
dysfunction, such as oral opportunistic infection (gingivitis, stomatitis, and periodontitis), 
immune-mediated glomerulonephritis, chronic rhinitis, and dermatitis [47, 48, 51, 52, 59, 60]. 
Oral opportunistic infections are prevalent in a high proportion of FIV-infected cats, and 
frequently present as erythematous, inflammatory lesions along the gingival margin (gingivitis), 
multifocal areas of necrotizing inflammation within the gingival sulcus or periodontal ligament 
(periodontitis), or ulcerative inflammatory lesions along the buccal mucosa, hard palate, or soft 
palate (stomatitis) [52, 61-63]. Changes in the salivary/oral microbiota have been increasingly 
associated with FIV infection, and shifts in the proportion of opportunistic pathogens in saliva of 
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FIV-infected cats have been associated with the development of oral inflammatory lesions [61, 
64]. Similarly, FIV-infected cats frequently present severe, necrotizing and/or ulcerative 
inflammatory lesions (dermatitis) due to opportunistic infection with various bacterial, fungal, 
protozoal, and parasitic etiologies, including mycobacteriosis, leishmaniasis, toxoplasmosis, and 
dermatophytosis [48, 59, 65, 66]. Upper respiratory disease is also a frequently finding in FIV-
infected cats, and may occur in conjunction with concurrent viral, bacterial, or fungal infections 
[4, 47, 67, 68].  
FIV-induced renal disease is also observed in both experimentally and naturally infected 
cats, and includes pathologic changes which include glomerulonephritis, proteinuria, protein 
tubular casts and tubular microcysts, as well as diffuse interstitial inflammatory infiltrates [60, 
69]. Mesangial widening with glomerular and interstitial amyloidosis is also observed in kidneys 
of FIV-infected cats, and when evaluated in the context of another frequent finding during FIV 
infection, hypergammaglobulinemia, indicate the potential for immune complex deposition to 
occur within the glomerulus as a result of chronic antigenic stimulation and immune activation 
[60, 70, 71].  Interestingly, FIV is also associated with the occurrence of various neoplastic 
diseases, which most frequently manifests in the development of lymphoma in infected cats [7, 
72].  Collectively, these two disease syndromes highlight direct consequences of viral-induced 
immune dysfunction that arise in response to prolonged viral infection.  
Neurologic disease is an important manifestation of FIV infection, and affected cats may 
present with either central nervous system (CNS) or peripheral nervous system (PNS) 
involvement [46, 49, 50, 73, 74].  In the PNS, FIV induces significantly increased numbers of 
CD3+ T cells and macrophages in dorsal root ganglia, and infected cats exhibit pronounced 
changes in epidermal nerve fiber densities [73, 75]. FIV enters the CNS during the acute stages 
of infection and is present within the brain and cerebral spinal fluid [46, 49, 76].  The primary 
neuropathogenic effect of FIV infection within the CNS manifests as infiltration and 
accumulation of perivascular lymphocytes and macrophages (encephalitis), activation of 
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microglial cells and astrocytes (gliosis), and occasional neuronal loss with myelin degeneration 
[46, 49, 50, 76, 77]. This infiltration of inflammatory cells and consequences associated with 
immune activation within the CNS frequently results in clinically apparent neurologic deficits and 
gradual decline in CNS function, functionally manifesting as abnormal stereotypic motor 
behaviors, anisocoria, increased aggression, prolonged latencies in brainstem evoked 
potentials, delayed righting and pupillary reflexes, decreased nerve conduction velocities, and 
deficits in cognitive-motor functions [78-81]. 
FIV as a model to study HIV pathogenesis 
Immune dysfunction 
The primary immunodeficiency of FIV, a gradual and progressive decline in CD4+ T 
lymphocytes, is a hallmark feature of both natural and experimental infection, and perhaps the 
most fundamental feature to parallel HIV infection.  During both FIV and HIV infection, CD4+ 
lymphocyte numbers decline over an extended asymptomatic phase, and is associated with an 
increase in activated CD8+ lymphocytes that have antiviral activity [82-85].  The net effect of 
this event is a decrease in the ratio of CD4+ cells to CD8 + cells (CD4:CD8), and is used as a 
clinical indicator of immunosuppression in both FIV and HIV infected patients [84-86]. 
Additionally, several studies have shown that FIV induces defects in immune function similar to 
HIV, such as a decreased proliferation response of T lymphocytes in response to mitogens, a 
deficit in the humoral immune response, and dysregulation of cytokine expression [10, 11, 56].  
 Clinical manifestations of FIV and HIV-induced immune dysfunction also include 
aberrant proliferative response and immune function.  Neoplasia, primarily the development of 
large B-cell lymphoma, is frequently observed in HIV patients, and this pathologic finding is 
paralleled in FIV-infected cats during late stages of infection [7, 72, 87].  Furthermore, a 
significant complication of HIV infection, systemic immune activation, is likewise implicated in 
FIV and results in several mutual clinical manifestations such as lentiviral-induced periodontitis, 
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meningoencephalitis, and vaccine-induced enhancement of infection (outlined in detail below) 
[88-90].  
Neurologic dysfunction 
Previous studies have shown that both FIV and HIV enter the central nervous system (CNS) 
at acute stages of infection, either via trafficking of infected monocytes and lymphocytes, or by 
penetration of free virus across the blood-brain or blood-CSF barriers [49, 91-96]. Once present 
in the CNS, both FIV and HIV infection spread to microglia and astrocytes, which then serve as 
a reservoir for latent viral persistence [45, 49, 95-97]. Although multinucleated giant cells are 
rarely observed in the CNS during FIV infection, the fundamental neuropathologic finding of 
encephalitis is well-documented in both HIV and FIV infected patients, and resultant proliferation 
and activation of these cells (gliosis) is associated with neurodegenerative processes such as 
myelin degradation and neuronal injury/loss [46, 49, 74, 77, 98]. Thus, the clinical 
manifestations associated with neuropathology of FIV are likewise observed in HIV infection, 
and because of this, FIV has been repeatedly used as a model to investigate the pathogenesis 
of dementia and cognitive-motor processing deficits in AIDS patients. In vitro models of FIV 
have been useful to expand our understanding of role of calcium dysregulation and neural 
dysfunction during lentiviral infection, and have provided a unique system for the development 
neuroprotective treatments such as neurotrophin ligands, which prevent the delayed 
accumulation of intracellular calcium and decreased cytoskeletal damage of neuronal dendrites 
[49, 99]. Furthermore, because of the low natural prevalence and slow clinical course 
associated with lentiviral-induced neurologic dysfunction, experimental in vivo studies have 
been developed in the FIV model which accelerate neuropathogenesis (neonatal inoculation, 
inoculation with neurovirulent strains, direct intracranial inoculation), allowing increased 
opportunity to evaluate viral kinetics of CNS infection, neurovirulence determinants, and the 
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potential for novel treatments designed to decrease neurocognitive defects during HIV infection 
[76, 80, 99, 100]. 
The use of neurovirulent strains of FIV has also allowed for the investigation of 
neuropathogenic effects on the peripheral nervous system (PNS) as a model of HIV distal 
symmetric polyneuropathy (DSP), demonstrating rapid onset of peripheral neuropathy in FIV 
infected cats with axonal injury, macrophage activation, and detection of virus within the nerve 
[73, 101]. Indeed, FIV infection results in pathological events in the PNS that are very similar to 
HIV, including increased numbers of CD3+ T lymphocytes and activated macrophages in skin 
and dorsal root ganglia (DRGs) that are associated with increased expression of the pro-
inflammatory cytokines, as well as changes in epidermal nerve fiber densities, indicative of 
axonal and myelin degeneration [73, 75]. Additionally, FIV has been useful in the evaluation of 
the neurotoxicity of antiretroviral toxic neuropathy (ATN), due to mitochondrial dysfunction 
associated with nucleoside analogue reverse transcriptase (NRTI) inhibitor treatment.  Thus, 
FIV has the potential to expand our understanding of the role of the immunopathology and 
progression of neuropathy in FIV-infected cats. 
SIV models of neuropathogenesis have widely been regarded as the premier model to study 
HIV-associated neurologic dysfunction (HAND), and has elucidated many mechanisms of 
neuroAIDS development such as acute CNS infection and the importance of 
monocyte/macrophage activation in driving CNS lesions [102-105].  Recently, the SIV model of 
neuroAIDS has been adapted to study peripheral neuropathy, and significant advances have 
been made that have implicated macrophages within dorsal root and trigeminal ganglia as a 
source of viral maintenance, in addition to their role in neuronal loss and neuronophagia [106, 
107].  These findings are coupled with additional studies that have defined impaired 
mitochondrial function in distal axons which are more pronounced in ART-treated animals, 
indicating the potential for antiretroviral-mediated mitochondrial toxicity [108].  However, the SIV 
model of HAND is most commonly employed in rhesus macaques, and the sequelae of SIV 
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infection in an unnatural host presents unique disadvantages in studying the progression of 
neurologic disease, chiefly manifested as rapid progression to AIDS and increased severity of 
CNS inflammation which amplify pathology compared to HIV-infected humans [104, 105]. 
Furthermore, NHP studies are also limited by increased zoonotic risk to researchers, high cost 
associated with animal care and housing, the low number of animals available for research, and 
the potential for co-infection with a wide array of other pathogens, including rhesus rhadinovirus 
(RRV), lymphocryptovirus (LCV), simian cytomegalovirus (CMV), simian foamy virus (SFV), 
simian virus 40 (SV40), and rhesus papillomavirus (RhPV) [109, 110].  While it is impractical to 
presume that the FIV model could replace the SIV model of neuroAIDS, the caveats of using 
non-human primates to study pathogenesis of lentiviral-induced neurologic dysfunction present 
an important opportunity for the FIV model to supplement the repertoire of current 
investigational methodologies.  As FIV infection presents a safer and more economical lentiviral 
model that more accurately recapitulates neuroAIDS progression in HIV-infected humans, such 
applications such as evaluation of ART-induced neurotoxicity, neurofibrillary tangle 
development, and calcium homeostasis during viral infection are at the forefront of advancing 
our understanding of HIV-associated neurologic dysfunction [46, 49]. 
Vaccine development 
Considerable effort has been directed at the development of an anti-HIV vaccine strategy 
that can produce protective immunity in humans, and this effort has been paralleled in regard to 
FIV.  A commercially available, whole inactivated virus vaccine containing two FIV subtypes 
(Fel-O-Vax FIV®) is currently licensed for use in the United States, and various reports have 
described virus neutralization and cellular immunity in a significant proportion of study animals 
[111-113].  However, the efficacy of this vaccine is still under debate, as recent studies and field 
evaluations have reported that the vaccine does not confer immunity against certain FIV strains 
(ie: FIVGL8), and that the neutralizing antibody response and protective rate may be low in 
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certain cat populations (i.e. protection is not conferred to certain virulent recombinant strains of 
FIV) [114-117].  Other attempts at FIV vaccine development have either failed to induce 
protective immunity against FIV infection, or have resulted in increased susceptibility to infection 
via antibody-dependent enhancement or general immune activation [118-123].   
The development of an anti-HIV vaccine has been impeded by a wide variety of similar 
complications, such as lack of efficacy or unanticipated side effects, as well as increased 
susceptibility to infection via analogous mechanisms of FIV vaccine enhancement (antibody-
dependent viral enhancement or general immune activation) [124-130].  Indeed, vaccine-
induced enhancement of viral infection has been previously reported in a large number of HIV 
studies [131-134], and has been shown to occur via antibody-dependent or antibody-
independent mechanisms of complement activation [135-142], as well as an increase in general 
immune activation and/or expansion of lymphoid target cells [143-147]; features that have also 
been observed in FIV studies [118-123].  However, despite these setbacks in lentiviral vaccine 
development, there are many similarities in the disease course of HIV and FIV infection, and the 
use of the FIV model to circumvent these may have great potential to provide a translational 
model for the development of novel immunotherapies to protect from HIV infection in humans.   
Traditionally, non-human primate (NHP) models have been at the forefront of anti-HIV 
vaccine development due to the similarities of SIV and HIV, and have revealed several 
promising vaccine targets such as nef-deleted SIV (which protects from wild-type SIV infection) 
and broad neutralizing antibodies utilizing chimeric SHIVs that express the HIV-1 envelope 
glycoprotein [148-151].  However, the successful outcome of these methods to prevent HIV 
infection in humans has been significantly impeded by various causes, such as restrictions on 
the use of live-attenuated HIV-1 in humans, as well as difficulty in producing a sufficiently 
efficacious neutralizing antibody response by vaccination [149]. Alternatively, various 
humanized mouse models have played a vital role in elucidating key aspects of the immune 
response to HIV, primarily through use of generally immunocompromised mice engrafted with 
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reconstituted human immune system tissues such as human fetal thymus and liver (scid-hu-
Thy/Liv) or peripheral blood lymphocytes (scid-hu-PBL) [152].  These models have been used 
for key studies in HIV immunopathogenesis, including mechanisms of CD4+ T-cells loss, 
antiretroviral therapy response, and passive immunization with monoclonal antibodies to HIV 
envelope protein (and testing of Env-based vaccines) [110, 152-156]. However, because only 
certain parts of the human immune system can be reconstituted in humanized mouse models, 
interactions between the introduced human cells and the murine immune system cannot be 
evaluated in these hosts, nor the effects of HIV infection in non-hematopoietic tissues [152]. 
Although FIV is not as molecularly similar to HIV as the NHP model of SIV, and may not be as 
economical at the humanized mouse model, it nevertheless represents the sole prospect to fully 
evaluate the immune response during natural lentiviral infection. Furthermore, the availability of 
a commercially-available vaccine in cats with efficacy against FIV may provide important clues 
to improving the efficacy of anti-HIV vaccines, and the elucidation of the mechanisms 
associated with vaccination failure in analogous FIV and HIV models of immunotherapy may 
provide key insights into improving the efficacy of lentiviral vaccines.  
HIV-induced oral disease 
Oral manifestations of HIV are exhibited through various disease syndromes such as Oral 
Candidiasis (OC, “thrush”), Linear Gingival Erythema (LGE), Necrotizing Ulcerative Gingivitis 
(NUG), and Necrotizing Ulcerative Periodontitis (NUP) [157-159]. Despite the success of 
combinational antiretroviral therapy (cART) in diminishing HIV viral replication and prolonging 
immune function, lesions associated with systemic and local immune activation and 
opportunistic oral infections persist in HIV-infected patients [157, 160-162].  Furthermore, 
therapies used to treat HIV infection and HIV-induced oral disease have limited success, and 
treatment strategies do not eliminate HIV in persistently infected oral tissues [157, 163]. 
Previous studies have shown that CD4+ T-cells are rapidly and severely depleted from the 
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intestinal mucosa following HIV infection due to direct effects of targeted virus infection and 
virus-induced Fas-mediated apoptosis, resulting in loss of mucosal integrity and a reduced 
capacity to control potential pathogens at mucosal surfaces - thereby triggering local and 
systemic pro-inflammatory responses [88, 164-166]. Based upon the analogous 
microenvironments of the oral and gastrointestinal mucosa, the same effects of viral-induced 
immunosuppression is predicted to occur in the oral cavity, resulting in a chronic cycle of 
immune stimulation, leukocyte recruitment, and target cell infection that produces HIV-induced 
oral disease lesions [157, 167].  
The FIV model is particularly well suited for studies of HIV-associated oral disease, as it not 
only parallels HIV in its structural, biochemical, and immunological properties, but it is also the 
only naturally occurring lentivirus to predictably induce oral lesions in its natural host, the 
domestic cat [1, 4, 9, 10, 61, 62]. Non-human primate (NHP) models of HIV do not reliably 
cause oral disease and are limited by zoonotic risk to researchers, high cost associated with 
animal care and housing, the low number of animals available for research, while humanized 
mouse models of HIV lack both the prevalence of oral lesions and the presence of tonsillar 
structures similar to humans [110, 168-170]. In contrast, FIV oral manifestations are common in 
naturally- and experimentally-infected cats [52, 61, 62], and the range of lesions seen include 
gingivitis, periodontitis, and feline chronic gingivostomatitis [62], with striking similarities to LGE, 
NUG, and NUP lesions noted in untreated HIV patients [1, 4, 83, 157, 171-174]. Furthermore, 
opportunistic infections detected in HIV-positive individuals are paralleled in feline oral disease 
syndromes [65, 175-184], and feline tonsillar tissues (palatine, pharyngeal, and lingual tonsils) 
are analogous to those in humans [169].  Coupled with recent advances in new generation 
cART protocols available for use in cats [185-188], the domestic cat model of FIV presents an 
easily manipulated animal model to evaluate drivers of immune dysfunction and microbial 




The research presented in this dissertation builds upon the background outlined above 
and the potential for feline immunodeficiency virus to serve as a model to study HIV 
pathogenesis and viable therapeutic targets. Although it is accepted that FIV is primarily 
transmitted by biting, few studies have evaluated FIV oral infection kinetics and transmission 
mechanisms over the last 20 years. Furthermore, recent studies in HIV prove that oral 
transmission can occur, and that saliva from infected individuals contains significant amounts of 
HIV RNA and DNA.  Therefore, in Chapter 1, I applied modern quantitative analyses to 
characterize FIV salivary viral kinetics and antibody secretions in order to investigate the 
pathogenesis of oral FIV infection and further our understanding of lentiviral oral disease and 
transmission.  The results of this research demonstrate that (i) oral lymphoid tissues serve as a 
site for enhanced FIV replication, resulting in accumulation of FIV particles and FIV-infected 
cells in saliva, and (ii) failure to induce a virus-specific oral mucosal antibody response, and/or 
viral capability to overcome inhibitory components in saliva may perpetuate chronic oral cavity 
infection.  Most importantly, these results provide a model of oral FIV pathogenesis and suggest 
alternative diagnostic modalities and translational approaches to study oral HIV infection. 
Because FIV and HIV utilize parallel modes of receptor-mediated entry, the ability of  
neutralizing antibodies to the FIV binding receptor (CD134) to block FIV infection ex vivo 
presents a unique opportunity for the development of anti-HIV immunotherapies which utilize 
anti-receptor antibodies to block viral infection. In Chapter 2, I immunized cats with soluble 
CD134, recombinant FIV-SU protein, and/or CD134+SU complexes prior to challenge with FIV 
to determine if vaccination with CD134-SU complexes could induce protection against FIV 
infection.  Immunization induced production of anti-CD134 and anti-SU antibodies in vaccinated 
cats, and purified anti-CD134 and anti-SU antibodies significantly inhibited FIV infection in vitro.  
However, no vaccine combination protected cats from FIV infection in vivo and vaccination 
induced high titers of antibodies directed at vaccine by-products relative to target antigens.  The 
	 15 
results of this research reinforce the need to monitor components of vaccine preparations, and 
emphasize that vaccination may induce proliferation of susceptible target cells and 
enhancement of heat-labile serum components that counteract neutralizing antibodies. 
Both HIV and FIV induce lifelong infection in their respective hosts, and may result in 
wide a spectrum of immunodeficiency-related opportunistic diseases.  Both prednisolone and 
cyclosporine A (CsA) are commonly used clinically to treat lymphoproliferative and immune-
mediated diseases in these patients, but the impact of these compounds on infection has not 
been well documented, and their understanding immunomodulatory effects on viral replication 
and persistence is critical to guide safe and effective use of these therapies.  Therefore, in 
Chapter 3, I administered immunosuppressive doses of prednisolone or CsA to cats chronically 
infected with FIV and monitored alterations in hematological parameters and FIV viral/proviral 
loads in response to therapy. Interestingly, both treatments caused (i) acute increases in CD4+ 
lymphocytes, (ii) increased FIV viremia, and (iii) significant alterations in cytokine expression 
that favored a shift toward a Th2 response.  The results of this research highlight the potential 
for immunosuppressive drug-induced perturbation of FIV replication and underscores the need 
for consideration of chronic viral infection status when prescribing immunomodulatory 
medications. 
As a result of my graduate studies, I developed a strong interest in the capacity for FIV 
to serve as an animal model to study HIV-induced opportunistic disease. Commonly used 
animal models for HIV, including SIV/SHIV infections of non-human primates (NHPs) or HIV 
infections in humanized mice, do not reliably incite oral lesions.  In contrast, gingivitis and 
periodontitis are primary clinical signs associated with untreated natural and experimental FIV-
infection, and are principal attributes of this model that may be exploited to investigate 
pathogenic mechanisms involved in the perturbation of the oral immune system and microbial 
environment. Therefore, in Chapter 4, I present findings of a pilot study in which I investigated 
changes in the oral microbiota and oral immune system during FIV infection, and outline future 
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directions and research goals for my career investigating the pathogenic mechanisms of HIV-
induced oral disease using the FIV model. By assessing FIV-associated changes in clinical 
status, oral microbiota, local and systemic viral burden, and immune profile under such 
treatment protocols, future studies implementing the feline model of lentiviral-induced oral 
disease may provide a cornerstone to expand our understanding of the complex interactions 
between HIV infection, oral immune dysfunction, and the perturbations to the oral microbiota 
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Feline immunodeficiency virus (FIV) is the feline analogue of human immunodeficiency 
virus (HIV) and features many hallmarks of HIV infection and pathogenesis, including the 
development of concurrent oral lesions.  While HIV is typically transmitted via parenteral 
transmucosal contact, recent studies prove that oral transmission can occur, and that saliva 
from infected individuals contains significant amounts of HIV RNA and DNA.  While it is 
accepted that FIV is primarily transmitted by biting, few studies have evaluated FIV oral infection 
kinetics and transmission mechanisms over the last 20 years.  Modern quantitative analyses 
applied to natural FIV oral infection could significantly further our understanding of lentiviral oral 
disease and transmission. We therefore characterized FIV salivary viral kinetics and antibody 
secretions to more fully document oral viral pathogenesis.  Our results demonstrate that: (i) 
saliva of FIV-infected cats contains infectious virus particles, FIV viral RNA at levels equivalent 
to circulation, and lower but significant amounts of FIV proviral DNA; (ii) the ratio of FIV RNA to 
DNA is significantly higher in saliva than in circulation; (iii) FIV viral load in oral lymphoid tissues 
(tonsil, lymph nodes) is significantly higher than mucosal tissues (buccal mucosa, salivary 
gland, tongue); (iv) salivary IgG antibodies increase significantly over time in FIV-infected cats, 
while salivary IgA levels remain static; and, (v) saliva from naïve Specific Pathogen Free cats 
inhibits FIV growth in vitro. Collectively, these results suggest that oral lymphoid tissues serve 
as a site for enhanced FIV replication, resulting in accumulation of FIV particles and FIV-
infected cells in saliva. Failure to induce a virus-specific oral mucosal antibody response, and/or 
viral capability to overcome inhibitory components in saliva may perpetuate chronic oral cavity 
infection.  Based upon these findings, we propose a model of oral FIV pathogenesis and 
suggest alternative diagnostic modalities & translational approaches to study oral HIV infection. 
______________________________ 
1Chapter published as: Miller, C., Boegler, K., Carver, S., MacMillan, M., Bielefeldt-Ohmann, H. 
and VandeWoude, S., 2017. Pathogenesis of oral FIV infection. PloS one, 12(9), p.e0185138. 
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Background 
Feline immunodeficiency virus (FIV) is a naturally occurring lentivirus of domestic cats 
and non-domestic feline species that is genetically, structurally, and biochemically similar to 
human immunodeficiency virus (HIV), thereby providing a valuable animal model for studying 
HIV infection [1-6]. While HIV transmission typically occurs via parenteral or transmucosal 
venereal contact, oral transmission of HIV via receptive oral intercourse, breast feeding, and 
human bites has been well-documented, especially in the presence of a disrupted oral mucosal 
barrier (ie: epithelial ulceration), inflammation, and/or concurrent oral infections [7-15].  These 
alternative modes of HIV transmission represent a significant health concern to at-risk 
individuals, including recipients of oral intercourse, infants of HIV-positive mothers, and dental 
health professionals. Additionally, recent studies have shown that both HIV viral RNA and 
proviral DNA are detectable in saliva of infected individuals, and salivary RNA levels are 
correlated with levels in circulation; facts that have been largely overlooked in studies of HIV 
pathogenesis [16, 17].  Furthermore, HIV antibodies in saliva may lend themselves to 
noninvasive diagnostic methodologies via rapid detection of saliva specific antibodies, and HIV 
therapies that incorporate antiviral properties of saliva have been considered, including the use 
of inhibitory molecules as components of commercial lubricants [14, 18-23].  
HIV, Simian Immunodeficiency Virus (SIV), and FIV have all been shown to target 
lymphocytes of the alimentary tract early during viral infection, resulting in long term 
consequences for mucosal immune function [24-28].  Several studies have linked lentiviral-
induced gastrointestinal mucosal insult to chronic immune activation associated with infection 
via translocation of bacteria or bacterial antigens [25, 29-32].  It is feasible that the oral cavity, 
with its rich lymphoid tonsillar structures, is similarly impacted by lentiviral infection, and may 
serve as important reservoir for lentiviral persistence [27]. Unlike primate lentiviral infections, 
which are primarily considered to be transmitted venereally, during maternal-offspring 
interactions, or via exchange of blood products, FIV is believed to be primarily transmitted from 
	 30 
cat to cat via bite wounds during antagonistic or mating interactions.  However, vertical 
transmission of FIV has been experimentally shown via colostrum and milk, and may provide an 
appropriate model to study mother-to-offspring transmission of HIV [33, 34].  Additionally, FIV 
periodontitis/gingivitis is a hallmark of both naturally occurring and experimental FIV infections, 
and characteristic lesions of FIV gingivitis are similar to those frequently reported for HIV-
associated dental disease, such as linear bands of erythema along the gingival margin and 
ulcerative to necrotizing lesions within the gingival and buccal mucosa [1, 6, 35-44].  Despite the 
fact that FIV associated gingival disease is widely diagnosed, very few studies have assessed 
mechanisms of FIV salivary excretion, transmission, and pathogenesis [42, 45].  Further, recent 
reports document that FIV infection is poorly or rarely transmitted among cats in multi-cat 
households, calling into question whether FIV salivary transmission is limited by innate immune 
barriers in stable social groups [46]. 
Studies of FIV salivary transmission and pathogenesis of oral disease have the potential 
to reveal sites of lentiviral replication and persistence, mechanisms of salivary excretion, and 
oral lentiviral immune responses and diseases - thereby expanding our knowledge of the 
pathogenesis of FIV disease and mechanisms of orally transmitted pathogens. Although it is 
widely accepted that FIV is primarily transmitted by biting, and much less efficiently during social 
grooming, few studies have evaluated FIV oral infection kinetics and transmission mechanisms 
over the last 20 years.  Modern quantitative analyses applied to natural FIV oral infection could 
significantly further our understanding of the temporal events that occur during FIV oral infection 
pathogenesis, and may thus aid in the design of improved diagnostics, vaccines and vaccine 
modalities, choice of adjuvants, and design and delivery of antiviral agents for FIV. As salivary 
excretion and kinetics of HIV infection is also understudied, identification of similarities and 
differences between FIV and HIV oral pathogenesis can also ultimately enhance our 
understanding of HIV-associated oral disease.   
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 Previous studies of FIV oral transmission and pathogenesis have sought to characterize 
viral excretion mechanisms by detection of saliva FIV RNA, DNA or antibodies, or though 
isolation of virus in saliva or oral tissues [42, 44, 45, 47, 48]. However, because much of this 
work was performed before the development of quantitative analyses, there has been limited 
understanding of the temporal events that take place in the oral cavity during FIV infection. To 
address these knowledge gaps, we opportunistically evaluated salivary transmission 
characteristics in cats intravenously inoculated with a well-characterized immunopathogenic 
strain of FIV (FIVC36) [36, 49]. Blood, saliva, and tissue samples from 18 cats enrolled in a 
clinical trial were evaluated for viral RNA and proviral DNA by real-time quantitative PCR 
(qPCR) analysis, in addition to other clinical and hematologic parameters associated with 
disease progression. Additionally, quantification of total IgA/IgG and FIV-specific IgA/IgG 
antibodies in saliva was performed using microsphere immunoassay (MIA), and histologic 
changes in tissues were assessed. Saliva from naïve SPF (specific pathogen free) cats was 
incubated with a viral stock of FIVC36 and tested for capacity to inhibit viral growth in Crandall 
feline kidney (CRFK) cell cultures. Coincident studies evaluating hematologic and clinical 
features of infection in these same cats allowed comparisons of oral and peripheral 
characteristics of viral infection [50, 51].   
 This study represents the first quantitative analysis of FIV RNA and DNA in saliva and 
oral tissues of FIV-infected cats, evaluated in conjunction with quantification of anti-FIV IgG and 
IgA antibodies in saliva and assessment of concurrent alterations in the oral mucosa to provide 
a comprehensive assessment of the pathogenic events that contribute to the development of 
oral FIV infection.  Overall, our findings characterize sites of FIV replication and persistence, 
and reveal that oral cavity viral kinetics and antibody responses mirror that of the periphery; 
suggesting that immunological and tissue level barriers are ineffective at inhibiting FIV viral 
replication and excretion at the oral mucosal surface. 
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Materials and Methods 
Ethics Statement 
This study was approved by the Colorado State University Institutional Animal Care and 
Use Committee; 09-064A-01 - New Therapies for Retroviral Diseases.  Colorado State 
University's animal care program is licensed by the United States Department of Agriculture 
(USDA), accredited by Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALA) International, and holds an Office of Laboratory Animal Welfare (OLAW) assurance 
(A3572-01).  In accordance with the approved IACUC protocol, if any animal exhibited 
significant clinical abnormalities (vomiting, diarrhea, lethargy, refusal of food > 24 hours, labored 
breathing, dehydration, >5% weight loss from one week to the next), a complete physical exam 
with additional bloodwork was performed.  In the case that a study animal exhibited severe 
discomfort or symptoms listed above which worsened and did not respond to symptomatic 
therapy, humane euthanasia was to be performed and followed by a complete necropsy. Time 
points for euthanasia of study animals was determined by previously established time intervals 
to assess acute FIV infection, or at the discretion of a clinical veterinarian based upon the 
severity of any associated clinical signs and/or response to symptomatic therapy. Humane 
euthanasia procedures were conducted by phenobarbital overdose in accordance with IACUC 
protocols and American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia 
of Animals.  Prior to euthanasia, all study animals were anesthetized by intramuscular injection 
of ketamine (20mg/kg) and acepromazine (2mg/kg) to minimize animal suffering and distress.  
No animals died without euthanasia during this study as a result of experimental procedures.  
All study animals were monitored daily by animal care personnel for development of clinical 
signs of FIV infection.  Any animals exhibiting clinical signs either associated with FIV infection 
or other untoward condition were evaluated and treated as prescribed by the clinical 
veterinarian. One animal developed clinical signs at week 6 post-infection, and was humanely 
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euthanized at the discretion of the attending veterinarian.  All other animals were euthanized at 
the end of the experimental study. 
In vivo protocol 
Twenty-four, 8-11 week old, specific pathogen free (SPF) cats, procured from Cedar 
River Laboratories, Mason City, IA, and the Andrea D. Lauerman Specific Pathogen Free Feline 
Research Colony, Fort Collins, CO, were housed within barrier rooms in accordance with 
Colorado State University (CSU) IACUC-approved protocols at a CSU AAALAC-international 
accredited animal facility.  All animals were part of an anti-retroviral protocol, and were 
acclimated to the facility for 2 weeks prior to initiation of the study.  At day 0, eighteen cats were 
intravenously inoculated with 1ml of a 1:10 dilution of a previously characterized FIVC36 viral 
stock that is acutely immunopathogenic and induces reproducible high titer viremia [37, 49]. Six 
additional cats were sham inoculated as negative controls.  Over the course of the study, 12 of 
the FIV-infected cats received experimental anti-retroviral treatment, while 6 FIV-infected cats 
and the 6 sham-inoculated cats received no anti-retroviral treatment and served as positive and 
negative controls, respectively.   
Evaluation of viral RNA and DNA in blood and saliva 
Blood and saliva samples were collected from cats at 7-day intervals, beginning at 15 
days post-infection and ending at 92 days post-infection.  Blood samples were obtained as 
previously described [50].  Saliva was obtained from under the tongue and cheek pouches of 
each cat using sterile cotton swabs, which were immediately broken off into 1.5ml 
microcentrifuge tubes containing 200μL of RNAlater Solution (Ambion, Austin, TX) and stored at 
-20°C.  At processing, stored swabs were thawed at room temperature, vortexed vigorously for 
1 min, and centrifuged at 400 x g for 1 min.  To collect saliva from the swab tip, swabs were 
inverted using sterile forceps, placed back into microcentrifuge tubes, spun at 2000 rpm for 2 
min, and then discarded, leaving the saliva/RNAlater solution in the microcentrifuge tube. 
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Viral RNA was extracted from saliva using an RNAqueous total RNA isolation kit 
(Ambion, Austin, TX), according to manufacturer’s instructions.  Samples were eluted in 50μL 
and ethanol precipitated overnight at -20°C (2.5 vol 100% ethanol, 0.1 vol 3M sodium acetate, 
and 1.0μL glycogen).  Precipitated RNA was pelleted at 18,000 x g for 20 min at 4°C and re-
suspended in 20μL of RNA Storage Solution (Ambion, Austin, TX).  RNA from each sample was 
converted to cDNA using the RETROscript reverse transcription kit (Ambion, Austin, TX). The 
total volume of extracted RNA was transferred into two 20μL reactions and converted using 
random decamer primers and following manufacturer’s instructions for reverse transcription 
without heat denaturation of RNA.  FIV-C was detected by qPCR in triplicate using an iQ5 
thermocycler (Bio-Rad, Hercules, CA) with reaction components, cycling parameters, and FIV-C 
primers and probes as previously described [52, 53].  To quantitate viral copy number in each 
reaction, a six-point standard curve was generated by diluting FIV-C virus stock in a 10-fold 
dilution series into RNAlater solution.  Each dilution was then extracted and converted to cDNA 
as described above, and assigned a copy number value based on comparison to a FIV C gag 
plasmid standard curve ranging from 105 to 10-1 copies per reaction.  A Ct threshold was set 
according to the run data for each plate, and Ct values greater than those of negative controls 
were included in the analysis.  The resulting copy number data for each sample was analyzed 
using Prism 4 (GraphPad Software, La Jolla, CA).  Triplicate values for each sample were 
averaged, and calculated to determine viral copies per mL saliva.  Standard error was 
calculated for each treatment group at each time-point.  Viral RNA was extracted from blood 
and quantified by qPCR as previously described [50]. 
Proviral DNA was extracted from saliva of all cats for time-points 43 and 64 days post-
inoculation using a DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) and a user-adapted 
protocol for purification of total DNA from animal saliva [54].  Samples were eluted in 100μL, 
and then ethanol precipitated (2.5 vol 100% ethanol, 0.1 vol 3M sodium acetate, and 1.0μL 
glycogen) overnight at -20°C.  Precipitated DNA was then pelleted at 18,000 x g for 20 min at 
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4°C and re-suspended in 20μL H2O.  FIV-C provirus was quantitated by qPCR in duplicate 
using an iQ5 thermocycler (Bio-Rad, Hercules, CA), FIV-C primers and probe, and FIV-C 
plasmid standards as previously described [52, 53]. Proviral copy number was then normalized 
to copies per 106 cells by quantitating genomic DNA using real-time qPCR targeted to feline 
GAPDH.  A GAPDH plasmid standard curve was prepared as previously described [55] and the 
following primers were used for qPCR: GAPDH-F forward primer, 5’- 
AAGGCTGAGAACGGGAAAC -3’; GAPDH-R reverse primer, 5’- 
CATTTGATGTTGGCGGGATC– 3’.  GAPDH qPCR for each sample was set up in 25 μl using 
the following reaction components: 2 μl sample DNA, 8.5 μl de-ionized water, 1 μl GAPDH-F, 1 
μl GAPDH-R, and 12.5 μl SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA).  Reaction 
mixtures were denatured at 95°C for 30 seconds and then followed by a two-step reaction cycle 
protocol of 40 cycles that alternated between 95°C for 5 seconds and 60°C for 10 seconds.  
Proviral DNA was extracted from blood, quantified by qPCR, and normalized to a GAPDH 
standard curve to determine the number of cell equivalents per DNA sample.  Proviral copy 
number per cell was calculated as previously described [49, 50].  
To confirm the presence of infectious FIV particles in saliva of infected cats, duplicate 
cell cultures consisting of GFox cells (CrFK cells overexpressing CD134) were established in 
96-well plates at 20,000 cells/well and allowed to attach at 37°C overnight [53, 56].  GFox cell 
cultures were maintained at 37°C and 5% CO2, in 240 μl of culture medium composed of 
Dulbecco's modified Eagle's medium (DMEM) with GlutaMAX-1, 10% fetal bovine serum (FBS), 
and 1x penicillin-streptomycin (10,000 U/liter penicillin and 10,000 μg/liter streptomycin), as well 
as 1 μg/ml of Fungizone® (Amphotericin B; Life Technologies) [57].  At day 0, 10 μl of saliva 
from 5 FIV-infected and 1 sham-inoculated (uninfected) cats (collected as previously described) 
were added to the previously established Gfox cell culture, bringing the total volume to 250 μl 
(1:25 dilution of saliva). A parallel set of wells containing Gfox cells without virus was incubated 
with media only (negative control).  Cell cultures were then incubated at 37°C for 12 hours, at 
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which point all culture media was removed from each well, discarded, and replaced with 250 μl 
of fresh culture media. GFox cells were visually inspected at days 7, 10, 14, 21, and 28 post-
inoculation by inverted light microscopy for evidence of cell growth, attachment, syncytial cell 
formation, detachment, and cell death.  At days 7, 14, 21 and 28 post-inoculation, 125 μl of 
supernatant was removed from each well, frozen at -80°C, and replaced with 125 μl of fresh 
culture media.  The supernatant collected from each well and each time point was then assayed 
for the detection of FIV p26 antigen by capture ELISA using previously described protocols [58]. 
For each treatment, absorbance (Abs) was measured at 450 nm and a background threshold 
value was established by calculating the mean Abs of FIV-negative (naïve) saliva plus 3 
standard deviations.  All Abs values above this threshold were considered positive.  
Evaluation of viral RNA and DNA in oral tissues  
DNA was extracted from frozen necropsy tissues using a DNeasy Blood and Tissue Kit 
(Qiagen, Valencia, CA), and eluted in 200μl AE buffer.  All samples were adjusted to 20ng/μl 
using 1X TE buffer and FIV-C provirus was quantitated by qPCR using previously described 
reaction components, cycling parameters, and FIV-C primers and probes [52, 53]. Proviral copy 
number within these tissues was quantitated using a standard curve with 1:10 serial dilutions of 
FIV-C gag plasmid into 1X TE buffer, ranging from 105 copies to 101 copies per reaction.  
Resulting proviral copy numbers were normalized to copies per 106 cells based on the total 
amount of DNA present in the reaction (100ng) as previously described [49]. 
RNA was extracted from frozen necropsy tissues using an RNeasy Mini Kit (Qiagen, 
Valencia, CA) and tissue homogenizer (MP Biomedicals, Solon, OH).  Superscript II 
(Invitrogen), random primers (Invitrogen), and RNase Out (Invitrogen) were used to synthesize 
cDNA by reverse transcription.  Real-time qPCR quantification of viral RNA was then performed 
on an iQ5 thermocycler (Bio-Rad, Hercules, CA) using previously described reaction 
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components, cycling parameters, and FIV-C primers and probes [52, 53].  Viral RNA was 
normalized to GAPDH expression as previously described [46] using the ΔΔCT method [59].   
Histological evaluation  
Necropsy was performed on sixteen FIV-inoculated cats at 92 days post inoculation; one 
sham-inoculated cat was coincidently necropsied to provide FIV negative control tissues.  
Palatine tonsils, retropharyngeal lymph nodes, submandibular salivary glands, tongue and 
buccal mucosa were collected.  Necropsy tissues were then halved and placed into either 1ml 
tubes and frozen at -80°C, or into standard tissue cassettes that were then fixed in 10% neutral-
buffered formaldehyde for 24 hours prior to trimming and processing for histology.  Five μm 
paraffin sections were collected onto charged slides (Superfrost; Colorado Histo-Prep, Fort 
Collins, CO), and one slide of each tissue was stained with hematoxylin and eosin (H & E) for 
microscopic examination.  Tissues were scored using the following criteria: 0 = no apparent 
pathology/change, 1 = minimal change (minimally increased numbers of small lymphocytes, 
plasma cells, macrophages, and/or mast cells), 2 = mild change (mild inflammation, edema, 
and/or parafollicular expansion, secondary follicle formation, and presence of tingible body 
macrophages within lymph nodes), 3 = moderate change (as previously described, but more 
moderately extensive), 4 = marked changes (as previously described, but with severe 
inflammation, edema, and/or lymphoid reactivity) 
Quantification of IgA and IgG antibodies in saliva 
  Saliva from FIV-infected and sham-inoculated cats was evaluated for circulating 
antibodies at days 22, 36, 57, and 71 post-inoculation.  Total IgA and IgG from saliva were 
quantified using microsphere immunoassay (MIA) protocols involving conjugation of magnetic 
microspheres with IgA or IgG capture antibodies [60].  Following conjugation protocols, a 
hemocytometer was used to determine microsphere concentrations and protein coupling was 
confirmed via incubation of microspheres with primary antibodies and/or PE-conjugated 
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detection antibodies [51].  Successful coupling of antibody to microspheres was determined by 
a median fluorescence intensity (MFI) of >2,000.  Saliva samples from FIV-infected and 
negative control cats were diluted 1:100 and 1:1000 in assay buffer for detection of IgG and IgA, 
respectively.  These samples were then incubated in duplicate with approximately 2,500 
conjugated beads per well in untreated, round-bottom 96-well plates [51, 60].  Total IgG and IgA 
antibody concentrations were calculated from an 8-point standard curve (2-fold dilution series, 
run in duplicate) using the MFI obtained from ≥100 microspheres per analyte per well (Bio-
Plex™ Manager 5.0).  Reagent concentrations, volumes, incubation times, acceptable standard 
recovery, and data analysis were performed as previously described [51, 60].  
FIV-specific antibodies were detected using microsphere immunoassay (MIA) protocols 
involving conjugation of magnetic microspheres with FIV-specific capsid (CA) or envelope 
surface glycoprotein (SUC36-Fc) recombinant proteins [51, 60].  Following conjugation protocols, 
a hemocytometer was used to determine microsphere concentrations, and protein coupling was 
confirmed via incubation of microspheres with primary antibodies and/or PE-conjugated 
detection antibodies [51].  Successful coupling was determined by a median fluorescence 
intensity (MFI) of >2,000.  All saliva samples from FIV-infected and negative control cats were 
diluted 1:10 in assay buffer and then incubated in duplicate with approximately 2,500 
conjugated beads per well. All samples were assayed in conjunction with FIV-C and naïve 
reference samples diluted 1:50 in assay buffer, as well as four diluent control wells per 
experiment. The MFI was calculated from ≥100 microspheres per analyte per well (Bio-Plex™ 
Manager 5.0) and then used for data analysis.  All reagent concentrations, volumes, incubation 
times, acceptable standard recovery, and data analysis were as previously described [51, 60].  
In vitro salivary inhibition of viral infection 
Approximately 80μl of saliva was obtained from each of 6 healthy, non-infected SPF 
cats, and was pooled and used in same day in vitro experiments. Duplicate cell cultures 
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consisting of GFox cells (CrFK cells overexpressing CD134) were established in 24-well plates 
at 180,000 cells/well and allowed to attach at 37°C overnight [53, 56].  GFox cell cultures were 
grown at 37°C in 5% CO2 in culture medium composed of Dulbecco's modified Eagle's medium 
(DMEM) with GlutaMAX-1, 10% fetal bovine serum (FBS), and 1x penicillin-streptomycin 
(10,000 U/liter penicillin and 10,000 μg/liter streptomycin), as well as 1 μg/ml of Fungizone® 
(Amphotericin B; Life Technologies) [57]. At day 0, 50,000 TCID50 of FIVC36 was incubated with 
varying dilutions of saliva (1:100, 1:50, or no saliva (positive control)) in 1 ml of fresh culture 
media for 1 hour at 37°C [61].  Following incubation, infected media was pipetted onto Gfox 
cells plated in 1 ml of culture media, bringing the total volume in each well to 2 ml.  Cell cultures 
were then incubated at 37°C for 12 hours, at which point all culture media was removed from 
each well, discarded, and replaced with 2ml of fresh culture media. At days 4, 6, 8 and 10 post-
inoculation, 1ml of supernatant was removed from each well, frozen at -80°C, and replaced with 
1 ml of fresh culture media.  The supernatant collected from each well and each time point was 
then assayed for the detection of FIV p26 antigen by capture ELISA, measured at an 
absorbance of 450nm in 96-well flat bottom plates as previously described [58].  Percent 
inhibition was calculated from mean absorbance values (Abs) using the formula [(X − Y)/X] × 
100, where X is fraction of cells infected in the absence of saliva (positive control) and Y is the 
fraction of cells infected in the presence of the saliva (1:100 or 1:50 saliva) [62].  For each plate, 
a parallel set of wells containing cells without virus was incubated with corresponding dilutions 
of saliva (1:100, 1:50, or no saliva (negative control)). GFox cells were visually inspected at 
days 4, 6, 8, and 10 post-inoculation by inverted light microscopy for evidence of cell growth, 
attachment, syncytial cell formation, detachment, and cell death. 
Statistical Analyses 
Kruskal–Wallis test, Pearson correlations, ANOVA, and repeated-measures ANOVA (RM-
ANOVA) were used to compare differences in salivary viral and/or proviral load among FIV-
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infected individuals, between sample type (saliva, plasma/PBMC), for each tissue individually, 
and between tissue types (lymphoid versus mucosal).  RM-ANOVA was used to assess 
antibody responses over time and treatment after log10-transformation. For in vitro experiments, 
RM-ANOVA with multiple comparisons was used to evaluate differences in mean absorbance 
values and percent inhibition among treatment groups over time.  For all significant results, pair-
wise comparisons were made by post-hoc analysis.  Analyses were conducted in R 
(http://www.r-project.org/) or using GraphPad Prism 6.0 software (La Jolla, CA).  P-values 
< 0.05 were considered significant. 
Results 
FIV viral RNA and proviral DNA is present in saliva of infected cats   
Cats infected with FIVC36 experienced plasma viremia, CD4/CD8 inversion and other 
clinical signs typically associated with acute pathogenic FIV infection [50]. Quantitative PCR 
analysis of saliva from FIV-infected cats revealed levels of viral RNA equivalent to that of 
plasma, with a trend for salivary viral load to be higher than plasma viremia over time (source 
p=0.119, interaction p=0.165, Fig 1.1A). Although present in lower quantities, saliva from FIV-
infected cats also contained detectable quantities of proviral DNA (Fig 1.1B).  Concurrent 
analysis of housekeeping gene GAPDH in saliva indicated that cellular DNA was abundant in 
saliva, was used as a proxy to determine cell equivalents per ml of saliva (range 3.19x105-
8.72x106 cells/ml), and allowed us to calculate proviral DNA copies per saliva cell equivalent.  
FIV DNA levels tended to be approximately 10-fold lower in saliva than in peripheral PBMCs, 
although this trend did not differ over time (source p=0.024, interaction p=0.214). Interestingly, 
when DNA proviral and RNA viral loads were normalized to the number of copies per 1ml of 
saliva, the ratio of FIV RNA to DNA in saliva of infected cats was significantly higher over time 
than in the peripheral circulation, suggesting the oral cavity is an important site for persistent 
and enhanced FIV replication relative to peripheral circulation (source p=0.001, interaction 
p=0.036, Fig 1.1C).  
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Fig 1.1.  FIV viral RNA and proviral DNA are detected in saliva of infected cats. (A) Mean FIV viral 
RNA in saliva of infected cats is greater than observed in plasma (Mean: 446,000 copies/ml saliva, 
85,100 copies/ml plasma). There is a trend (p=0.165) for salivary viral load to be higher than plasma over 
the course of the study (RM-ANOVA). (B) Proviral DNA is present in saliva of infected cats, although 
levels tended to be 10-fold lower than circulating PBMC (p=0.214; RM-ANOVA). (C) The ratio of FIV RNA 
to DNA is significantly higher in saliva than circulating levels in blood over the entire study (p=0.036) and 
at each time point measured (day 43, p=<0.001; day 64, p=0.014; RM-ANOVA with multiple 
comparisons). (D) Saliva from FIV-infected cats contains infectious FIV virus, as evidenced by FIV 
replication in GFox (CRFK) cells and the production of FIV viral particles following inoculation of saliva 
(day 21 post-inoculation, positive Cutoff = Mean Naïve Abs + 3*SD). 
FIV is recovered from saliva of infected cats   
The presence of infectious virus in saliva was confirmed by FIV p26 ELISA of tissue 
culture supernatants collected from GFox cells incubated for 21 days with saliva from 5 FIV-
infected cats collected at 28 days post-FIV-infection (Fig 1.1D) [56].  Cells from infected cultures 
also exhibited characteristic cytopathic effect at this timepoint. This collection point correlated 
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with high plasma viremia in FIV-infected cats [50], and confirms results reported by Matteucci et 
al. in 1993 [45] that infectious FIV is present in saliva of infected cats.  FIV-negative saliva 
collected from sham-inoculated (naïve) cats was included as a negative control.  
 
Fig 1.2. FIV RNA and DNA in oral lymphoid tissues is significantly higher than levels in non-
lymphoid oral tissues. (A) FIV RNA levels in oral lymphoid tissues (retropharyngeal LN and tonsil) are 
significantly higher than non-lymphoid oral tissues (tongue, buccal mucosa, salivary gland) (p<0.0001), 
suggesting that oral lymphoid tissues serve as the site of viral replication and release into saliva. (B) FIV 
proviral DNA levels in oral lymphoid tissues are not as high as in circulating PBMC, but are significantly 
greater than in non-lymphoid tissues (p<0.0001), indicating that lymphoid organs may serve as oral 
reservoirs of FIV latency and persistence. 
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FIV viral and proviral loads are higher in oral lymphoid tissues   
The retropharyngeal lymph node, tonsil, tongue, buccal mucosa, and salivary gland of 
FIV-infected cats contained appreciable quantities of viral RNA (Fig 1.2A). FIV RNA present 
within oral lymphoid tissues (retropharyngeal lymph node, tonsil) was significantly higher than 
oral mucosal tissues (p<0.001; tongue, buccal mucosa, salivary gland). Proviral DNA was also 
detected in all oral tissues, and oral lymphoid tissues contained significantly more FIV DNA than 
oral mucosal tissues (p<0.001) (Fig 1.2B), however, the quantity of FIV DNA in oral lymphoid 
tissues and mucosal tissues was lower than in circulating PBMC (p<0.001).  Viral RNA and 
proviral DNA were not detected in the saliva or oral tissues from naïve animals (data not 
shown). 
FIV infection induces pathological changes in oral tissues   
All tissue sections from a sham-inoculated control animal were histologically 
unremarkable (Fig 1.3A). Of the 16 FIV-infected animals, the retropharyngeal lymph node 
(n=10) (Fig 1.3B) and the palatine tonsil (n=11) (Fig 1.3C) exhibited mild to moderate lymphoid 
hyperplasia, characterized by multifocal enlarged germinal centers with thin mantle zones and a 
frequent “starry-sky” appearance due to numerous tingible body macrophages. Eight FIV-
infected individuals exhibited mild (n=7) to moderate (n=1) lymphoplasmacytic and histiocytic 
glossitis.  In three of these animals, the submucosa was multifocally expanded by mild to 
moderate numbers of mast cells (Fig 1.3D).  Additionally, 4 FIV-infected animals had a mild, 
multifocal, lymphoplasmacytic stomatitis of the buccal mucosa, with scattered mast cell 
infiltration observed in the same 3 animals in which the tongue was similarly affected (Fig 1.3E). 
Small numbers of scattered small lymphocytes and plasma cells were occasionally observed at 
the periphery and surrounding individual acini of the salivary glands in 7 of the FIV-infected cats 
(Fig 1.3F).  Overall, the degree of histologic change in oral lymphoid tissues (retropharyngeal 
lymph node and tonsil) was significantly higher than in non-lymphoid tissues (tongue, buccal  
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Fig 1.3.  FIV induces mild to moderate pathology in oral tissues.  (A) Retropharyngeal lymph node. 
Sham-inoculated control, HE stain, 40x. (B) Retropharyngeal lymph node and (C) palatine tonsil from FIV-
infected cats exhibit moderate lymphoid hyperplasia with multifocally enlarged germinal centers and thin 
mantle zones, 40x.  Higher magnification (insets, 200x) demonstrates tingible body macrophages 
(arrows). HE stain. The submucosa of the tongue (D) and buccal mucosa (E) are multifocally infiltrated by 
small to moderate numbers of small lymphocytes and plasma cells (arrows, 100x), as well as small 
numbers of scattered mast cells (arrows, inset, 200x).  HE stain.  (F) Submandibular salivary gland.  
Minimal numbers of small lymphocytes and plasma cells multifocally surround acini (arrowheads). HE 
stain, 400x.  
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mucosa, and salivary gland; p<0.001, Fig 1.4).  Individually, the degree of histologic change in 
the retropharyngeal lymph node (p<0.001), palatine tonsil (p<0.001), and tongue (p=0.002) was 
significantly greater than in the salivary gland, and there were more histologic changes in the 
retropharyngeal lymph node compared to the buccal mucosa (p<0.001) (Fig 1.4). 
 
Fig 4. Oral lymphoid tissues exhibit a greater degree of histologic change than non-lymphoid 
tissues. The degree of histologic change in oral lymphoid tissues (retropharyngeal lymph node and 
tonsil) was significantly higher than in non-lymphoid tissues (tongue, buccal mucosa, and salivary gland) 
(p<0.001). The degree of histologic change was significantly greater in the retropharyngeal lymph node 
(p<0.001), palatine tonsil (p<0.001), and tongue (P=0.002) than in the salivary gland.  A greater degree of 
histologic change was also observed in the retropharyngeal lymph node compared to the buccal mucosa 
(p<0.001) (ANOVA with Tukey test for multiple comparisons). 
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FIV-specific IgG increases in saliva of FIV+ cats, while IgA remains static   
Saliva samples were collected from FIV-infected and negative control cats at four time 
points, and total IgA and IgG antibodies from saliva were quantified by microsphere 
immunoassay (MIA).  The concentration of total IgG in FIV-infected cat saliva ranged from 0.001 
to 0.037mg/ml over the course of infection, while the total IgA concentration in FIV-infected cat 
saliva ranged from 0.005 to 0.026mg/ml. There was a slight trend for total salivary IgG to be 
increased in FIV-infected cats compared to naive individuals (treatment p=0.216), however, total 
IgA antibody levels did not differ in saliva from FIV-infected and sham-inoculated cats (treatment 
p=0.999) (Fig 1.5).  FIV-specific anti-SU and anti-CA IgG antibodies were consistently detected 
in saliva of FIV-infected cats and increased significantly over time (anti-SU interaction p<0.001; 
anti-CA interaction p<0.05, Fig 1.6A-B).  Although anti-SU IgA antibodies were elevated in 
saliva from FIV-infected cats (treatment p<0.05, Figure 1.6C), they did not increase over time 
compared to the background of uninfected saliva (interaction p=0.569). Furthermore, anti-CA 
IgA antibodies were not significantly elevated in FIV-infected saliva (treatment p=0.809, Fig 
1.6D).   
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Fig 1.5.  Limited IgA mucosal antibody response during FIV infection. There is a trend for salivary 
IgG concentrations to be slightly increased in FIV-infected cats following infection (solid blue line/squares) 
(mean ±SE; p=0.216, RM-ANOVA). Salivary IgG remained constant in naïve animals (blue dashed 
line/clear squares). Salivary IgA concentrations did not differ significantly between FIV-infected cats (solid 
green line/circles) and naïve cats (dashed line/clear circles) over time (p=0.969), but as expected, levels 
of IgA were higher in saliva than IgG. 
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Fig 1.6:  FIV specific IgG and IgA antibodies are detected in saliva of infected cats.  (A) Anti-SU IgG 
and (B) anti-CA IgG antibody levels in saliva of FIV infected cats (solid blue lines) were significantly 
elevated (mean ±SE; treatment p<0.01 and p<0.001, respectively, ) compared to naïve animals (dotted 
blue lines) and increased significantly over time  compared to naïve saliva (interaction anti-CA: p<0.05; 
anti-SU: p<0.001; RM-ANOVA). (C) Anti-SU IgA antibody levels in saliva of FIV infected cats (solid green 
lines) were significantly elevated compared to naïve animals (dotted green lines)(treatment p<0.01), but 
did not increase significantly over time compared to naïve saliva (interaction p=0.569; RM-ANOVA). (D) 
No difference in salivary anti-CA IgA antibody levels was observed between FIV-positive animals and 
naïve animals.   
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Saliva exhibits an inhibitory effect on FIV infection in vitro  
Naïve cat saliva significantly inhibited FIVC36 growth in GFox cells (CrFK cells overexpressing 
feline receptor CD134) over time, indicated by lower FIV p26 ELISA absorbance values in the 
presence of saliva (interaction p<0.001, Fig 1.7A). Percent viral inhibition compared to no-saliva 
controls differed significantly over time, peaking at 8 days post-inoculation and declining slightly 
thereafter (interaction p<0.05, Fig 1.7B). 
 
Fig 1.7.  Naïve cat saliva inhibits FIV replication. FIVC36 was incubated with 1:50 or 1:100 dilutions of 
naïve cat saliva in duplicate and inoculated onto CRFK cultures as described in the text.  A ‘No Saliva’ 
virus-only positive control represented 100% FIV growth as measured by ELISA absorbance.  (A) Mean 
	 50 
ELISA absorbance values increased for all treatments except for virus-negative control (blue-checkered 
bars). Absorbance values for FIV pre-incubated with saliva at both 1:100 and 1:50 dilutions were 
significantly lower (p<0.001; RM-ANOVA) than the no saliva control (gray-striped bars), indicating a lower 
FIV replication rate in the presence of saliva. (B) Analysis of percent inhibition over time revealed a 
significant inhibitory effect with saliva treatments differing over time (p<0.05; RM-ANOVA) and at 
individual time points (days 4, 8 post-inoculation) relative to the ‘No Saliva’ virus-only positive controls. 
Discussion 
Our findings document that: (1) FIV infection predominates in oral lymphoid tissues 
versus mucosal and salivary gland, resulting in mild to moderate histologic pathology (Figs 1.2-
1.4,), and provide evidence of a site of viral persistence and chronic immune dysregulation; (2) 
FIV viral RNA ratio to proviral load, a surrogate for viral replication rate, is significantly higher in 
saliva than in plasma/circulating PBMC (Fig 1.1C), suggesting enhanced FIV replication occurs 
at a site where viral shedding is thought to take place; (3) though FIV-specific IgG antibodies 
increase in saliva during infection, secretion of FIV-specific IgA in saliva is impaired (Figs 1.5-
1.6), suggesting one potential mechanism for chronic oral infection, the development of 
opportunistic oral disease, and transmission of FIV via oral secretions;  and, (4) saliva from 
uninfected SPF cats harbors in vitro anti-viral properties (Fig 1.7), which may be an important 
mechanism for limiting ‘passive’ FIV transmissions among FIV-infected and uninfected cats in 
stable social structures.   
Collectively, these data provide a descriptive analysis of viral, immunological, and 
pathogenic features of oral FIV infection, and highlight a continuum between salivary and 
peripheral viral kinetics that is represented in Fig 1.8.  Initial events of FIV infection occur 
systemically, resulting in peripheral lymphocyte infection, viremia, and an anti-FIV antibody 
response in which IgG antibodies predominate over IgA [39, 51, 52, 63].  During HIV and SIV 
infection, CD4+ T-cells are rapidly infected and severely depleted from the intestinal mucosal 
surface, resulting in loss of mucosal integrity, reduced capacity to control potential pathogens at 
mucosal surfaces, and subsequent triggering of pro-inflammatory responses [25, 26, 28, 29, 31, 
32]. Comparatively, we demonstrate that FIV exhibits a significant tropism for oral lymphoid 
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tissues, which may potentially serve as initial sites for circulating virus to infect resting T-
lymphocytes and dendritic cells (Fig 1.8A).  As an extension of the digestive tract, similar effects 
of viral-induced immunosuppression may likely occur at the oral mucosa, resulting in a chronic 
cycle of lymphocyte depletion, microbial translocation, immune stimulation, and leukocyte 
recruitment and consequent infection (Fig 1.8B), as evidenced by FIV accumulation and 
histologic changes in oral tissues.   
 
Fig 1.8. Proposed model of oral FIV pathogenesis. Similar to the gastrointestinal tract, FIV exhibits a 
tropism for oral tissues, providing a pathway for circulating virus to extravasate and infect resting T-
lymphocytes (rT) and dendritic cells (DC).  (A) As documented in the intestinal mucosa, infection and 
depletion of resting mucosal lymphocytes in the oral mucosa may cause inflammation, damage mucosal 
barriers, and subsequent translocation of oral microbes; resulting in lymphocyte activation and 
recruitment to oral mucosal tissues. (B) Mucosal injury initiates a chronic cycle of immune activation and 
provides a renewable source for target cell infection by recruiting susceptible cells to the site of injury. 
Peripheral FIV-infected cells traffic to oral lymphoid tissue via lymphatics (C) or direct migration to tonsils 
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(D) resulting in antigen presentation, T-lymphocyte activation (aT), and infection of resident leukocytes, 
establishing a reservoir of persistent FIV replication in latently infected T-lymphocytes (iT) in oral lymphoid 
tissues.   (E) FIV infected cells are likely shed from oral mucosal sites into saliva, resulting in the 
presence of salivary proviral DNA. Cells within oral lymphoid tissues have enhanced FIV replicative 
activity, resulting in a higher ratio of FIV viral RNA to proviral DNA than noted in the peripheral circulation.  
(F) FIV RNA in saliva may be achieved by direct release of virus particles from infected cells into saliva 
via the intimate association of tonsillar lymphoid tissue with the oral mucosa. (G) While FIV specific IgG 
responses are detected in saliva, anti-FIV IgA antibodies are not specifically enhanced, allowing FIV virus 
and infected cells to persist in saliva at high levels. 
FIV virus particles and/or infected cells traffic to oral lymphoid tissues via circulation (Fig 
1.8C) or by direct migration to the tonsils from the oral mucosa (Fig 1.8D), subsequently 
infecting resident leukocytes and establishing a reservoir of persistent FIV replication in latently 
infected T-lymphocytes within oral lymphoid tissues.  Viral RNA and proviral DNA are also 
detected in non-lymphoid oral tissues, but at a much lower quantity than in lymphoid tissues, 
indicating that these sites (tongue, buccal mucosa, salivary gland) are not a primary site of FIV 
persistence.  However, accumulation of proviral DNA in these tissues suggests that passive 
migration of FIV-infected cells may occur from the periphery to non-lymphoid oral tissues, which 
may then perpetuate FIV-infection at these sites. 
Although detectable, the quantity of FIV DNA is lower in saliva than in circulating 
PBMCs, and reflects the concept that the FIV-infected cells being shed into saliva may be shed 
via the oral mucosal epithelium in lieu of oral lymphoid reservoirs (Fig 1.8E), which contain 
larger amounts of FIV proviral DNA.  In contrast, FIV RNA appears later in saliva than in plasma 
[63], but salivary FIV RNA concentration is equivalent to plasma, and FIV RNA is present in high 
quantities in oral lymphoid tissues (Fig 1.1). Our finding that FIV RNA is proportionally higher 
(compared to proviral load) in saliva than in plasma suggests that the oral cavity is a preferential 
site for viral RNA transcription.  The observed predilection of FIV for oral lymphoid tissues 
indicates that these tissues may serve as an important reservoir and primary source of viral 
replication and shedding of viral RNA into the saliva (Fig 1.8F).  Systemic hyperplasia of 
lymphoid structures is a prominent feature of FIV infection, and the histologic changes observed 
support an analogous impact on oral lymphoid tissues; thus supplying an ample source of target 
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cells for persistent FIV replication [39, 64-66]. Moreover, the anatomic distribution of the 
palatine, paraepiglottic, pharyngeal and lingual tonsils provides an intimate association with the 
overlying oral mucosa, and highlights the potential for these organs to serve as sites of 
extrusion of FIV into saliva through trafficking of infected cells across the adjacent mucosal 
epithelium [67].  
 IgA represents the primary mucosal antibody that limits numbers of mucosa-associated 
bacteria and prevents bacterial penetration of host tissues.  This is best demonstrated by IgA 
deficiency, which results in increased penetration of symbiotic bacteria into the host tissues and 
consequent inflammation [68-71].  In the oral cavity and gastrointestinal tract, differentiated 
plasma cells secrete IgA, which then transcytoses across the epithelial layer to the apical 
surface of the epithelium where it works to crucially maintain homeostasis through luminal 
compartmentalization of intestinal bacteria [68].  However, during FIV infection, IgG antibodies 
increase in saliva and in the peripheral circulation of infected cats [51], but the IgA antibody 
response remains static at both of these sites.  Furthermore, FIV-specific IgA antibodies against 
capsid are undetectable in saliva, and anti-SU IgA does not increase over time.  In contrast, 
both anti-SU and anti-CA IgG antibodies increase significantly in saliva during FIV infection 
(Figs 1.6B and 1.8G). These results indicate a failure to mount an effective mucosal antibody 
response during FIV infection, which may perpetuate oral mucosal viral infection as well as 
changes in the oral microbiome, thus contributing to microbial translocation and a cycle of 
immune dysfunction. 
Currently, FIV infection is diagnosed clinically by either lateral-flow serum ELISA or 
microwell, and western blot and immunofluorescent antibody (IFA) assays are frequently used 
as confirmatory tests following positive ELISA results [72].  Unfortunately, these assays require 
blood samples to screen for serum FIV-specific antibodies, which may be impractical to acquire 
in intractable patients, or during field operations to capture and control the feral cat population.  
The presence of anti-FIV IgG antibodies in saliva suggests that a reliable alternative diagnostic 
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assay can be developed based upon saliva sampling, and may allow for methods to differentiate 
between vaccinated and un-vaccinated cats as previously suggested by Wood et al. [51].  
Microsphere immunoassay technology or other sensitive antibody detection assays may be of 
great use in clinical applications to test for FIV in a less invasive manner, as these assays only 
require passage of an oral swab along the interior of the oral cavity.  Furthermore, optimization 
to detect FIV in saliva may be directly adapted to test human saliva for HIV without the need for 
blood sampling, thus increasing the capacity to screen large numbers of patients in endemic 
areas. 
Results of this study demonstrate that uninfected feline saliva contains a component with 
anti-FIV properties, a feature that may have implication for FIV transmission in natural settings.  
Prolonged contact between animals is typically required for transmission of FIV, and feral male 
cats are most at risk for FIV infection. Numerous studies have indicated that horizontal 
transmission through casual contact such as grooming is extremely inefficient and rarely occurs 
in the absence of biting, i.e. amongst cats maintained indoors or in stable groups [47, 73-75]. 
Our findings suggest that cats which groom each other may be less susceptible to FIV 
transmission via fomites and cat to cat oral contact because of unidentified innate factors in 
saliva, which inhibit infection via the oral route.  While experimental transmission studies have 
documented potential for oral transmission by inoculation of virus into the oral cavity [76, 77], 
these studies provided an artificially high dose of concentrated virus, which would be an unusual 
situation to encounter in a natural transmission setting.  
Previous studies in humans infected with HIV have demonstrated that significant anti-
viral activity in human saliva is conferred by numerous cofactors and immune modulators, such 
as anti-HIV antibodies, defensins, thrombospondin-1, proline-rich proteins, salivary agglutinin, 
and secretory leukocyte protease inhibitor (SLPI) [14, 15].  It is possible that naïve feline saliva 
may confer anti-viral activity in vivo by similar mechanisms and effector molecules.  However, 
the capacity of FIV to be transmitted via saliva despite its potential inhibitory properties may 
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indicate alterations in the composition of saliva in infected cats, or perhaps other viral-induced 
mechanisms by which FIV may overcome these inhibitory effects. Further investigation is 
warranted to determine whether feline saliva contains inhibitory molecules similar to those in 
human saliva and how the composition of feline saliva changes following FIV infection.   
Although HIV transmission typically occurs via parenteral or transmucosal venereal 
routes, recent epidemiological studies have provided definitive evidence that HIV can be 
transmitted by receptive oral intercourse, and occasional cases of transmission by biting have 
been documented [7-13].  Furthermore, significant quantities of both HIV viral RNA and proviral 
DNA have been detected in saliva of infected individuals, with significant correlations between 
salivary and plasma RNA levels [16, 17]. Oral HIV transmission occurs less frequently than in 
FIV transmission, likely due to the absence of aggressive biting in human populations versus cat 
populations [7, 11, 21, 78]. The use of SIV animal models has provided further proof that oral 
transmission of primate lentiviral infections is possible, and experimental SIV studies have 
helped to understand the oral immune response during infection [13, 79-81].  Moreover, 
retroviral-induced oral disease continues to affect a high proportion of individuals despite the 
success of highly active antiretroviral therapy (HAART), and is a common manifestation of both 
HIV and FIV infection [38, 41-43, 76].  Oral lesions are not typically observed during SIV 
infection and may highlight significant limitations of the SIV model to study HIV-induced oral 
disease [82, 83]. In contrast, FIV produces oral lesions in cats that closely resemble Linear 
Gingival Erythema and Necrotizing Ulcerative Gingivitis in humans with HIV-induced disease, 
and opportunistic microorganisms detected in saliva of HIV-positive individuals (Candida 
albicans, Fusobacterium sp., Streptococcus sp., Prevotella sp., Campylobacter sp., and 
Porphyromonas gingivalis) are also implicated in feline oral disease [1, 6, 31, 38, 39, 41-43, 47, 
84-88].  Indeed, shifts in oral microbial structure during HIV and FIV infection have been 
increasingly linked to disease phenotypes, and the use of a feline animal model is a pragmatic 
solution to assess the impact of novel therapeutic strategies [1, 25, 38, 41, 84, 86, 89, 90]. An 
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effective anti-HIV vaccine or prophylactic therapeutic agent that will cure or prevent HIV 
infection will likely need to function at the mucosal surface, and FIV provides a relevant animal 
model that might be exploited to specifically assess oral mucosal lentiviral disease and 
interventions [13, 91, 92]. 
The results of this study provide new evidence for unique pathogenic features of oral FIV 
infection and suggest mechanisms that overcome host resistance. Manipulation of constituents 
of saliva, inhibition of viral replication at oral lymphoid sites, or enhancement of anti-viral IgA 
production may represent novel therapeutic interventions to reduce or eliminate oral FIV 
infection, as well as the potential to treat HIV-induced oral disease. Our results additionally 
provide a plausible hypothesis linking site-specific viral replication, mucosal immune deficiency, 
and salivary inhibition to the natural transmission and infection cycle of FIV. 
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Feline immunodeficiency virus (FIV) is the feline analogue to human immunodeficiency 
virus (HIV) and utilizes parallel modes of receptor-mediated entry. The FIV surface glycoprotein 
(SU) is an important vaccine target for induction of virus neutralizing antibodies, and 
autoantibodies to the FIV binding receptor (CD134) block FIV infection ex vivo; highlighting the 
potential for immunotherapies which utilize anti-receptor antibodies to block viral infection. To 
determine if vaccination with CD134-SU complexes could induce protection against FIV 
infection, cats were immunized with soluble CD134, recombinant FIV-SU protein, and/or 
CD134+SU complexes prior to challenge with FIV. In vivo generation of anti-CD134 and anti-SU 
IgG antibodies was measured by microsphere immunoassay (MIA), and neutralizing ability of 
antibodies and antibody-containing serum fractions was quantified in vitro.  Post-challenge FIV 
RNA and DNA levels and hematologic alterations were measured for evidence of vaccinal 
success.  Immunization induced production of anti-CD134 and anti-SU antibodies in vaccinated 
cats, and purified anti-CD134 and anti-SU antibodies significantly inhibited FIV infection in vitro.  
However, no vaccine combination protected cats from FIV infection in vivo, and neat serum from 
vaccinated cats enhanced FIV growth in vitro.  Prior to challenge, CD134+SU vaccinated cats 
exhibited an enhanced CD4:CD8 ratio, and vaccination induced high titers of antibodies directed 
at vaccine by-products relative to target antigens. Results suggest that vaccination against viral 
and cryptic receptor epitopes yields neutralizing antibodies that synergistically inhibit FIV 
infection in vitro.  Factors that may have contributed to vaccine failure include: (1) Heat-labile 
serum factors that enhance viral replication, (2) changes in circulating target cell populations 
and/or vaccine-induced immunomodulation, and (3) weak immunogenicity of neutralizing 
epitopes compared to off-target vaccine components.  Results reinforce the need to monitor 
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vaccine components, and emphasize that vaccination may induce expansion of target cells and 
enhancement of heat-labile serum components that counteract neutralizing antibodies.  
Background 
Feline immunodeficiency virus (FIV) is a naturally-occurring lentivirus that is genetically 
similar to human immunodeficiency virus (HIV) and shares many immunopathogenic features of 
HIV infection [1-6].  Like HIV, FIV primarily infects and replicates within CD4+ T cells, and is 
characterized by progressive depletion of CD4+ T lymphocytes and an AIDS-like syndrome 
during natural infection of domestic cats [7-9]. Both lentiviruses require an initial interaction with 
a primary binding receptor for infection, and utilize analogous modes of receptor-mediated entry 
via the chemokine co-receptor, CXCR4 [10-12]. HIV binds to CD4+ target cells through a high-
affinity interaction with the CD4 receptor that induces a conformational change in the envelope 
glycoprotein gp120 to expose binding sites necessary for chemokine co-receptor binding 
(CXCR4 or CCR5) and subsequent fusion with the cell membrane (Figure 2.1A) [10, 11]. FIV 
utilizes CD134 as primary binding receptor, and studies have demonstrated that binding of the 
CD134 receptor alters the conformation of FIV envelope protein gp95 (SU) in a similar fashion 
to that which occurs in the CD4/ HIV gp120 interaction, to promote high affinity binding with the 
entry receptor CXCR4 (Figure 2.1A) [13, 14].  
 Since the discovery of FIV, considerable effort has been directed at the development of 
safe vaccine strategies that can produce protective immunity in cats.  A commercially available, 
whole inactivated virus vaccine containing two FIV subtypes (Fel-O-Vax FIV®) is currently 
licensed for use in the United States, and various reports have described virus neutralization 
and cellular immunity in a significant proportion of study animals [15-17].  However, the efficacy 
of this vaccine is still under debate, as recent studies and field evaluations have reported that 
the vaccine does not confer immunity against certain FIV strains (ie: FIVGL8), and that the 
neutralizing antibody response and protective rate may be low in certain cat populations (i.e. 
 65 
protection is not conferred to certain virulent recombinant strains of FIV) [18-21].  Other 
attempts at FIV vaccine development have either failed to induce protective immunity against 
FIV infection, or have resulted in increased susceptibility to infection via antibody-dependent 
enhancement or general immune activation [22-27].  Thus, the development of novel 
immunotherapies aimed at preventing viral entry may have great potential to increase the level 
of protection against naturally-occurring FIV infection. 
 
Figure 2.1. (A) FIV and HIV utilize analogous modes of receptor-mediated cell entry. HIV binds to 
CD4+ target cells through a high-affinity interaction with the CD4 receptor, inducing a conformational 
change in the envelope glycoprotein gp120 (SU) that exposes the CXCR4 co-receptor binding site and 
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subsequent fusion with the cell membrane. FIV utilizes a primary receptor CD134, and similar to HIV, 
binding of FIV Env to the CD134 receptor alters the conformation of envelope glycoprotein gp95 surface 
(SU) component to facilitate CXCR4 co-receptor binding, and viral entry. (B) Anti-CD134 antibodies 
prevent FIV infection in the presence of viral glycoproteins. Binding of FIV SU to CD134 induces a 
conformational change in the receptor and exposes a cryptic epitope that results in anti-CD134 
generation. Anti-CD134 antibody binding to CD134 cause a second conformational change in the CD134 
receptor that displaces SU from the cell surface, inhibiting FIV infection [28]. 
Previous studies by Grant et al. [28] reported that antibodies to the CD134 receptor 
(anti-CD134) and the viral surface glycoprotein (anti-SU) are expressed in a high proportion of 
chronically FIV-infected cats, and that increased levels of anti-CD134 are correlated with lower 
viral loads and improved health status in these animals [28].  Furthermore, anti-CD134 
antibodies purified from serum of infected cats have been shown to exhibit significant 
neutralizing activity and are able to block FIV infection ex vivo [28]. This activity is related to 
binding of FIV SU to CD134 on the target cell, inducing a conformational change that exposes a 
cryptic epitope of CD134 that is recognized and blocked by feline anti-CD134 [28]. Binding of 
anti-CD134 autoantibodies to CD134 causes a second conformational change in the CD134 
receptor and results in displacement of SU from the cell surface (Figure 2.1B), demonstrating 
an active contribution of anti-receptor antibody responses to controlling viral infection [28]. 
Parallel mechanisms of cell entry are also observed in HIV infection, whereby neutralizing 
epitopes are exposed following interaction of SU with the CD4 binding receptor [29-33].  Thus, 
the analogous modes of receptor-mediated viral entry that exist between FIV and HIV likely 
reflect common immunological pressures in the two hosts, and may indicate a convergent 
pathway for the development of strategies to compromise the virus' ability to escape immune 
surveillance [2]. 
Such propensity for anti-CD134 and anti-SU antibodies to block FIV infection ex vivo, 
coupled with the increased survival of cats expressing high levels of anti-CD134 antibodies, 
highlights the potential for novel immunotherapies which utilize anti-receptor antibodies to 
protect from viral infection. In the present study, we assessed the potential for immunization with 
soluble CD134 and FIV-SU complexes (CD134+SU) to induce a neutralizing antibody response 
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and protection against FIV infection in domestic cats.  Our results demonstrate that 
immunization with soluble CD134 and recombinant SU protein induces production of anti-
CD134 and anti-SU antibodies, and that these antibodies significantly inhibit FIV infection in 
vitro.  However, vaccinated cats became infected following FIV challenge, and vaccination 
altered circulating cell populations with potential consequences for subsequent infection.  
Furthermore, antibodies were generated against irrelevant antigens in the vaccine preparation 
at levels that significantly exceeded antibodies produced in response to target antigens. This 
study highlights potential targets and requirements for vaccine optimization for anti-receptor and 
anti-immunodeficiency virus development. 
Materials and methods 
Vaccine Design 
Two vaccine trials were conducted to test whether addition of Fe-CD134 antigen to the 
vaccine preparation would augment the efficacy of a vaccine that contained only FIV-Env.  
Phase I vaccine trial included immunization with soluble CD134-huFc and FIV-PPR-SU-huFc 
immunoadhesins, either alone or together as a complex.  These proteins were expressed in and 
purified from Chinese hamster ovary (CHO) cells as previously described [34], and the human 
Fc tag, in-frame with either protein, served as a means to purify the proteins using 
Staphylococcus Protein A-Sepharose [13, 35].  Phase II vaccine trial employed soluble, His-
tagged CD134 and FIV-PPR-SU derived by expression and purification from human 293S T 
cells. Soluble feline CD134 (aa28-215) with a C-term 6X histidine tag, and FIV-PPR-SU (aa170-
601) were cloned into pCMV mammalian expression vectors (Life Technologies, Carlsbad, CA) 
and transfected into human 293S T cells using Lipofectamine 2000 (Life Technologies). His-
CD134 (CD134-293S) was purified by nickel chromatography and untagged PPR- SU (PPR-
SU-293S) was purified using Galanthus lectin-sepharose (Vector Laboratories, Burlingame, CA) 
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from supernatants of 293S cells grown in defined serum-free medium (FreeStyle medium, 
Invitrogen).   
In vivo protocols  
This study was approved by the Colorado State University Institutional Animal Care and 
Use Committee; 14-4872A - Molecular Characterization of FIV.  Colorado State University's 
animal care program is licensed by the United States Department of Agriculture (USDA), 
accredited by Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) International, and holds an Office of Laboratory Animal Welfare (OLAW) assurance 
(A3572-01).  All animal experiments complied with the National Institutes of Health guide for the 
care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). Prior to 
experimental procedures, all study animals were anesthetized by intramuscular injection of 
ketamine (20mg/kg) and acepromazine (2mg/kg) to minimize animal suffering and distress. All 
study animals were monitored daily by animal care personnel for development of clinical signs 
of FIV infection and observed by clinical veterinarians. No animals exhibited clinical signs 
associated with FIV infection or any other untoward conditions during vaccine and challenge 
experiments.  
Phase I.  Fifteen (15), 8-11 week-old specific pathogen free (SPF) cats (Andrea D. Lauerman 
Specific Pathogen Free Feline Research Colony, Fort Collins, CO) were housed within barrier 
rooms in accordance with Colorado State University (CSU) IACUC-approved protocols at a 
CSU AAALAC-international accredited animal facility, and were acclimated to the facility for 2 
weeks prior to the initiation of the study.  An outline of the study design for Phase I is presented 
in Figure 2.2A.  At weeks 0, 4, and 8, all cats were subcutaneously inoculated with 1ml of 
vaccine composed of Dulbecco’s phosphate-buffered saline (D-PBS; Life Technologies 
Corporation, Grand Island, NY), 5mg of Alum (aluminum hydroxide, an adjuvant licensed for use 
in cats that induces significant humoral vs cellular immune responses), and one of the following 
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immunogens: (1) sham-vaccine (D-PBS and Alum only)(sham group; n=5); (2) PPR-SU-huFc 
peptide-immunoadhesion (SU-huFc group; n=5); and (3) FIV-PPR-SU-huFc peptide-
immunoadhesion complexed with soluble CD134 (CD134+SU-huFc group; n=5)).  At week 12, 
all fifteen cats were intravenously inoculated with 75,000 infectious units of FIVPPR (1ml of a viral 
stock solution with a TCID50 titer of 1X105.87).  Blood samples were obtained for all cats at 7-day 
intervals using previously established protocols, beginning at week 0 and ending at week 24 
[36, 37].  
Phase II.  Twelve (12), 8-11 week-old SPF cats (Andrea D. Lauerman Specific Pathogen Free 
Feline Research Colony, Fort Collins, CO) were housed as previously described above in 
accordance with CSU IACUC-approved protocols.  An outline of the study design for Phase II is 
presented in Figure 2.2B.  At weeks 0, 4, and 8, eight (8) cats were subcutaneously inoculated 
with 1ml vaccine composed of Dulbecco’s phosphate-buffered saline (D-PBS; Life Technologies 
Corporation, Grand Island, NY), 5mg of Alum, and 100µg of soluble CD134-293S.  The 
remaining 4 cats were inoculated with a sham vaccine composed of D-PBS and 5mg Alum.  At 
weeks 12 and 17, four cats that had previously received the vaccine containing soluble CD134-
293S were instead inoculated with a vaccine composed of D-PBS, 5mg of Alum, and 100ug 
PPR-SU-293S complexed with CD134-293S (CD134+SU-293S group; n=4).  The CD134-293S 
group (n=4) and sham group (n=4) were vaccinated as previously described at weeks 12 and 
17 (Figure 2.2B). Blood samples were collected from all cats using previously established 
protocols at 7-day intervals, beginning at week 0 and ending at week 24 [36, 37].  At week 20, 
all twelve cats were intravenously inoculated with 75,000 infectious units of FIVPPR (1ml of a viral 
stock solution with a TCID50 titer of 1X105.87). 
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Figure 2.2. (A) Phase I vaccine study design. (B) Phase II vaccine study design. 
Quantification of vaccine-specific IgG antibody production 
Evaluation of vaccine-specific antibodies was performed using previously established 
microsphere immunoassay (MIA) protocols involving conjugation of carboxylated magnetic 
microspheres (MagPlex® Microspheres, Luminex, Austin, TX) with FIV glycoprotein (SUPPR) and 
soluble CD134 recombinant proteins (rProteins) [38, 39].  Following conjugation protocols, a 
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hemocytometer was used to determine microsphere concentrations, and protein coupling was 
confirmed via incubation of microspheres with primary antibodies and/or PE-conjugated 
detection antibodies [38].  Successful coupling was defined by a median fluorescence intensity 
(MFI) of >2,000.  All samples from FIV-infected and negative control cats were diluted 1:50 in 
assay buffer and then incubated in duplicate with approximately 2,500 conjugated beads per 
well. All samples were assayed in conjunction with FIV-A and naïve reference samples diluted 
1:50 in assay buffer, as well as four diluent control wells per experiment. The MFI was 
calculated from ≥100 microspheres per analyte per well (Bio-Plex™ Manager 5.0) and then 
used for data analysis.  All reagent concentrations, volumes, incubation times, acceptable 
standard recovery, and data analysis were as previously described [38, 39]. 
Phase I.  Plasma samples from all study animals collected at weeks 4, 6, 8, 10, 13, 15, 18, and 
22 (Figure 2.2A) were evaluated by MIA to detect anti-CD134 and anti-SU IgG antibodies. To 
detect antibodies specific to CD134 and/or FIV-PPR-SU, and to limit interference and detection 
of background antibodies specific to the huFc tag used to purify the Phase I vaccine 
immunoadhesion peptides, alternate immunoadhesion molecules without huFc were purified 
from 293S cells (CD134-293S and FIV-PPR-SU-293S) and conjugated to microspheres for use 
in all MIA assays involving samples from Phase I of this study (Figure 2.3).  Microspheres 
conjugated to huFc rProtein and albumin were included with all samples and served as internal 
controls. Additionally, samples were analyzed in parallel using microspheres conjugated to 
huFc-purified FIV-PPR-SU (FIV-PPR-SU-huFc) to assess background levels of anti-huFc IgG 
generated in response to vaccination.  Levels of anti-huFc were estimated by subtracting levels 
of anti-SU IgG (as detected by SU-293S-conjugated microspheres) from the anti-huFc/anti-SU 




Figure 2.3. Microsphere immunoassay differentiates antibodies to specific vaccine antigens from 
irrelevant antibodies (anti-huFc, Phase I, and anti-293S Phase II). (A) Serum from cats vaccinated with 
huFc-derived CD134 and SU in Phase I was analyzed using microspheres coupled to soluble CD134 and 
recombinant SU purified in 293S cells in order to detect anti-CD134 and anti-Su IgG antibodies. (B) 
Phase II serum (cats vaccinated with 293S-derived CD134 and SU) was analyzed using huFC-purified 
soluble CD134 and recombinant SU. See text for additional details. 
 
Phase II.  Vaccine-specific antibodies were detected in plasma samples of study animals at 
weeks 10, 14, and 19-23 (Figure 2.2B) as described above.  Similar to Phase I, SU and CD134 
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rProtein produced in CHO cells from Phase I (huFc-purified; CD134-huFc and FIV-PPR-SU-
huFc) were conjugated to microspheres and used in all MIA assays involving samples from 
Phase II of this study to detect antibodies specific to CD134 and/or FIV-PPR-SU, and to limit 
interference and detection of background antibodies specific to vaccine by-products associated 
with the 293S-purified SU and CD134 (Figure 2.3). All samples were analyzed in parallel using 
microspheres conjugated to 293S-purified CD134 and FIV-PPR-SU to assess background 
levels of anti-293S IgG generated in response to vaccination.  The presence of anti-293S 
antibodies was confirmed by capture ELISA at an absorbance of 450nm in 96-well flat bottom 
plates coated overnight 293S cell supernatant at a concentration of 10μg/ml diluted in 100µl of 
0.1M Carbonate Buffer (7.5 g/L Sodium Bicarbonate, 2.0 g/L Sodium Carbonate, pH ~9.5).  
Immunodepleted serum samples were diluted 1:25 in ELISA diluent and incubated for 2 hours at 
room temperature.  Each well was then washed 5 times (TEN buffer + 0.2% Tween 20) and 
then incubated with Cappel™ horseradish peroxidase (HRP)-conjugated goat anti-cat IgG (MP 
Biomedicals, Santa Ana, CA) diluted 1:5000 in ELISA diluent with 5% mouse sera for 1 hour at 
room temperature.  Each well was then washed 5 times and incubated for 10 minutes with 3, 3', 
5, 5' tetramethyl benzidine (TMB) substrate and peroxidase (Biolegend, San Diego, CA) at room 
temperature before adding 2.5N H2SO4.  Photometric measurements of absorbance were then 
recorded for each plate at 450nm as previously described [40]. 
Detection and quantification of FIV viral RNA and proviral DNA in blood   
Blood samples collected during Phase I and Phase II were analyzed by real-time polymerase 
chain reaction (PCR) analysis to quantify FIV proviral DNA and FIVgag RNA at timepoints 
illustrated in Figure 2.2.  Plasma was isolated from EDTA-treated whole blood following 
centrifugation and frozen at −70°C until processing. Viral RNA was extracted from 140µl plasma 
using a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s 
instructions. Viral RNA from each sample was converted to cDNA using Superscript II 
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(Invitrogen) in individual reactions with random hexamers (Invitrogen) and then treated with 
RNase Out (Invitrogen) prior to real-time PCR quantification. Peripheral blood mononuclear 
cells (PBMC) from all cats were purified on a Histopaque (Sigma, St. Louis, MO) gradient, 
washed, pelleted, and then frozen at −80°C. Proviral DNA was extracted from PBMCs using a 
DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) prior to real-time PCR quantification. 
Real-time PCR reactions were performed on a CFX96™ Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA) to detect and quantify FIV proviral DNA in PBMCs and 
FIV gag RNA in plasma using previously described FIV-A primers and probes [41], and an 
iTaq™ Universal Probes Supermix (Bio-Rad, Hercules, CA) containing an antibody-mediated 
hot-start iTaq DNA polymerase. Copy number of viral RNA in plasma was calculated as 
previously described [37, 42], implementing a standard curve generated by diluting FIV-PPR 
virus stock in naïve cat plasma and analyzed by reverse-transcriptase quantitative PCR as 
outlined above. To quantify proviral DNA in PBMCs, a real-time PCR standard curve was 
generated from serial dilutions of feline PBMCs from 1000 to 5x106 subjected to real time PCR 
for the cellular house-keeping gene, Glyceraldehyde-3-Phosphate Dehydrogenase (GADPH) as 
previously described [42, 43]. Resulting proviral copy numbers were normalized to copies per 
106 cells based on the total amount of DNA present in the reaction (100ng).   
Hematologic analyses.  
Phase II.  Complete blood counts (CBC) and serum biochemistry analysis were performed for 
all blood samples in Phase II by the CSU Veterinary Diagnostic Lab (CSU-VDL). Blood was 
collected from all cats prior to the study to establish baseline values, then at each time point 
indicated in Figure 2.2B.  At weeks 20-24, the percentage of cells positive for CD4, CD8, Fas, 
and B220 surface antigens was determined by incubating 30µl of EDTA-treated blood from each 
cat in 96-well round-bottom plates with 0.6µl of RPE-labeled anti-feline CD4 (Southern Biotech; 
clone 3-4F4), FITC-labeled anti-feline CD8 (Southern Biotech; clone fCD8), PE/Cy7-labeled 
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anti-feline CD45R/B220 (Biolegend; clone RA3-6B2), and APC/Cy7-labeled anti-feline 
Fas/TNFRSF6 (R&D Systems; clone 431006) mouse monoclonal antibodies diluted in FACS 
buffer (5% BSA, 0.1% sodium azide in PBS).  Following incubation for 30 min in the dark at 
room temperature, red blood cells (RBCs) were lysed, and stained cells were fixed using a 
Beckman Coulter Q-Prep work station with 600 µl of 0.1% Formic Acid, 270 µl of 0.06 M 
Na2CO3 anhydrous, 0.25 M NaCl, 0.25 M Na2SO3, and 90 µl 1% wt/vol paraformaldehyde in 
1×PBS. Flow cytometry was performed on a Coulter Gallios (Beckman Coulter Inc, Brea, CA) 
and results were analyzed using FlowJo® software (FlowJo, Ashland, OR).  Immunophenotype 
cell counts were calculated as previously described [37, 42] and compared with CBC data to 
evaluate changes in circulating immunophenotype over the course of vaccination and 
subsequent FIV infection. All CD4, CD8, and CD45R/B220 antibodies were directly labeled by 
the manufacturer.  Anti-Fas antibody was unlabeled but subsequently conjugated to APC/Cy7 
using a APC/Cy7® Labeling Kit (Abcam). 
In vitro antibody inhibition and enhancement of viral replication. 
Phase II.  Duplicate cell cultures consisting of GFox cells (CrFK cells overexpressing CD134) 
[44, 45] were established in 48-well plates at 40,000 cells/well and allowed to attach at 37°C 
overnight.  GFox cell cultures were grown at 37°C and 5% CO2 in 250µl of culture medium 
composed of Dulbecco's modified Eagle's medium (DMEM) with GlutaMAX-1, 10% fetal bovine 
serum (FBS), and 1x penicillin-streptomycin (10,000 U/liter penicillin and 10,000 μg/liter 
streptomycin), as well as 1 μg/ml of Fungizone® (Amphotericin B; Life Technologies) [46].  At 
day 0, 10µl of FIVPPR stock (containing 50,000 infectious units) was incubated for 1 hour at 37°C 
with 230µl of culture media and 10µl of whole serum from sham vaccinated, CD134 vaccinated, 
or CD134+SU vaccinated cats collected at week 19 (1 week pre-FIV challenge).  Following 
incubation, infected media was then added to cell culture plates, bringing the total volume to 
500µl (1:50 serum/FIV). Duplicate negative control (1:50 serum only, no FIV) and positive 
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control (FIV only, no serum) wells were included for each sample. At days 4, 6, 8, and 10 post-
inoculation, 200µl of supernatant was removed from each well, frozen at -80°C, and replaced 
with 200µl of fresh culture media.  At day 10, the supernatant collected from each well and each 
time point was assayed by a previously described capture ELISA protocol to detect FIV p26 
antigen at an absorbance of 450nm in 96-well flat bottom plates [40].  Percent inhibition was 
calculated from mean absorbance values (Abs) using the previously described formula 
((X − Y)/X) × 100, where X is fraction of cells infected in the absence of serum (virus only 
positive control) and Y is the fraction of cells infected in the presence of various serum 
treatments [47].   
To elucidate the discrete effects of anti-SU, anti-CD134, and anti-293S antibodies 
generated in vivo in response to immunization, serum from vaccinated cats collected at week 19 
(1 week pre-FIV challenge) was immunodepleted of anti-CD134 and anti-SU antibodies via 
serial passages over Actigel ALD agarose bead resin (Sterogene, Carlsbad, CA) that had been 
coupled to either CD134-huFc or FIV-PPR-SU-huFc rProteins per manufacturer’s instructions. 
Anti-CD134 and anti-SU immunodepleted serum was then filtered through a microcentrifuge 
column by centrifugation at 8,000 rpm for 5 minutes.  Vaccinated cat serum was 
immunodepleted of anti-293S antibodies by incubating 5mg of acetone-powdered 293S cells 
with 500µl of serum at 4°C overnight with gentle agitation, followed by centrifugation at 8,000 
rpm for 5 minutes and pipet recovery of the immunodepleted supernatant.  Immunodepleted 
samples and a subset of whole serum were depleted of complement by heat inactivation (56°C 
for 30 minutes).  Immunodepletion of anti-CD134, anti-SU, and anti-293S antibodies was 
confirmed by capture ELISA (as previously outlined) at an absorbance of 450nm in 96-well flat 
bottom plates coated overnight with either CD134-huFc, FIV-PPR-SU-huFc, or 293S cell 
supernatant at a concentration of 10μg/ml diluted in 100µl of 0.1M Carbonate Buffer (7.5 g/L 
Sodium Bicarbonate, 2.0 g/L Sodium Carbonate, pH ~9.5).  ELISA absorbance values indicated 
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statistically significant depletion of all targeted antibodies (Two-tailed t tests; anti-CD134 
p<0.0001; anti-SU p=0.005; anti-293S p=0.0002). 
Duplicate cell cultures consisting of GFox cells (CrFK cells overexpressing CD134) [44, 
45] were established in 48-well plates as described above. At day 0, 10µl of FIVPPR stock 
(containing 50,000 infectious units) was added to 480µl of fresh culture media along with 10µl 
(1:50 dilution) of various combinations of immunodepleted serum, with the contents of each well 
as follows: (1) No FIV (Negative Control), (2) FIV only (positive control), (3) Heat-treated CD134 
vaccinated serum (to inactivate complement) (4) Heat-treated CD134+SU vaccinated serum (5) 
anti-SU serum, (6) anti-293S serum, and (7) anti-CD134 serum.  Following incubation for 1 hour 
at 37°C, infected media was pipetted onto duplicate GFox cell cultures and incubated at 37°C 
for 12 hours, at which point all culture media was removed from each well, discarded, and 
replaced with 500µl of fresh culture media. GFox cells were visually inspected daily by inverted 
light microscopy for evidence of cell growth, attachment, syncytial cell formation, detachment, 
and cell death.  At days 6, 8, and 10 post-inoculation, 200µl of supernatant was removed from 
each well, frozen at -80°C, and replaced with 200µl of fresh culture media.  At day 10, the 
supernatant collected from each well and each time point was assayed by FIV p26 ELISA and 
the Abs value used to calculate percent inhibition as previously outlined. 
To further identify the individualized effects of vaccine-produced antibodies in serum of 
immunized cats, previously absorbed anti-SU and anti-CD134 antibodies from each serum 
sample were recovered from agarose bead resins by elution with Pierce™ IgG Elution Buffer 
per manufacturer’s instructions.  Elutions containing purified anti-CD134 or anti-SU IgG were 
pooled separately and then stored in 100µl of D-PBS at 4°C.  Duplicate GFox cell cultures were 
established in 48-well plates as previously outlined, and at day 0, 10µl of FIVPPR stock 
(containing 50,000 infectious units) was combined with either 10µl or 5µl (1:50 or 1:100 dilution) 
of either purified antiCD134 or anti-SU IgG, and added to sufficient culture media to bring the 
total volume to 500µl.  Duplicate negative control (no virus) and positive control (virus only) 
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wells were included for each sample.  Following incubation for 1 hour at 37°C, infected media 
was pipetted onto GFox cells and incubated at 37°C for 12 hours, at which point all culture 
media was removed from each well, discarded, and replaced with 500µl of fresh culture media. 
At days 5, 7, and 9 post-inoculation, 200µl of supernatant was removed from each well, frozen 
at -80°C, and replaced with 200µl of fresh culture media. At day 10, the supernatant collected 
from each well and each time point was assayed by FIV p26 capture ELISA protocol and 
percent inhibition was calculated from mean absorbance values (Abs) as previously outlined. 
Statistical Analyses 
All analyses were conducted in the program R v3.0.2 (www.r-project.org) using the ‘stats’ 
package or using GraphPad Prism 6.0 software (La Jolla, CA).  P-values < 0.05 were 
considered significant.  Repeated measures ANOVA was utilized to evaluate the difference in 
viral RNA and proviral DNA (copies/ml) among the three vaccine groups (Naïve, CD134, 
CD134+SU) over time.  Viral RNA, proviral DNA, and were log transformed to achieve normality 
prior to analysis.  Repeated measures ANOVA was utilized to evaluate differences in anti-
CD134, anti-PPR-SU, and anti-Capsid IgG antibodies in serum from the three vaccine groups 
(Naïve, CD134, CD134+SU) over time, and was also used to evaluate differences in FIV 
replication (Absorbance) and Percent Inhibition among the vaccinated groups over time. 
Logically, inhibition was not analyzed for the negative and positive groups owing to all values 
being 1 or 0 respectively.  
Results 
Anti-CD134 and anti-FIV-SU antibodies generated in vivo prior to viral challenge.  
Phase I.  Serum samples from weeks 4, 6, 8, 10, 13, 15, 18, and 22 were tested by 
microsphere immunoassay (MIA) to detect anti-SU and/or anti-CD134 IgG antibodies in cats 
vaccinated with FIV-PPR-SU-huFc or a combination of CD134+SU-huFc; results of which are 
presented in Figure 2.4. Increased levels of anti-CD134 antibodies were detected as early as  
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Figure 2.4. Anti-CD134, anti-SU, and irrelevant antibodies (a-huFc) are elicited during Phase I 
vaccination. (A) Microsphere immunoassay (MIA) detected anti-CD134 IgG antibodies in CD134+SU 
vaccinated cats beginning at week 4 post-vaccination and peaking at 10 weeks post-vaccination (3 weeks 
after final CD134 boost) (B) Anti-SU IgG was detected by MIA in SU vaccinated and CD134+SU 
vaccinated cats beginning at week 6 post-vaccination and these levels differed significantly over time 
compared to Sham-vaccinated controls (p<0.0001). (C) MIA measured IgG antibodies against huFc tag 
used to purify soluble CD134 and PPR-SU rProteins in Phase I vaccine preparation.  Anti-huFc IgG levels 
(indicated by MFI) significantly exceeded levels of anti-SU and anti-CD134+SU (p<0.0001). Relative 
concentration of antibody response to huFc was estimated to be 10-fold higher than anti-SU specific IgG 
response (as described in text).  
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week 4post-vaccination in CD134+SU-huFc vaccinated cats and were significantly elevated at 
week 19 (1 week pre-FIV infection) compared to background levels (treatment p=0.014), but 
decreased slightly after infection (Figure 2.4A).  As expected, anti-CD134 IgG antibodies were 
not detected in serum from SU-huFc vaccinated or sham vaccinated study animals prior to FIV-
infection (Figure 2.4A).  
 Increased levels of anti-SU IgG were detected in SU-huFc vaccinated and CD134+SU-
huFc vaccinated cats beginning at week 4 post-vaccination (Figure 2.4B), and these levels 
differed significantly over time when compared to background levels (interaction p<0.0001). 
Anti-SU IgG antibody levels remained elevated in all SU-huFc and CD134+SU-huFc vaccinated 
animals after FIV infection.  Anti-SU IgG antibodies were not detected in sham vaccinated cats 
prior to FIV infection, but increased slightly following intravenous viral inoculation as expected 
(Figure 2.4B).  When serum samples were evaluated for antibodies against the huFc tag used 
to purify the soluble CD134 and PPR-SU rProteins in the vaccine preparation, significantly 
increased levels of anti-huFc IgG were detected in SU-huFc and CD134+SU-huFc vaccinated 
cats (p<0.0001) which often exceeded anti-SU IgG by more than 10-fold (Figure 2.4C).  
Phase II. Serum samples from weeks 10, 14, and 19-23 were tested by MIA to detect anti-
CD134 and anti-SU IgG antibodies in cats vaccinated with soluble CD134 and PPR-SU 
rProteins purified from 293S cells. Anti-CD134 IgG antibodies were detected in serum from 
CD134 vaccinated cats beginning at week 14 post-vaccination (6 weeks pre-FIV infection) and 
increased significantly over time compared to sham vaccinated background levels (interaction 
p=0.003) (Figure 2.5A). Similarly, anti-CD134 IgG was detected in CD134+SU vaccinated 
animals beginning at week 10 post-vaccination (10 weeks prior to FIV infection), but the anti-
CD134 IgG response was not as robust in this vaccine group and did not differ significantly from 
background levels (interaction p=0.135) (Figure 2.5A).   
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Figure 2.5. Phase II vaccination scheme boosts vaccine-specific antibody response in vivo, but 
irrelevant antibodies are still present. (A) MIA detected significant quantities of anti-CD134 IgG 
antibodies in serum from CD134 and CD134+SU vaccinated cats beginning at week 14 post-vaccination 
(6 weeks pre-FIV infection) which increased significantly over time in CD134 vaccinated cats compared to 
sham vaccinated background levels (p=0.003). (B) Anti-SU IgG antibodies were detected in CD134+SU 
vaccinated cats by MIA at 1 week prior to FIV challenge (2 weeks after final SU boost), and antibody 
levels increased significantly over time compared to controls (p=0.001). (C) Capture ELISA detected high 
levels of anti-293S antibodies in serum of both CD134 vaccinated (p<0.0001) and CD134+SU vaccinated 
(p<0.0001) cats immunized with the 293S-purified CD134 and/or FIV-SU vaccine construct compared to 
sham vaccinated cats.  
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Anti-SU IgG antibodies were detected in CD134+SU vaccinated cats beginning at week 19 (1 
week prior to FIV infection), and antibody levels increased significantly over time compared to 
the background levels (interaction p=0.001) (Figure 2.5B).  As expected, anti-SU antibodies 
were not detected in sham vaccinated or in CD134 vaccinated cats prior to FIV infection, but 
increased slightly over time after intravenous viral inoculation.  Similar to phase I, high levels of 
anti-293S antibodies were detected by ELISA in serum of cats vaccinated with 293S-purified s 
oluble CD134 and/or PPR-SU rProteins (Figure 2.5C).  Specifically, serum from CD134 and 
CD134+SU vaccinated cats exhibited significantly elevated absorbance (Abs) values compared 
to serum from sham vaccinated cats (interaction, p<0.0001), indicating that significant in vivo 
antibody production occurred in response to the 293S cell products used in vaccine production. 
FIV challenge 
Phase I.  At week 12 post-vaccination, study animals were intravenously inoculated with FIVPPR 
as described above. Plasma samples from all study animals in all vaccine groups had 
detectable FIV plasma RNA by week 2 post-FIV infection (Figure 2.6A).  Moreover, FIV RNA 
levels were significantly elevated at week 2 in SU-huFc vaccinated (p<0.001) and CD134+SU-
huFc vaccinated (p<0.05) study animals when compared to sham vaccinated animals (Figure 
2.6A), suggesting a transient enhancement of FIV infection in these vaccine groups.  PBMC FIV 
proviral DNA was detected in all study animals by week 2 post-FIV infection, and proviral load 
peaked at week 8 post-infection (Figure 2.6B).  No significant differences in FIV DNA proviral 
loads were detected between vaccine groups over time. 
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Figure 2.6. CD134 and/or SU vaccinated cats were not protected against FIV challenge. (A) All 
Phase I study animals demonstrated positive viremia by week 2 post-FIV infection, and FIV RNA levels 
were significantly elevated at week 2 in SU vaccinated (p<0.001) and CD134+SU vaccinated (p<0.05) 
cats; suggesting a transient enhancement of FIV infection. (B) Proviral DNA was detected in PBMCs of all 
Phase I study animals by week 2 post-FIV infection, but did not differ between vaccine groups over time. 
(C) All Phase II study animals demonstrated FIV RNA in plasma by week 2 post-infection. FIV RNA levels 
decreased significantly over time in all groups (time p<0.001), however, no significant differences were 
observed between vaccine groups over time during this phase. (D) Proviral DNA was detected in PBMCs 
of all Phase II study animals at week 1 post-FIV infection, and were significantly elevated above baseline 
in all study groups by week 2 post-inoculation. Proviral DNA levels did not differ over time or between 
vaccine groups during Phase II.  
 
Phase II.  At week 20 post-vaccination, study animals were intravenously inoculated with FIVPPR 
as detailed above.  Quantitative PCR analysis of plasma detected FIV RNA in most study 
animals within 1 week of FIV inoculation (Figure 2.6C).  All CD134+SU vaccinated cats 
demonstrated FIV RNA in plasma by week 1 post-FIV infection, and all sham and CD134 
vaccinated cats were positive for FIV RNA by week 2 post-infection.  Although the level of 
viremia (FIV RNA) decreased significantly over time in all groups (time p<0.001, Table 2.1), no 
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significant differences in FIV RNA levels were observed between vaccine groups.  PBMC 
proviral DNA was detected in all study animals at week 1 post-FIV infection (Figure 2.6D) and 
was significantly elevated above baseline in all study groups by week 2 post-inoculation.  
However, proviral loads did not differ significantly between groups over time in this phase of the 
study. Results indicate that vaccination with CD134 or CD134+SU complexes as prepared in 
either trial does not provide protection from FIV infection in vivo. 
Table 2.1. No significant differences in vaccine treatment are observed over time in Phase I or Phase II. 
  
Purified anti-CD134 and anti-SU antibodies inhibit FIV replication in vitro 
Phase II.  Prior to FIV infection, serum was collected from sham, CD134 and CD134+SU 
vaccinated cats and incubated directly with FIVPPR prior to in vitro inoculation.  Additionally, 
serum from CD134+SU vaccinated cats was heat-treated (to inactivate complement) and 
depleted of anti-SU, anti-CD134, and/or anti-293S antibodies to evaluate the individual effects 
of these components on FIV replication in vitro.  Results of these experiments are summarized 
in Table 2.2.  Surprisingly, whole serum from both CD134 and CD134+SU vaccinated cats 
significantly enhanced FIV replication in vitro, as indicated by significantly higher FIV p24 ELISA 
absorbance values and decreased percent inhibition below threshold (Figure 2.7A).  In 
contrast, heat-inactivated serum depleted of anti-CD134 and anti-293S antibodies (containing 
only anti-SU antibodies) significantly inhibited FIVPPR replication in GFox cell culture, as 
evidenced by significantly lower FIV p24 ELISA absorbance values and calculated percent 
inhibition compared to the FIV-only positive control (Figure 2.7B).  Similarly, serum containing 
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only anti-CD134 antibodies inhibited FIV growth in vitro on day 6 of culture (Figure 2.7B).  
Interestingly, a significant and sustainted inhibitory effect was observed at all timepoints utilizing 
heat-treated serum from CD134+SU vaccinated cats, in which complement was inactivated but 
contained all antibodies generated in vivo (anti-SU, antiCD134, and anti-293S).  In contrast, no 
inhibitory effect was observed in wells treated with heat-treated serum from CD134 vaccinated 
 
Figure 2.7. Anti-CD134 and anti-SU antibodies significantly inhibit FIV replication in vitro.  
(A) Whole serum from CD134 and CD134+SU vaccinated cats produced significant enhancement of 
FIV replication in GFox cells (CD134 p=0.0005; CD134+SU p=0.047), indicated by significantly 
decreased percent inhibition compared to FIV only infections.  Sham vaccinated serum did not 
significantly inhibit infection. (B) Antibody fractions representing anti-CD134, anti-SU, and anti-293S 
were enriched or depleted from serum as described in the text, and analyzed for ability to inhibit in 
vitro viral infection.  Significant inhibitory effects were observed with purified anti-SU IgG and heat-
inactivated serum containing anti-SU, anti-CD134, and anti-293S IgG (Table 2.2). Enriched anti-
CD134 (C) and anti-SU (D) antibodies recovered from serum of CD134 and CD134+SU vaccinated 
cats demonstrated significant inhibition of FIV replication in vitro (Table 2.3), confirming the individual 
capacity to inhibit FIV infection reported by Grant et al. [28].   
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cats (complement-inactivated serum with anti-CD134 and anti-293S IgG).  Serum depleted of 
anti-CD134 and anti-SU, but still containing anti-293S (ie., contaminating) antibodies from 
CD134+SU vaccinated cats had a negligible effect of FIV replication, signaling that these 
irrelevant antibodies were not a cause of inhibition/neutralization interference in vitro. 
Importantly, enhancing effects were not observed for any of the heat-treated samples,  
Table 2.2.  Anti-SU IgG fraction neutralizes in vitro FIV infection whereas whole serum enhances 
infection.  Whole serum from CD134 and CD134+SU vaccinated cats significantly enhanced FIV 
replication in vitro. Heat inactivation of whole serum from CD134+SU vaccinated cats resulted in in vitro 
inhibition, suggesting enhancing factors in whole serum are heat-labile.  Anti-SU antibodies generated in 
CD134+SU vaccinated cats exhibit significant individual or combined inhibitory effects on FIV replication 
following heat-treatment to remove heat-labile proteins in serum, while serum enriched for anti-CD134 
and anti-293S fractions neither inhibited or enhanced in vitro infection. 
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regardless of antibody content, indicating that significant enhancement of FIV replication in vitro 
may occur as a result of heat-labile proteins such as complement.   
Purified anti-CD134 and anti-SU antibodies from serum of vaccinated cats were used to 
further evaluate the individual capacity of these antibodies to inhibit FIV replication in GFox cells 
(Table 2.3). Analysis of mean absorbance values demonstrated that both purified anti-CD134 
IgG (p<0.01) and anti-SU IgG (p<0.04) significantly inhibited FIV replication in vitro.  Post-hoc 
analysis revealed that both 1:50 and 1:100 dilutions of purified fractions of anti-CD134 (Figure 
2.7B) and anti-SU (Figure 2.7C) were able to significantly inhibit FIV.  
Table 2.3.  Purified anti-CD134 and anti-SU IgG antibodies neutralize FIV infection in vitro.   
Anti-SU and anti-CD134 antibodies from CD134+SU vaccinated cat serum were adsorbed onto agarose 
bead resins and recovered with Pierce™ IgG Elution Buffer.  Elutions containing purified anti-CD134 or 
anti-SU IgG were then inoculated onto GFox cells infected with FIVPPR stock.  Results demonstrate that 
both purified anti-CD134 and anti-SU antibodies significantly inhibit FIV replication independently  
(Figure 2.7B-C), but not in the presence of heat-labile elements in serum (such as complement). 
 
Vaccinated cats exhibit divergent immunologic responses   
In Phase II, phenotype analysis of circulating immunocytes was performed to determine 
whether: (1) vaccine-associated changes in peripheral blood immunophenotype at the time of 
inoculation may have contributed to vaccine failure; or (2) vaccination protocols altered post-FIV 
challenge peripheral blood immune profile.  Prior to FIV challenge, CD8+, CD4+, and B220+ 
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lymphocytes were significantly elevated in CD134+SU vaccinated cats compared to CD134 
vaccinated cats (p<0.03, p<0.04, p<0.03, respectively) (Figure 2.8A-C).  Average numbers of 
CD4+ and B220+ lymphocytes also tended to be slightly higher in CD134+SU vaccinated cats 
than in sham vaccinated cats, but this finding was not statistically significant (Figure 2.8A, 
2.8C). Additionally, there was a trend (p=0.081) for CD8+ lymphocytes to be decreased in 
CD134 vaccinated cats compared to sham vaccinated cats prior to FIV challenge (Figure 2.8B). 
In CD134+SU vaccinated cats, the CD4:CD8 ratio prior to FIV challenge was correlated with 
early proviral load (p=0.05, R2=0.89) (Figure 2.8D), indicating that increased viral integration 
may be associated with decreased numbers of CD4+ lymphocytes relative to CD8+ cells  
 
Figure 2.8. Immunization results in alterations in lymphoid immunophenotype in vaccinated cats. 
Prior to FIV challenge in Phase II studies, CD8+ (A) CD4+ (B), and B220+ (C) lymphocytes were 
significantly elevated in CD134+SU vaccinated cats compared to CD134 vaccinated cats (p<0.03, 
p<0.04, p<0.03, respectively). CD4+ and B220+ cell levels were slightly higher in CD134+SU vaccinated 
cats compared to Sham vaccinated cats prior to FIV challenge, and there was a trend for CD8+ cells to 
be decreased (p=0.081) in CD134 vaccinated cats. (D) In CD134+SU vaccinated cats, decreased 
CD4:CD8 ratios prior to FIV challenge correlated with higher proviral DNA loads during acute stages of 
FIV infection, indicating that changes induced in circulating T cell populations by vaccination-associated 
immunostimulation may predispose to enhanced susceptibility to viral infection.  
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Discussion 
 The development of a partially effective commercial FIV vaccine, coupled with previous 
findings that anti-receptor autoantibodies are associated with better clinical outcomes, suggests 
that co-immunization with viral and receptor antigens might augment vaccine effectiveness.   
However, despite the promising results of in vivo production of neutralizing antibodies, cats in 
this study were not protected against homologous FIV infection, and occasionally exhibited 
transient enhanced infection (as evidenced by increased FIV RNA levels post challenge). 
Several studies in FIV vaccine design have resulted in enhanced susceptibility to infection 
rather that protection [22-24, 48].  These complications are frequently paralleled in SIV and HIV 
vaccine development [48-54] and have impeded progress in vaccine efficacy by a variety of 
mechanisms, including antibody-dependent viral enhancement or general immune activation 
[22-27].  Accordingly, we performed several further analyses in this study in attempt to elucidate 
the mechanism for vaccine failure, including: (1) potential contribution of anti-SU or anti-CD134 
vaccine induced antibodies to enhanced FIV-replication; (2) assessment of alterations in 
circulating PBMC induced by vaccination (potentially in response to immune activation) which 
might render vaccinated cats more susceptible to viral challenge via expanded target cell 
population; (3) evaluation of antibodies generated in response to irrelevant antigens present in 
the vaccine preparation that could contribute to enhancement; and, (4) magnitude of relevant (ie 
anti-SU, anti-CD134) versus irrelevant (ie anti-huFc, anti-293S antigen) antibody responses.  By 
determining which aspects of vaccination contribute to failure of this trial, future efforts can be 
modified to avoid pitfalls of this study. 
Primary results of this study confirm that vaccination with soluble CD134-SU complexes 
induces in vivo production of both anti-SU and anti-CD134 antibodies, and when purified from 
serum of vaccinated cats, both antibodies are independently effective at neutralizing FIV 
infection in tissue culture.  However, even in the presence of circulating neutralizing antibodies, 
cats challenged with homologous FIV virus were not protected against infection in vivo, and in 
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some cases, succumbed to transient enhanced infection in the presence of SU rProtein.  
Correspondingly, in vitro analysis of whole serum from CD134+SU vaccinated cats indicated 
significantly enhanced viral infection in cell culture (Figure 2.7A), but when heat-treated to 
inactivate complement and other heat-labile elements, serum containing anti-CD134 and anti-
SU antibodies exhibited significant inhibitory effects. Indeed, heat-inactivated serum from 
CD134+SU (but not CD134) vaccinated cats significantly inhibited in vitro FIV replication at all 
time points evaluated, indicating a sustained inhibitory effect when both anti-CD134 and anti-SU 
antibodies were present (Figure 2.7B).  These findings highlight the potential for a synergistic 
mechanism of viral inhibition between anti-CD134 and anti-SU antibodies produced in response 
to vaccination with CD134-SU complexes, but only in the absence of heat-labile serum factors.  
Complement enhancement of viral infection has been previously reported in HIV [55-58] 
and SIV [59-61] studies, and may occur via both antibody-dependent and antibody-independent 
mechanisms of complement activation [62-69].  Similar consequences of complement activation 
may be responsible for the enhancement effects noted in this study. For example, immunization 
with anti-receptor complexes may induce complement activation in vivo, resulting in viral 
opsonization or deposition of antibody-complement complexes on the cell to provide prolonged 
receptor contact and subsequent fusion within the cell membrane [48, 56, 70]. Interestingly, 
non-heat-treated whole serum from sham vaccinated cats did not enhance FIV-replication in 
vitro (Figure 2.7A), despite the presence of serum complement in treated wells. This suggests 
that in vivo complement activation may not occur in the absence of soluble CD134 or 
recombinant SU protein, and that the presence of anti-receptor complexes in vaccinated cats 
may in fact influence the activation of complement and enhancement of FIV replication in vitro. 
Other heat-labile factors, such as cytokines, chemokines, growth factors, and adhesion 
molecules, are also present in serum and may similarly contribute to enhanced replication of 
FIV in vitro [71], particularly if the vaccination protocol has altered the immune landscape. 
Additionally, because sham vaccinated whole serum did not cause enhancement effects like 
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CD134 and CD134+SU vaccinated whole serum, it is reasonable to assume that activation of 
such viral enhancing elements in this study are likely attributable to vaccination with soluble 
CD134, recombinant SU protein, and/or purification by-products (huFc or 293S cells).  Future 
studies will be directed at elucidating the role that complement activation and other heat-labile 
serum components play in the interference of the anti-receptor antibody response during viral 
infection. 
An additional factor to consider is the disproportionate antibody response generated in 
vaccinated cats against the vaccine by-products; huFc and 293S cell contaminants co-purified 
with the recombinant proteins.  Microsphere immunoassay results demonstrated a substantial 
quantity of anti-Fc antibodies in Phase I vaccinated cats, as well as a marked anti-293S 
antibody response in Phase II animals.  While in vitro experimental results indicated that these 
antibodies did not directly interfere with or enhance FIV infection, it is possible that their 
production may have indirectly interfered with vaccine efficacy by compromising the neutralizing 
antibody response.  Based upon the magnitude of antibodies generated to these antigens (huFc 
and 293S), the proportion of coincident anti-CD134 and anti-SU antibodies produced in 
response to the targeted immunogens was on average 10-fold lower, indicating that the bulk of 
antibody production was directed at these “irrelevant” antigens instead of their intended target.  
As such, the potential level of anti-CD134 and anti-SU antibody necessary for protection from 
FIV infection was likely never attained in vivo, thus preventing the current immunization strategy 
from providing a neutralizing antibody response strong enough to prevent infection in vaccinated 
cats. Moreover, the potential for these foreign antigens to activate complement and other heat-
labile immune response factors may have contributed to the transient enhancement effects 
observed in vivo, and the magnitude of the antibody response to such antigens may account for 
the in vitro enhancement effects observed in cats vaccinated with anti-receptor complexes. 
Lastly, it is possible that exposure to foreign/irrelevant antigens may have driven antibody 
production toward a predominant IgG1 response rather than a more protective IgG2a response.  
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The potential for this may be subsequently avoided through use of non-alum based adjuvants 
such as Ribi, which enhance IgG2a production and the Th1 response, as well as production of 
protective interferon-gamma [72-74]. Future vaccine design methods will incorporate the use of 
more highly-purified immunoadhesion peptides which lack purification by-products, thereby 
limiting the potential for interference in neutralizing antibody production and innate immune 
activation by irrelevant antigens. 
In SIV and HIV immunization studies, much of the capacity to enhance susceptibility to 
infection has been attributed to an increase in general immune activation and/or expansion of 
lymphoid target cells, and this feature has also been observed in FIV studies [25, 54, 75-79].  
Flow cytometry analysis of lymphoid immunophenotypes in Phase II identified significant 
variations in CD4+, CD8+, and B220+ lymphocytes among CD134 and CD134+SU treatment 
groups prior to infection (Figure 2.8), and a positive correlation was observed between the 
CD4:CD8 ratio and acute DNA proviral load in CD134+SU immunized cats. Collectively, these 
results indicate that an acute, vaccine-induced increase in CD4+ lymphocytes relative to CD8+ 
cells in CD134+SU immunized cats may contribute to viral integration and the establishment of 
FIV infection. However, no significant differences in immunophenotype prior to infection were 
observed between sham vaccinated cats and either CD134 or CD134+SU vaccinated cats in 
Phase II of this study, suggesting that alterations in circulating immunophenotype due to 
vaccination with anti-receptor complexes may not play a major role in vaccine failure. 
Alternatively, it is possible that vaccination with alum (aluminum hydroxide), a widely-
used immunopotentiating reagent frequently used in vaccine preparations to boost humoral 
immunity [80-82], resulted in increased amounts of target cells and general immune activation in 
this study, thus priming the immune system for infection prior to FIV inoculation.  However, 
sham vaccinated cats also received alum during this study, and no evidence of viral 
enhancement was observed in these animals in vivo (Figure 2.6) or through use of their serum 
in vitro (Figure 2.7). These results suggest that any enhancing effect observed in SU-huFc 
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vaccinated cats of Phase I and CD134+SU vaccinated cats of Phase II was less dependent 
upon the use of alum, and implicate the immunogen among these groups: SU rProtein. The 
direct indictment of SU as a sole cause of vaccine failure is, however, unlikely considering the 
following evidence:  (1) all CD134 vaccinated cats in Phase II became infected by week 1 post-
infection, yet these animals were not immunized with SU, and did not generate an anti-SU 
antibody response prior to infection; and, (2) purified anti-SU antibodies from CD134+SU 
vaccinated cats significantly inhibited FIV replication in vitro, substantiating that the presence of 
these antibodies elicit protective effects against FIV infection as previously reported [28].   
 In summary, the results of this study identify specific obstacles to overcome in the 
development of anti-receptor antibody immunization, and highlight potential targets for 
optimization and in vivo study design.  Immunization with soluble receptors (CD134) and viral 
surface glycoprotein (FIV-SU) elicits in vivo production of neutralizing antibodies (anti-CD134 
and anti-SU IgG) in vaccinated cats, both of which significantly inhibit FIV replication in vitro.  
Immunization with anti-receptor complexes did not prevent FIV infection, though efficacy may 
have been negatively affected by a substantially disproportionate antibody response to vaccine 
by-products that likely compromised an effective neutralizing antibody response.  Importantly, 
the role of heat-labile factors, including complement, in serum of vaccinated cats may play a 
role in the interference of anti-receptor antibody function and vaccine efficacy, and vaccination 
protocols need to be developed that do not enhance populations of circulating cells with 
enhanced susceptibility to FIV infection.  Collectively, these findings illustrate several key 
features of the receptor-mediated immunogenic response in cats, and suggests that alteration of 
immune landscape during vaccination may improve efficacy in the development of a lentiviral 
vaccine.   
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Feline immunodeficiency virus (FIV) induces lifelong infection in cats and may result in a 
spectrum of immunodeficiency-related diseases.  Both prednisolone and cyclosporine A (CsA) 
are commonly used clinically to treat lymphoproliferative and immune-mediated diseases in 
cats, but the impact of these compounds on FIV infection has not been well documented, and 
their understanding immunomodulatory effects on FIV replication and persistence is critical to 
guide safe and effective use of these therapies in FIV infected cats. To fill this knowledge gap, 
FIV-infected cats or age-matched controls were administered immunosuppressive doses of 
prednisolone (2mg/kg) or CsA (5mg/kg) for 28 days in a cross-over experiment. Alterations in 
hematological parameters and FIV viral loads were monitored by flow cytometry and 
quantitative PCR. Both prednisolone and CsA induced acute and transient increases in FIV 
proviral load and viremia, and significant differences in lymphocyte phenotype were observed 
between FIV-infected and naïve cats treated with CsA and prednisolone.  Both treatments 
caused: (1) acute increases in CD4+ lymphocytes; (2) increased FIV viremia; and, (3) significant 
alterations in cytokine expression that favored a shift toward a Th2 response.  Antiretroviral 
therapy inhibited CsA-induced viremia, but not proviral load, indicating CsA treatment induces 
new viral replication but does not result in complete reactivation of latently infected cells. 
Results from this study highlight the potential for immunosuppressive drug-induced perturbation 
of FIV replication and underscores the need for consideration of chronic viral infection status 
when prescribing immunomodulatory medications. 
Background 
Feline immunodeficiency virus (FIV) is a naturally occurring lentivirus of domestic cats 
that produces progressive immune depletion resulting in an AIDS-like syndrome [1-10]. Similar 
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to human immunodeficiency virus (HIV), FIV-infected cats frequently develop secondary or 
opportunistic infections as a consequence of viral-induced immune dysfunction, including 
anterior uveitis, chronic rhinitis, gingivostomatitis and periodontitis, encephalitis and neurologic 
dysfunction, and lymphoma [10-19]. While antiretroviral therapy (ART) has demonstrated 
modest success at controlling FIV infection in vivo, the capacity of ART to alleviate symptoms 
and control the development of secondary disease syndromes has been limited [9,20-22]. 
Adjunct immunosuppressive therapies may be prescribed to ameliorate symptoms of secondary 
diseases associated with FIV infection, or unrelated inflammatory conditions that might occur in 
FIV infected cats.  Two commonly used compounds in this category are prednisolone and 
cyclosporine A (CsA), but the effects of these compounds on FIV infection kinetics are unknown 
[23-32]. Thus, there is a critical need for a better understanding of the immunomodulatory 
effects of these drugs on FIV replication and persistence in order to guide safe and effective 
therapies during FIV infection. 
While prednisolone and CsA differ distinctly in regard to pharmacokinetics and 
mechanism of action, they produce similar therapeutic effects that are mediated primarily 
through modulation of interleukin 2 (IL-2) expression [32-38]. IL-2 is a pro-inflammatory cytokine 
with many regulatory functions during the development and differentiation of T-lymphocytes 
[39,40]. Additionally, IL-2 expression plays a central role in the proliferation and activation of 
effector and memory T-lymphocytes, and both prednisolone and CsA exhibit a similar impact on 
this important regulatory pathway [39,40]. The primary immunomodulatory effects of 
prednisolone are achieved through binding of glucocorticoid receptors, followed by nuclear 
translocation and binding of glucocorticoid response elements (GRE) within target genes [36-
38]. By this mechanism, prednisolone inhibits gene transcription of inflammatory genes, causing 
suppression of IL-2 expression that results in decreased T-lymphocyte proliferation [36-38]. 
Alternatively, CsA binds to the intracellular protein receptor cyclophilin and inhibits the 
phosphatase activity of calcineurin, a critical component of the T-cell activation pathway [32-35]. 
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By blocking calcineurin activity, CsA inhibits the translocation of the cytosolic component of the 
nuclear factor of activated T cells (NF-AT), resulting in suppression of IL-2 gene 
promoter/enhancer function and consequent inhibition of T-lymphocyte proliferation [32-35]. 
Thus, although they utilize divergent pharmacokinetic pathways, these compounds produce a 
similar immunomodulatory effect by decreasing proliferation and activation of T-lymphocytes. 
Because FIV predominately targets CD4+ T-lymphocytes during infection in domestic 
cats [1-4,6,8], it is possible that immunosuppressive doses of prednisolone and CsA could 
broadly reduce lymphocyte proliferation and activation in FIV-infected cats; thereby decreasing 
the number of target cells for FIV infection and as a result, reduce FIV viral and proviral loads in 
circulation. Conversely, the immunosuppressive effects of these compounds could weaken the 
anti-FIV immune responses that suppress FIV replication during the chronic phase of infection, 
resulting in increases in viral loads.  Thus, to determine the impact of prednisolone and CsA on 
FIV replication kinetics, chronically-infected SPF cats were administered immunosuppressive 
doses of prednisolone or CsA in a cross-over study design. Following a wash-out period, CsA 
was administered prior to antiretroviral therapy (ART - zidovudine + lamivudine) to assess the 
effects of immunomodulation on ART efficacy, and to determine whether CsA might result in 
activation of viral replication. Hematological parameters were monitored by flow cytometry, and 
compared with changes in circulating FIV RNA and DNA levels as detected by quantitative PCR 
(qPCR). Shifts in circulating lymphocyte immunophenotype and virologic parameters were 
compared with peripheral cytokine levels quantified by microsphere immunoassay (MIA) to 
assess changes in innate immune function induced by drug treatment. We determined that both 
prednisolone and CsA induced acute and transient increases in FIV proviral DNA level and FIV 
viremia, which correlated with acute increases in lymphocyte subsets during treatment. This 
finding implies that acute changes in circulating lymphocytes increase FIV transcription, 
resulting in transient increases in FIV viral load. Moreover, significant alterations in cytokine 
expression that favored a shift toward a Th2 response were detected in both prednisolone and 
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CsA treated, FIV-infected cats. Finally, (iv) ART therapy abrogated CsA-induced FIV viremia, 
but did not affect FIV proviral loads, suggesting CsA induces FIV replication but does not drive 
all latent genomes into an actively replicating state (which would subsequently be diminished by 
ART). Collectively, these results document unexpected effects of both prednisolone and CsA 
during FIV-infection, and highlight the need to assess the long-term immunopathogenic 
consequences of these immunomodulatory compounds. 
Materials and Methods  
In vivo protocols 
This study was approved by the Colorado State University Institutional Animal Care and 
Use Committee; 14-4872A.  Colorado State University's animal care program is licensed by the 
United States Department of Agriculture (USDA), accredited by Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) International, and holds an Office of 
Laboratory Animal Welfare (OLAW) assurance (A3572-01). All animal experiments complied 
with the National Institutes of Health guide for the care and use of Laboratory animals (NIH 
Publications No. 8023, revised 1978). Prior to experimental procedures, all study animals were 
anesthetized by intramuscular injection of ketamine (20mg/kg) and acepromazine (2mg/kg) to 
minimize animal suffering and distress. All study animals were monitored daily by animal care 
personnel for development of clinical signs of FIV infection and observed by clinical 
veterinarians.  
An outline of the study design is presented in Figure 3.1. Twelve (12), 8-11 week-old 
SPF cats (Andrea D. Lauerman Specific Pathogen Free Feline Research Colony, Fort Collins, 
CO) were housed as previously described above in accordance with CSU IACUC-approved 
protocols, and were acclimated to the facility for 2 weeks prior to initiation of the study. All 
animals were part of an unrelated study and had been infected with 75,000 infectious units of 
FIVPPR (1ml of a viral stock solution with a TCID50 titer of 1X10
5.87) approximately 9 months (35 
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weeks) prior to enrollment in this protocol. A group of age-matched, uninfected SPF cats (n=12) 
served as negative controls.  
 
Figure 3.1. Study design. Cross-over treatment study. Twelve cats were divided into 2 groups (n=6) and 
treated with either ATOPICA® for Cats (cyclosporine A; 5 mg/kg PO SID) or prednisolone (2 mg/kg PO 
SID) for 28 days.  Following a 6-week wash-out period, groups were alternated so that each cat received 
the opposite treatment for 28 days.  ART study. Following a 6-week wash-out period at the end of the 
cross-over treatment study, Group 1B (n=5) received CsA for 5 days, after which they received no further 
treatment. Group 2B (n=6) received CsA for 5 days, after which CsA treatment was terminated.  Group 
2B then received antiretroviral therapy (ART +CsA) for 28 days (zidovudine 10 mg/kg + lamivudine 50 
mg/kg, PO BID). See text for additional details. 
 
Cross-over treatment study. FIV-positive cats were divided into 2 groups (n=6, randomized for 
previous vaccine treatment, gender, and litter) and treated as follows: Group 1A - ATOPICA® 
for Cats (cyclosporine oral solution, Novartis) at 5 mg/kg PO SID for 28 days; Group 2A - 
prednisolone at 2 mg/kg PO SID for 28 days. Following this treatment protocol, all cats were 
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subjected to a wash-out period of 6 weeks where no treatments were administered. During this 
period, plasma drug concentration was evaluated every 2 weeks. Blood samples were collected 
at days -7, 1, 3, 5, 7, 10, 14, 21, 28, 35, 42 of Phase I for qPCR, CBC, and flow cytometry 
analysis using previously established protocols [10,41] (Figure 3.1).  Following the 6-week 
wash-out period, drug treatment protocols for each cat group were treated with the alternate 
therapy prescribed during phase I of the study. Blood samples were collected as previously 
described for qPCR, CBC, and flow cytometry analysis (Figure 3.1). For the cross-over study, 
uninfected, age-matched negative control cats (n=12) were included, divided into 2 groups (n=6 
each), and administered either ATOPICA® (CsA, 5 mg/kg PO SID) or prednisolone (2 mg/kg 
PO SID) as previously described for FIV-infected cats.  
ART study. FIV-positive cats were again divided into 2 randomized groups and treated as 
follows: Group 1B - (CsA Only, n=5) CsA at 5 mg/kg PO SID for 5 days prior to day 0; Group 2B 
– (CsA + ART, n=6) CsA at 5 mg/kg PO SID for 5 days prior to day 0, followed by zidovudine 
(ZDV) 10 mg/kg + lamivudine (3TC) 50 mg/kg, PO BID for 28 days (Figure 3.1). Blood samples 
were collected for qPCR, CBC, and flow cytometry analysis as outlined in Figure 3.1 [10,41].   
Hematologic analyses 
Complete blood counts (CBC) and serum biochemistry analysis were performed for all 
blood samples in both the cross-over treatment study and the ART study by the CSU Veterinary 
Diagnostic Lab (CSU-VDL). Blood was collected from all cats prior to the study to establish 
baseline values, then at each time point indicated in Figure 3.1.  The percentage of cells 
positively labeld by CD4, CD8, Fas, and B220 surface antigens was determined by incubating 
30µl of EDTA-treated blood from each cat in 96-well round-bottom plates with 0.6µl of RPE-
labeled anti-feline CD4 (Southern Biotech; clone 3-4F4), FITC-labeled anti-feline CD8 (Southern 
Biotech; clone fCD8), PE/Cy7-labeled anti-feline CD45R/B220 (Biolegend; clone RA3-6B2), and 
APC/Cy7-labeled anti-feline Fas/TNFRSF6 (R&D Systems; clone 431006) mouse monoclonal 
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antibodies diluted in FACS buffer (5% BSA, 0.1% sodium azide in PBS). Following incubation 
for 30 min in the dark at room temperature, red blood cells (RBCs) were lysed, and stained cells 
were fixed using a Beckman Coulter Q-Prep work station with 600 µl of 0.1% Formic Acid, 270 
µl of 0.06 M Na2CO3 anhydrous, 0.25 M NaCl, 0.25 M Na2SO3, and 90 µl 1% wt/vol 
paraformaldehyde in 1×PBS. Flow cytometry was performed on a Coulter Gallios (Beckman 
Coulter Inc, Brea, CA) and results were analyzed using FlowJo® software (FlowJo, Ashland, 
OR). The percentage of lymphocytes positive for each marker was evaluated over time and 
compared to baseline values and naïve control data to compare alterations in lymphocyte 
immunophenotype in response to treatment and in the presence of FIV infection. 
Immunophenotype cell counts were calculated as previously described [41,42] and compared 
with CBC and qPCR data to evaluate changes in circulating immunophenotype compared to FIV 
viral and proviral loads over the course of the study and at individual time points. All CD4, CD8, 
and CD45R/B220 antibodies were directly labeled by the manufacturer.  Anti-Fas antibody was 
unlabeled but later conjugated to APC/Cy7 using a APC/Cy7® Labeling Kit (Abcam). 
Quantification of FIV viral RNA and proviral DNA in blood 
Blood samples collected during the cross-over study and the ART study were analyzed 
by real-time polymerase chain reaction (PCR) analysis to quantify FIV proviral DNA and FIVgag 
RNA at time points illustrated in Figure 3.1.  Plasma was isolated from EDTA-treated whole 
blood following centrifugation and frozen at −70°C until processing. Viral RNA was extracted 
from 140µl plasma using a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA) according to 
manufacturer’s instructions. Viral RNA from each sample was converted to cDNA using 
Superscript II (Invitrogen) in individual reactions with random hexamers (Invitrogen) and then 
treated with RNase Out (Invitrogen) prior to real-time PCR quantification. Peripheral blood 
mononuclear cells (PBMC) from all cats were purified on a Histopaque (Sigma, St. Louis, MO) 
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gradient, washed, pelleted, and then frozen at −80°C. Proviral DNA was extracted from PBMCs 
using a DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) prior to real-time PCR.   
Real-time PCR reactions were performed on a CFX96™ Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA) to detect and quantify FIV proviral DNA in PBMCs and 
FIV gag RNA in plasma using previously described FIV-A primers and probes [43], and an 
iTaq™ Universal Probes Supermix (Bio-Rad, Hercules, CA) containing an antibody-mediated 
hot-start iTaq DNA polymerase. Copy number of viral RNA in plasma was calculated as 
previously described [41,42], implementing a standard curve generated by diluting FIV-PPR 
virus stock in naïve cat plasma and analyzed by reverse-transcriptase quantitative PCR as 
outlined above. To quantify proviral DNA in PBMCs, a real-time PCR standard curve was 
generated from serial dilutions of feline PBMCs from 1000 to 5x106 subjected to real time PCR 
for the cellular house-keeping gene, Glyceraldehyde-3-Phosphate Dehydrogenase (GADPH) as 
previously described [42,44]. Resulting proviral copy numbers were normalized to copies per 
106 cells based on the total amount of DNA in the reaction (100ng). Repeated measures 
ANOVA (RM-ANOVA) with multiple comparisons was used to evaluate differences in FIV RNA 
and DNA loads among treatment groups over time and at individual time points. Analyses were 
conducted using GraphPad Prism 6.0 software (La Jolla, CA) and p-values < 0.05 were 
considered significant. 
Evaluation of peripheral cytokine expression during immunomodulatory therapy 
Plasma samples collected at days -5 (pre-treatment) and day 5 (post-treatment) of the 
cross-over study (Figure 3.1) were analyzed by a commercially available MILLIPLEX® MAP 
Feline Cytokine/Chemokine Magnetic Bead Panel (fluorophore-conjugated microspheres, 
Millipore) per manufacturer’s instructions. Briefly, 25ul from each triplicate sample was 
combined into one sample per animal per sample.  50ul of each combined sample was 
incubated with a composite panel of microspheres coupled with capture antibodies to INFγ, IL-
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1β, IL- 2, IL-8, IL- 10, MCP-1,TNFα , Fas, SDF-1, SCF, RANTES, PDGF-BB, KC, IL-18, IL-13, 
IL-12 (p40), IL-6, IL-4, GM-CSF, and Flt-3 ligand. Following incubation with biotinylated 
secondary antibodies and streptavidin-conjugated phycoerythrin (PE), soluble cytokine 
molecules were detected in each sample using a Luminex® 200™ detection system. Final 
analyte concentration was calculated using manufacturer-provided standard curves for each 
analyte and Bio-Plex™ Manager 5.0 software (Bio-Rad). RM-ANOVA with multiple comparisons 
was used to evaluate differences in cytokine concentration among treatment groups over time 
and at individual time points. Analyses were conducted using GraphPad Prism 6.0 software (La 
Jolla, CA) and p-values < 0.05 were considered significant. 
Results 
Prednisolone & CsA induce acute and transient increases in circulating FIV RNA and DNA 
Cross-over treatment study. Quantitative PCR analysis of plasma detected FIV RNA in study 
animals prior to treatment with both prednisolone and CsA, and at all time points during and 
following treatment (Figure 3.2). Changes in FIV viral copies per ml of plasma were compared 
over time to detect changes in RNA viral load during treatment by RM-ANOVA. Although FIV 
RNA viral loads did not differ over time between treatment groups in this study, significant 
differences in FVA RNA were detected at individual time points when compared to pre- 
treatment FIV RNA viral loads. Levels of FIV RNA were significantly elevated in plasma of  
 
Figure 3.2. Prednisolone and CsA induce acute and transient increases in FIV RNA and DNA.   
(A) Prednisolone-treated cats exhibited significantly increased levels of FIV RNA at days 1, 7, and 14 
compared to pre-treatment measurements, while CsA-treated cats had increased FIV RNA at day 7 post-
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treatment. (B) Both prednisolone and CsA-treated cats exhibited significantly increased levels of FIV DNA 
at 1 day post-treatment. 
prednisolone-treated cats at days 1, 7, and 14 during treatment, and increased at day 7 of CsA 
treatment (Figure 3.2A). Similarly, FIV proviral DNA loads did not differ between treatment 
groups over time, however, levels of FIV DNA were significantly increased in PBMCs of both 
prednisolone and CsA-treated cats after one day of treatment (Figure 3.2B).  
ART study. Cats were treated with CsA prior to antiretroviral therapy (ART) to assess whether 
CsA induced viremia can be inhibited by antiretroviral therapy (ART) replication.  Quantitative 
PCR was used to evaluate changes in FIV RNA and DNA viral and proviral loads over time in 
response to therapy.  As previously observed, cats receiving CsA treatment (CsA Only) 
exhibited a significant transient increase in FIV RNA at day 5 post-CsA treatment (p=0.013) 
(Figure 3.3A). While cats treated with CsA + ART exhibited a slight decrease in FIV RNA levels 
at day 5 (compared to pre-treatment levels), this finding was not statistically significant. 
However, FIV RNA levels increased after day 5 in cats treated with CsA and then ART, resulting 
in significantly increased viral loads at day 21 of ART (p=0.002) (Figure 3.3A). Interestingly, 
acute and transient increases in FIV proviral DNA were observed in cats treated with both CsA 
Only (day 5, p=0.004; day 14, p=0.005) and CsA followed by antiretroviral therapy (CsA+ART) 
(day 1, p=0.011; day 5, p=0.002) (Figure 3.3B).   
 
Figure 3.3. CsA induces recurrent increases in FIV RNA and DNA. (A) Cats treated only with CsA 
(CsA Only) exhibit a transient increase FIV RNA at day 3 post-treatment.  FIV-infected cats pre-treated 
with CsA exhibit a slight decrease in FIV RNA at days 3 and 7 of antiretroviral treatment, but viral loads 
are significantly increased by day 21. (B) Cats treated with CsA alone and CsA+ART exhibit significantly 
increased levels of FIV DNA at day 7 post-CsA treatment. 
 110 
Peripheral cytokine expression is altered by prednisolone and CsA during FIV infection 
Circulating cytokine and chemokines were quantified in plasma by microsphere 
immunoassay (MIA) at day -5 (pre-treatment) and day 5 (post-treatment) to detect changes in 
cytokine expression in FIV-infected cats treated with prednisolone or cyclosporine A. Overall, 
FIV-infected cats treated with CsA exhibited increased levels of Fas (p<0.001), IL-4 (p=0.001), 
SDF-1 (p=0.004), IL13 (p=0.013), and IL-8 (p=0.013) compared to baseline levels, while levels 
of Flt-3L (p=0.002), IL-12 p40 (p=0.008), and SCF (p=0.022) were significantly decreased 
(Figure 3.4A).  Similar findings were observed in FIV-infected cats treated with prednisolone, 
 
Figure 3.4. FIV-infected cats treated with CsA and prednisolone exhibit alterations in circulating 
cytokines.  (A) FIV-infected cats exhibit increased levels of Fas, IL-4, IL-13, and IL-8 at 5 days of CsA 
treatment, while levels of Flt-3L, IL-12 p40, and SCF were decreased compared to pre-treatment levels.  
(B) Prednisolone treated cats with FIV exhibit similar changes in cytokine expression (increased Fas, IL-
4, IL-8 and decreased Flt-3L, IL-12 p40, SCF) at 5 days of treatment. 
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which exhibited increased levels of Fas (p<0.001), Il-4 (p=0.002), and IL-8 (p=0.049) compared 
to baseline data, while levels of Flt-3L (p=0.019), IL-12 p40 (p=0.018), and SCF (p=0.022) were 
comparatively decreased (Figure 3.4B).  
FIV-infected cats exhibit divergent lymphocyte immunophenotypes with CsA and prednisolone  
Cross Over Treatment Study. Flow cytometry was used to evaluate changes in the percentage 
of lymphocytes positive for CD4, CD8, Fas, and B220 surface antigens over time in FIV-infected 
and naïve cats. Changes in FIV-infected cats were compared to baseline values and data from 
naïve control cat samples to compare alterations in lymphocyte 
 
Figure 3.5. CsA and prednisolone induce a transient increase in CD4+ lymphocytes in FIV-infected 
cats that correlates with increased FIV viral load. CD4+ lymphocytes are significantly increased in 
FIV-infected cats at day 14 of CsA treatment (A), and at day 14 of prednisolone treatment  (B). Increased 
levels of CD4+ lymphocytes correlate with increased FIV RNA in CsA treated cats (C) and prednisolone-
treated cats (D). 
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immunophenotype in response to treatment and in the presence of FIV infection. Overall, the 
percentage of CD4+ lymphocytes differed significantly over time in FIV-infected cats treated 
with both CsA (interaction, p=0.05) and prednisolone (interaction, p=0.03) when compared to 
FIV-negative control cats. Post-hoc analyses indicated that FIV-infected cats exhibited transient 
increases in CD4+ lymphocytes at 14 days of treatment with both CsA (p=0.004) and 
prednisolone (p=0.05) when compared to baseline data (pre-treatment)(Figure 3.5A-B).  
When compared to FIV viral and proviral loads, a significant positive correlation was observed 
between numbers of CD4+ lymphocytes and circulating copies of FIV RNA in CSA (p=0.025) 
and prednisolone treated cats (p=0.037) (Figure 3.5C-D). Although CD4+ lymphocytes were 
slightly decreased at day 1 of CsA treatment in naïve control animals, this change was not 
significant, and the percentage of CD4+ lymphocytes did not differ over time during CsA and 
prednisolone treatment in control animals.The percentage of B220+ lymphocytes also differed 
significantly over time in FIV-infected cats treated with CsA (interaction, p=0.02) and 
prednisolone (interaction, p=0.02) compared to naïve controls. However, in contrast with 
changes in CD4+ lymphocytes, FIV-infected cats exhibited significant decreases in B220+ after 
28 days of treatment with CsA (p=0.033-0.013) and after 21 days of prednisolone (p=0.034-
0.005) (Figures 3.6A and 3.7A).  
Although CD8+ lymphocytes tended to be slightly lower in FIV-infected cats treated with 
CsA when compared to naïve controls (Figures 3.6B and 3.7B), these findings were not 
significant, and no significant differences over time were observed when compared to baseline 
levels. Similarly, Fas+ lymphocytes did not differ between FIV-infected and naïve cats treated 
with CsA (Figure 3.6C). However, the percentage of Fas+ lymphocytes differed significantly 
over time in FIV-cats treated with prednisolone (p=0.037) compared to naïve controls, and post-
hoc analysis revealed transient increases in Fas+ lymphocytes at 14 days (p=0.004) and 21 
days (p=0.016) of prednisolone treatment, followed by a significant spike in Fas+ cells with 
cessation of treatment (day 35, p<0.0001) (Figure 3.7C). The percentage of CD8+, B220+, and 
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Fas+ lymphocytes did not differ over time during CsA and prednisolone treatment in naive 
control animals.  
 
Figure 3.6. B220+ lymphocytes decrease over time in FIV-infected cats treated with CsA.   
(A) B220+ lymphocytes are significantly decreased in FIV-infected cats after 28 days of treatment with 
CsA.  (B-C) While CD8+ and Fas+ lymphocytes tended to be slightly lower in FIV-infected cats treated 
with CsA when compared to naïve controls, these findings were not significant, and no significant 
differences over time were observed when compared to baseline levels. 
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Figure 3.7. B220+ lymphocytes decrease over time in FIV-infected cats treated with prednisolone.  
(A) B220+ lymphocytes are significantly decreased in FIV-infected cats after 28 days of treatment with 
prednisolone. No significant changes in CD8+ lymphocytes are observed in FIV-infected cats during 
Phase I (B). However, Fas+ lymphocytes are significantly increased at days 14 and 21 of prednisolone 
treatment in FIV-infected cats (D), although this population of lymphocytes significantly decreases with 
cessation of treatment (day 42).  
ART study.  Flow cytometry was used to evaluate changes in the percentage of lymphocytes 
positive for CD4, CD8, Fas, and B220 surface antigens over time in FIV-infected in response to 
treatment with CsA with or without antiretroviral therapy (CsA only, CsA+ART). During the ART 
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study, no significant differences were observed in response to 5 days of CsA treatment, or in 
response to 28 days of ART (Figure 3.8A-D). 
 
Figure 3.8. Pre-treatment with CsA prior to ART does not result in significant changes in 
lymphocyte immunophenotype. No significant differences between (A) CD4+, (B) CD8+, (C) B220+, or 
(D) Fas+ lymphocytes are observed following 5 days of CsA Treatment (CsA Only group, n=5; CsA+ART 
group, n=6) or with 28 days or antiretroviral therapy (CsA+ART group, n=6). 
Discussion 
The results of this study represent unexpected and previously undocumented effects of 
prednisolone and cyclosporine A during chronic FIV infection, and highlight important 
complications to consider when using immunosuppressive therapy to treat opportunistic disease 
in FIV-infected cats. Because prednisolone and CsA exhibit well-documented, dose-dependent 
immunosuppressive effects via inhibition of IL-2 mediated T-lymphocyte proliferation and 
activation [32-34,36,37], it was expected that treatment with these immunomodulatory agents in 
FIV-infected cats would result in broad reduction of circulating lymphocytes necessary for FIV-
infection and persistence; fundamentally reducing the capacity for FIV to infect and replicate 
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within appropriate target cells. However, immunosuppressive doses of CsA and prednisolone in 
FIV-infected cats failed to elicit an inhibitory effect on T lymphocytes and FIV replication in this 
study, and in fact, exacerbated FIV replication rates in conjunction with acute increases in CD4+ 
lymphocytes and alterations in the inflammatory cytokine profiles of FIV-infected cats. While an 
unequivocal cause for the discrepancy in the anticipated therapeutic effect is not immediately 
apparent, correlative increases in FIV viral load and CD4+ T lymphocytes suggest that direct 
interplay between these factors may account for such unanticipated outcomes.  
 Perhaps the most important findings of this study are the acute and transient increases 
in FIV RNA and DNA loads during CsA and prednisolone treatment, as well as the positive 
correlation of FIV RNA levels with that of CD4+ lymphocytes. This direct relationship suggests 
that both CsA and prednisolone may not only prevent CD4+ lymphocyte depletion during FIV 
infection, but may also improve CD4+ counts, albeit to the detriment of enhanced viral 
propagation. Indeed, the fact that CD4+ lymphocytes increase in response to CsA and 
prednisolone treatment indicates that these immunomodulatory agents may cause an increase 
in circulating target cells, which thereby increase levels of FIV infection and replication within 
naïve effector T-cells, and thus contradict the expected therapeutic effect of these drugs and our 
intended outcome. While prednisolone has not previously been documented to induce such 
changes in FIV-infected cats, one prior study demonstrated increased FIV viral loads in plasma 
at 4 weeks (28 days) of CsA treatment, which transiently subsided as observed in the present 
cohort of FIV-infected cats [45]. However, increased viral isolation and RNA viral loads have 
been well-documented in HIV-infected humans treated with both prednisolone and CsA, and 
these drug-induced changes are frequently associated with increased CD4+ lymphocytes [46-
48], suggesting a causative relationship that provides latent virus with the means to reinitiate 
infection of naïve T-cells. Such interactions may therefore account for the corresponding 
transient increase in FIV proviral DNA, likely mediated through successive integration and viral 
maintenance within this renewed source or target cells. 
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 In accordance with these findings, we subsequently investigated the potential for an 
innovative immunomodulatory approach to compliment antiretroviral therapy. We hypothesized 
acute increases in FIV replication induced by CsA might result in highly effective anti-FIV 
therapy induced by selected nucleoside analogue reverse transcriptase inhibitors (NARTIs), 
zidovudine and lamivudine (ART), previously shown to be effective in vivo at reducing FIV viral 
loads in chronically infected cats [21]. Because NARTIs exert their primary therapeutic effect 
during active viral replication through competitive inhibition and reduction in the activity of 
reverse transcriptase [49-51], we theorized that CsA-mediated induction of an enhanced 
replicative state might improve the efficacy of antiretroviral therapy. We pre-treated all FIV-
infected cats with CsA prior to day 0, after which CsA treatment ceased and a subset of cats 
were then administered ART for 28 days. As previously observed in the cross-over treatment 
study, cats that received CsA treatment only (no ART at day 0) exhibited an identical transient 
increase in FIV RNA viral load, confirming that CsA treatment induces enhancement of FIV 
replication in infected cats. Interestingly, a slight reduction in viral load was observed in FIV-
infected cats receiving CsA then ART, although this change was not significant when compared 
to pre-treatment levels. In retrospect, it is likely that this trend may have continued if CsA 
treatment had been continued in conjunction with ART, rather than terminating CsA treatment at 
day 0. Because ART diminished viral replication in CsA + ART treated cats compared to cats 
that received CsA only, it is likely that the CsA-mediated increase in viral load was due to new 
viral replication/viral activation. The subsequent rise in FIV RNA levels by day 21 of ART may 
likely reflect the withdrawal of CsA from the treatment protocol, which effectively terminated the 
activated state of viral replication that was conducive to improving ART efficacy. Future studies 
will assess whether prolonged combinational therapy with CsA + ART can sustain this antiviral 
effect.  
  Appreciable changes in lymphoid immunophenotype also extended to B220+ 
lymphocytes, which decreased significantly over time during the course of treatment with both 
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CsA and prednisolone. B220 is a heavily glycosylated isoform of CD45R, and a surface antigen 
expressed in immature and mature naïve B-cells, as well as other lymphocyte subsets such as 
activated T-cells and dendritic cells [52,53]. It is well documented that at high doses, 
prednisolone broadly decreases both T and B lymphocytes, but at lower doses, prednisolone 
produces selective depletion of B lymphocytes [54,55]. It is possible that although we selected a 
higher, immunosuppressive dose of prednisolone, the dose may have not been high enough to 
suppress both T and B lymphocytes in our FIV-infected cohort, thus accounting for the selective 
depression of B220+ cells and not CD4+ T cells. In contrast, cyclosporine A is known to be 
primarily selective for T lymphocytes, producing less inhibitory effects on their B lymphocyte 
counterparts [56-58]. However, certain subsets of B lymphocytes, such as those responding to 
thymus independent (TI) antigens, have been shown to be sensitive to CsA treatment, while 
primed (or activated) T lymphocytes are resistant [58]. Previous studies have shown that FIV is 
capable of directly activating T lymphocytes, either by primary virus infection or chronic 
antigenic stimulation [59-61], while not affecting the function of B cells recognizing T-
independent antigens [8,62]. In this present study, the predisposing condition of FIV-infection 
may therefore account for the decreased efficacy of CsA to reduce CD4+ lymphocytes in 
circulation, and provide cause for the selective depletion of CsA-sensitive subpopulation of B 
lymphocytes. Future studies should assess the activation status and antibody response to T-
dependent and T-independent antigens during prednisolone and CsA treatment to elucidate the 
divergent mechanisms of action during lentiviral infection. 
 Prednisolone and CsA are both well-known inducers of apoptosis in lymphocytes [63-
66]. Interestingly, Fas expression, a marker of apoptosis in lymphocytes was significantly 
elevated in prednisolone treated cats, but not in CsA-treated cats. Glucocorticoid and CsA 
induced apoptosis occurs primarily via caspase-dependent activation, and predominately occurs 
independent of the FasL/Fas system [38,64,66]. Fas-induced apoptosis may occur in viral-
infected cells via binding of FasL on CD8+ T cells, and may be upregulated in this study as a 
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result of increased infection of CD4+ lymphocytes in prednisolone and CsA treated animals [67]. 
However, the cause for increased Fas expression on lymphocytes during prednisolone 
treatment but not CsA treatment is unknown and likely multifactorial due to overlying viral 
infection. Future studies will investigate other markers of apoptosis (i.e. caspase activation) and 
lymphocyte activation to elucidate mechanisms of apoptosis during concurrent lentiviral infection 
and immunosuppressive therapy.  
 Similar to the expression of surface markers detected by flow cytometry, microsphere 
immunoassay detected significant increases in soluble Fas expression in FIV-infected cats 
treated with both CsA and prednisolone. Increased levels of apoptosis in CD4+ T-cells and 
CD19+ B-cells have been well-described during HIV infection, and have been correlated with 
viral RNA levels in plasma and a reduction in these important lymphocyte subsets [68,69]. 
Interestingly, such a correlation was not observed in this study, however, CD4+ lymphocytes 
were observed to increase in response to CsA and prednisolone treatment, and may have 
counterbalanced any viral-induced decrease in lymphocyte numbers in the face of continued 
CD8-mediated apoptosis. Increases in Il-4 was also observed in both treatment groups, in 
addition to increased IL-13 observed in CsA-treated cats infected with FIV. Interleukin 4 (IL-4) is 
produced predominately by T helper 2 (Th2) cells, as well as smaller T cell subsets such as 
Natural Killer (NK) T cells and g/d T cells, and primarily confers anti-inflammatory effects on Th1 
cells, macrophages, and interferon gamma (IFNg) production, as well as plasma cell 
differentiation, IgE class switching, and differentiation of antigen-stimulated naive T cells into the 
Th2 subset [70-73]. IL-13 exhibits similar effects on the inhibition of inflammatory cytokines, and 
is functionally related to IL-4 [74]. Increased levels of these anti-inflammatory cytokines have 
been previously associated with HIV infection [75-77], indicating a shift to a predominant Th2 
subtype during infection, but these effects have not been well studied in cats with FIV. 
Furthermore, prior studies have demonstrated that both prednisolone and CsA treatment are 
 120 
associated with decreases in IL-4 expression, yet in this study, circulating IL-4 concentrations 
increased in response to treatment [78-81]. The cause for such a shift in cytokine expression in 
response to CsA or prednisolone treatment is not apparent, but may be due to underlying viral 
infection. If FIV infection produces a shift to a Th2 response as observed in HIV, it is possible 
that the pharmacological effect of these compounds may have stimulated differentiation of these 
CD4+ lymphocytes along the Th2 pathway, thus increasing expression of these associated 
cytokines. Future studies will evaluate additional surface markers and transcription factors to 
establish the role of CD4+ T cell development and differentiation during FIV infection. 
 FIV-infected cats treated with both prednisolone and CsA also exhibited increased levels 
of circulating IL-8 when compared to baseline levels (pre-treatment). IL-8 is pro-inflammatory 
cytokine that is primarily involved in neutrophil chemotaxis, but also exhibits chemotactic activity 
against T cells and basophils [82]. Previous studies have shown that both prednisolone and 
CsA exhibit significant inhibitory effects on IL-8 production [83-85], but in this study, IL-8 was 
significantly increased following treatment. Studies in HIV have demonstrated significant 
increases in circulating levels of IL-8 in plasma of infected patients, and have shown that IL-8 
plays a significant role in stimulating HIV replication [86-88]. It is therefore reasonable to 
assume that IL-8 may exhibit similar kinetics during FIV-infection, and that the increased rate of 
FIV replication during prednisolone and CsA treatment may account for the corresponding 
increase in IL-8 expression during treatment with these immunomodulatory agents.  
 Contrary to the above findings, FIV-infected cats treated with prednisolone and CsA 
exhibited a significant decrease in the expression of several pro-inflammatory cytokines, such 
as IL-12 p40, Flt-3L, and SCF-1. IL-12 p40 is secreted by active macrophages and is critical in 
the production of IFNg and the induction of Th1 cells [89]. Prednisolone and cyclosporine may 
directly suppress IL-12 p40 expression and likely account for the decreased levels in this study 
[90-92], however previous studies have also shown that HIV-infected patients have impaired IL-
12 p40 secretion, and the contribution of FIV infection and replication may likewise play a role in 
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this study as well [93]. Flt-3L and SCF play an important role in hematopoiesis and function by 
increasing lymphocyte proliferation by activating hematopoietic progenitors [94-97]. Decreased 
Flt-3L and SCF has been well-documented during prednisolone and CsA treatment, which most 
likely account for decreased levels of these cytokines, yet the inhibition of these inducers of cell 
proliferation was not sufficient to cause a decrease in CD4+ lymphocytes in FIV-infected cats 
[98-100]. While the exact mechanism is not clear in this present study, it is likely that CD4+ 
lymphocyte increases occurred independently of these stimulatory cytokines during treatment 
with CsA and prednisolone in FIV-infected cats.  Unfortunately, levels of IL-2 were undetectable 
is nearly all FIV-infected cats treated with prednisolone and CsA, which prevented evaluation of 
IL-2-mediated changes in hematologic parameters.  Future studies will be focused on the 
optimization and extended analysis of this pivotal cytokine the determine its role during 
prednisolone and CsA treatment in FIV-infected cats. 
While the findings presented here demonstrate a paradoxical outcome of a therapeutic 
regimen designed to improve clinical FIV infection, these results provide new insight into the use 
of these commonly prescribed immunomodulatory agents. In summary, both prednisolone and 
CsA induce acute and transient increases in the percentage of CD4+ lymphocytes in FIV-
infected cats, which directly correlate with increased FIV RNA viral loads. FIV proviral DNA 
levels also exhibit a similar, transient increase following prednisolone and CsA treatment, and 
pre-treatment with CsA in FIV-infected cats has the potential to reduce viral loads when 
combined with nucleoside analog reverse transcriptase inhibitors through induction of an active 
state of viral replication conducive to competitive inhibition and reduced reverse transcriptase 
activity. Furthermore, evidence suggests treatment with these immunomodulatory agents during 
FIV infection may perpetuate a shift toward a Th2-mediated inflammatory response with 
concurrent reduction in mediators of a pro-inflammatory Th1 response. Future studies will 
investigate prolonged combinational therapy with CsA + ART to determine the potential for 
sustained decrease in FIV viral loads, as well as evaluation of other innate mediators of T 
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lymphocyte proliferation during immunomodulatory therapy. Overall, these results highlight the 
potential for drug-induced perturbation of FIV infection and underscore the need for more 
information regarding immunopathologic consequences of therapeutic agents on concurrent 
viral infections. 
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HIV infection results in well-documented changes to gut-associated lymphoid tissue 
(GALT), but few studies have evaluated whether similar mucosal immunological dysfunction 
occurs in the oral cavity. Studies of these phenomena have been hampered by lack of a suitable 
animal model, as commonly used animal models for HIV (SIV/SHIV infections of non-human 
primates and HIV infections in humanized mice) do not reliably result in oral disease. In 
contrast, FIV results in immunological dysfunctions and opportunistic infections similar to HIV-
AIDS, including periodontal and oral inflammatory disease that occurs in more than 50% of 
untreated, FIV-infected animals. As a result of previous work described in this dissertation, I 
have developed a strong interest in (i) investigating the role of the oral microbiome and immune 
function in the development of lentiviral-induced oral disease (CHAPTER 1), as well as (ii) the 
investigation of new modalities of ART that might be more efficacious in treating this refractory 
condition in HIV patients (CHAPTER 3).  Thus, in Chapter 4 of this dissertation, I conducted a 
pilot study to assess FIV-associated changes in clinical status, oral microbiota, local and 
systemic viral burden, and immune profile as a model to study HIV-induced oral disease 
development. Results of this pilot study demonstrate that FIV infection of domestic cats is 
associated with: (1) oral microbiota dysbiosis, with a marked loss of microbial diversity during 
FIV-associated periodontitis; (2) changes in salivary cytokine levels, even in the absence of FIV 
clinical oral disease; and, (3) systemic markers of immune stimulation, signaling local and 
peripheral immune activation, and suggesting bacterial translocation.  These findings highlight 
the potential for the feline model of lentiviral-induced oral disease to expand our understanding 
of the complex interactions between HIV infection, oral immune dysfunction, and the 
perturbations to the oral microbiota that occur in the context of HIV infection. 
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Background 
Mucosal immune dysfunction, bacterial translocation, systemic immune activation, and 
chronic inflammation are well-documented features of chronic HIV infection. Despite the 
success of combinational antiretroviral therapy (cART) in diminishing HIV viral replication and 
prolonging immune function, a multitude of systemic and local manifestations of HIV infection 
persist. For example, cART is associated with a decrease in the occurrence of many oral 
manifestations of HIV, yet a subset of oral infections and chronic periodontitis persist in HIV-
infected individuals [1-6].  Furthermore, HIV infection precipitates alterations of the oral 
microbiome and secretory and cellular components of the oral cavity during infection, and these 
changes are not restored by cART [2].  The oral cavity, as an immunologically active extension 
of the gastrointestinal tract, may be an important site for HIV replication and persistence, yet this 
aspect of HIV disease has not been closely studied, and the relationship between viral-induced 
immune dyscrasias, oral dysbiosis, and the chronic inflammatory lesions have not been well 
established [8-11]. Gaps in our understanding of the drivers of HIV-associated oral dysbiosis, 
mediators of chronic oral and systemic inflammation, and association with clinical oral disease 
underscore the need for studies to investigate the pathogenesis and relationship of these 
alterations. 
 HIV-induced deficits in gut-associated lymphoid tissue (GALT) are associated with 
bacterial byproduct translocation resulting in chronic systemic immune activation [1, 3, 14-22].  
Conversely, the role of oral mucosal associated lymphoid tissue (MALT) in promoting HIV-
associated chronic inflammation has not been comprehensively evaluated. cART protocols may 
not eliminate HIV persistence in oral tissues, and underlying chronic immune activation 
associated with HIV infection may promote oral dysbiosis [2, 23-25].  Few studies have 
characterized perturbations in the microbial ecology of the oral cavity during HIV infection, and it 
is unknown whether bacterial translocation and disruption of oral MALT contributes to persistent 
systemic immune activation in HIV-infected patients [1, 3, 15-17, 26].  Measuring the impact of 
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cART on oral microbiome composition, secretory and cellular oral immune parameters, or 
systemic inflammation during HIV infection is untenable as untreated control groups cannot 
ethically be studied; thus, the use of an animal model to evaluate these associations is a critical 
component of furthering translational studies.  
 Commonly used animal models for HIV, including SIV/SHIV infections of non-human 
primates (NHPs) or HIV infections in humanized mice, do not reliably incite oral lesions [27, 28]. 
Feline immunodeficiency virus (FIV) is the feline analog of HIV, and the only non-primate 
lentivirus to cause AIDS in its natural host. The molecular biology of FIV is strikingly similar to 
HIV, and the FIV animal model has been employed for many studies relevant to HIV, including 
development of anti-retroviral drugs, determination of the role of regulatory T cells during 
lentiviral infections, modeling for HIV latency, and for studies of lentiviral vaccine development 
[29-36]. Importantly, gingivitis and periodontitis are primary clinical signs associated with 
untreated natural and experimental FIV-infection, and are principal attributes of this model that 
may be exploited to investigate pathogenic mechanisms involved in the perturbation of the oral 
immune system and microbial environment [37, 38].  
 Oral manifestations of HIV infection, including opportunistic infections (OI) and 
immunodeficiency associated periodontal lesions, were estimated to occur in a large proportion 
of adult HIV patients prior to cART [2, 26, 39-46]. Fortunately, cART has significantly decreased 
many HIV oral manifestations, especially candidiasis and necrotizing gingivitis [2, 26, 47-56]. In 
fact, oral manifestations of HIV are now considered a clinical hallmark of cART failure, and/or 
diagnosis of these conditions may be the first indication of HIV infection [2, 26, 57].  Despite 
progress, the incidence of periodontitis may be increased in HIV patients beyond the general 
population, and increases in some OI, notably HPV, has been observed [58-60]. Advances in 
high throughput sequencing technologies have revealed that microbial shifts occur in the oral 
cavity during HIV infection, even in the presence of cART [16, 26]. The recognition that the 
microbiome contributes to health and disease states, and the complex interplay between oral 
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mucosal integrity, microbial colonization, co-infections, and mucosal immunity suggests 
microbiome composition may play an important role in HIV pathogenesis [61].   
 Most cats with FIV are not treated with cART, and oral manifestations are common in 
naturally and experimentally infected cats [37, 62, 63].  These manifestations are frequently 
characterized by periodontitis, and feline chronic gingivostomatitis [37] that exhibit striking 
similarity to lesions noted in untreated HIV patients (Figure 4.1). [2, 7, 64-69]. Additionally, 
opportunistic microorganisms detected in saliva of HIV-positive individuals are similarly 
implicated in feline oral disease (C. albicans, Fusobacterium sp., Streptococcus sp., Prevotella 
sp., Campylobacter sp., and Porphyromonas gingivalis) [4, 16, 70-78], indicating that the impact 
of FIV on feline oral microbial populations may parallel changes observed in HIV infection. 
   
Figure 4.1. Periodontal disease and gingivostomatitis are common manifestations of untreated FIV 
and HIV infection. FIV-infected cats exhibit ulcerative and necrotizing gingivitis and stomatitis (1A) 
resembling Necrotizing Ulcerative Gingivitis (NUG) in HIV-infected humans (1B) Reprinted from [7]. 
Previous studies have shown that HIV and FIV induce characteristic depletion of 
circulating CD4+ lymphocytes, resulting in global immunosuppression, and that widespread loss 
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of lymphocytes o at the surface of the gastrointestinal tract mucosa results in compromised local 
immune function [1, 19-22, 79-81].  This change is correlated with increased populations of 
opportunistic pathogens and shifts in microbiota composition [1, 14, 19]. Oral dysbiosis likely 
occurs by a similar mechanism during acute HIV and FIV infection, and immunodeficiency-
associated shifts in the oral microbiota presumably result in activation of immunocytes and 
perturbation of inflammatory mediators; thus contributing to oral lesion development in affected 
individuals [1, 14, 19]. As such, an animal model designed to investigate in vivo kinetics and 
immunopathologic mechanisms contributing to oral disease during lentiviral infection may 
provide critical information for the development of more effective strategies to manage chronic 
impacts of HIV-infection. 
Material and Methods 
FIV alterations of oral microbiota 
Saliva was collected from the sublingual area and ventral cheek pouches from naïve juvenile 
SPF cats (12-14 month-old) and age-matched cats infected with FIV (PPR strain) of 8 months 
duration (n=5/group).  FIVPPR is a relatively apathogenic strain of FIV that typically results in mild 
self-limiting gingivitis and/or periodontitis during acute infection [82].  Animals did not have overt, 
visual signs of clinical periodontitis at the time of sampling. FIV-infected and naïve SPF animals 
were maintained on a similar diet, and similar anatomic regions were swabbed from all animals 
at the same time of day. DNA was extracted as previously described [83], and amplicon 
sequencing was performed using illumina MiSeq to generate paired-end 2x250bp sequences of 
the hyper-variable region 4 (V4) of the 16S rDNA. Data were normalized using cumulative sum 
scaling [84], and used to construct a nonmetric multidimensional scaling 3D plot (bioinformatics 
analysis conducted by University of Missouri Metagenomics Center (MUMC) and Z. Abdo, 
DMIP, CSU). 
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FIV alterations of oral cytokine expression 
Saliva was collected from naïve and FIV-infected cats without detectable oral lesions (as 
described above; n=5/group), and analyzed by a commercially available MILLIPLEX® MAP 
Feline Cytokine/Chemokine Magnetic Bead Panel (fluorophore-conjugated microspheres, 
Millipore) per manufacturer’s instructions. Briefly, 50ul of saliva (diluted 1:3 in assay buffer) was 
incubated with a composite panel of microspheres coupled with capture antibodies to INFγ, IL-
1β, IL- 2, IL-8, IL- 10, MCP-1,TNFα , Fas, SDF-1, SCF, RANTES, PDGF-BB, KC, IL-18, IL-13, 
IL-12 (p40), IL-6, IL-4, GM-CSF, and Flt-3 ligand. Following incubation with biotinylated 
secondary antibodies and streptavidin-conjugated phycoerythrin (PE), soluble cytokine 
molecules were detected in each sample using a Luminex® 200™ detection system. Final 
analyte concentration was calculated using manufacturer-provided standard curves for each 
analyte and Bio-Plex™ Manager 5.0 software (Bio-Rad). One-way ANOVA with multiple 
comparisons was used to evaluate differences in cytokine concentration among treatment 
groups. Analyses were conducted using GraphPad Prism 6.0 software (La Jolla, CA) and p-
values < 0.05 were considered significant. 
Innovative cART Regimen  
Triplicate cell cultures consisting of GFox cells (CrFK cells overexpressing CD134) [82, 85] were 
established in 96-well plates at 20,000 cells/well and allowed to attach at 37°C overnight.  GFox 
cell cultures were grown at 37°C and 5% CO2 in 100µl of culture medium composed of 
Dulbecco's modified Eagle's medium (DMEM) with GlutaMAX-1, 10% fetal bovine serum (FBS), 
and 1x penicillin-streptomycin (10,000 U/liter penicillin and 10,000 μg/liter streptomycin), as well 
as 1 μg/ml of Fungizone® (Amphotericin B; Life Technologies) [86].  At day 0, 9µl of FIVC36 
stock (containing 50,000 infectious units) was incubated for 1 hour at 37°C with culture medium 
and varying concentrations of Dolutegravir (DTG), Tenofovir disoproxil fumarate (PMPA), and 
Emtricitabine (FTC) in a ratio previously utilized in in vivo studies in SIV-infected macaques (see 
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Figure 4.4) (total volume 100µl) [12, 13]. Following incubation, infected media was then added 
to cell culture plates, bringing the total volume to 200µl. Triplicate negative control (no FIV, 
cART only: 10uM DTG, 80uM PMPA, 100uM FTC) and positive control (FIV only, no cART) 
wells were included for each sample. At days 4, 6, 8, and 11 post-inoculation, 120µl of 
supernatant was removed from each well, frozen at -80°C, and replaced with 120µl of fresh 
culture media.  At day 11, the supernatant collected from each well and each time point was 
assayed by a previously described capture ELISA protocol to detect FIV p26 antigen at an 
absorbance of 450nm in 96-well flat bottom plates [87].  Percent inhibition was calculated from 
mean absorbance values (Abs) using the previously described formula ((X − Y)/X) x 100, 
where X is fraction of cells infected in the absence of cART (FIV only positive control) and Y is 
the fraction of cells infected in the presence of various cART treatments [88]. 
Results  
FIV alterations of oral microbiota 
Significant differences were detected in the oral microbiota composition of FIV-infected 
cats relative to naïve animals (Figure 4.2A). Normalized data were tested using the Zero 
Inflated Gaussian model implemented in the R package from metagenomeSeq [89] to identify 
the putative OTUs driving differences between FIV+ and FIV- cats. Significant log-fold change in 
abundance in 12 genera were noted between groups at the 0.1 level of significance after 
correction for multiple testing (Figure 4.2B).  One FIV-positive cat developed moderate to 
severe erythematous gingivitis during the course of infection and saliva was collected and 
analyzed as described above.  Upon analysis of saliva, this individual demonstrated a 
dramatically altered microbiome population with >95% operational taxonomic units (OTUs) 
corresponding to the genus Moraxellaceae (Figure 4.2C, MUMC and Z. Abdo, DMIP, CSU).  
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FIV alterations of oral cytokine expression 
Circulating cytokine and chemokines were quantified in saliva of naïve and FIV-infected 
SPF cats (n=5 per group) by microsphere immunoassay (MIA) to detect changes in innate 
immune parameters in the presence of FIV infection. At a single time point with small group 
sizes in cats without gingivitis, FIV-infected cats exhibited trends for decreased levels of IFNγ 
(p=0.149), IL-8 (CXCL8, p=0.108), IL-1B (p=0.103), and IL-12p40 (0.096) compared to naïve 
cats, while levels of IL-2 (p=0.184) and KC (CXCL1, p=0.101) tended to be slightly decreased 
(Figure 4.3).  
Figure 4.2: Salivary microbiome alterations during FIV infection. (A) 3D Nonmetric 
Multidimensional Scaling (NMDS) separates clusters of FIV- and FIV+ cat microbiome samples. Ovals 
represent the 90% confidence ellipsoids around the centroid of the clusters (FIV+ = red; FIV- = blue). 
(B) OTUs with significant log-fold change in abundance between FIV+ and FIV- cats at the 0.1 level of 
significance (after correcting for multiple testing). The list on the left shows the genera of each of these 
OTUs. Red indicates over representation of that OTU in the FIV+ cats. (C) FIV+ cat with clinical 



















Innovative cART Regimen 
The ability of Dolutegravir, Tenofovir, and Emtricitabine to inhibit FIV replication was 
tested on GFox cells in vitro in the presence of 50,000 infectious units of FIVC36. When used in 
combination (cART), Dolutegravir (DTG), Tenofovir disoproxil fumarate (PMPA), and 
Emtricitabine (FTC) exhibited a significant inhibitory effect for all drug concentrations over time 
(p=0.0003; RM-ANOVA), even at the lowest tested drug concentrations (Figure 4.4).  
Figure 4.3. FIV-infected cats show trends towards oral cytokine expression differences. Saliva 
of FIV-infected cats without clinical oral lesions and saliva from naïve animals (n=5/group) was tested 
by MIA for cytokines as described. IL-8, IFNg, IL-1b, and IL-12 p40 tended to be decreased in FIV 




Figure 4.4.  Combination antiretroviral therapy (cART) strongly inhibits FIV infection in vitro, even 
at low concentrations.  FIVC36 was incubated with varying concentrations of Dolutegravir (DTG), 
Tenofovir disoproxil fumarate (PMPA), and Emtricitabine (FTC) in a ratio utilized in in vivo studies [12, 13] 
and tested for inhibition on GFOX cells. “No cART” FIV-only positive control represented 100% FIV 
growth as measured by ELISA absorbance at 450nm. Analysis of percent inhibition over time revealed a 
significant inhibitory effect for all drug concentrations over time (p=0.0003; RM-ANOVA), even at the 
lowest tested drug concentrations. 
Discussion  
Results of this pilot study highlight the potential to develop relevant therapeutic 
interventions in an animal model that closely recapitulates HIV-AIDS oral cavity dysfunction, 
with the goal of translating findings to HIV oral infections.  As noted previously, many features of 
FIV oral cavity disease parallel findings in humans with HIV.  The work outlined in Chapter 1 of 
this dissertation documents that FIV oral cavity infection is concentrated in oral lymphoid tissues 
[38], and results of these preliminary studies denote changes in salivary cytokine expression 
during FIV infection, indicating viral-induced alterations in innate immune function (Figure 4.3). 
Furthermore, these preliminary results highlight significant alterations in the microbiota of FIV-
infected cats, and document a striking shift to a near monoculture of Moraxellaceae in one case 
of FIV-associated moderate to severe gingivitis using 16s rRNA metagenomics analysis (Figure 
4.2). Because HIV and FIV infections are both associated with perturbations in the oral 
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microbiota and chronic immune dysfunction [2-4, 14-17, 70-74, 77], future studies will be 
directed at defining perturbations in oral microbiota and oral/systemic inflammation during 
treatment with an innovative cART protocol.  
While cART has been successful at limiting some oral manifestations of HIV, it has not 
completely eliminated oral pathologies [2, 16, 90], and has only been marginally successful in 
cats with FIV (CHAPTER 3). The relationship between cART therapy and oral microbial shifts 
during HIV infection is unknown and impossible to study in HIV patients.  Dolutegravir, 
Tenofovir, and Emtricitabine have recently been used as safe and effective therapies in SIV 
infection [12, 13], and are convenient as they can be applied via daily injection.  The efficacy 
and pharmacokinetics of these individual or related compounds has been documented in FIV-
infected cats [91-94], however, their combined effect in vivo has yet to be evaluated.  The 
preliminary results presented above indicate a profound synergistic effect in vitro, even at the 
lowest concentration utilized in this study (Figure 4).  Collectively, this data indicates that such a 
cART regimen will also be highly effective against FIV infection in vivo. By comparing FIV naïve 
cats to cats with FIV infections treated with cART or placebo, the FIV model may provide means 
to assess the impact of active viral replication on oral dysbiosis, viral-induced oral cavity and 
MALT immune dysfunctions, and systemic parameters; thus providing a basis for understanding 
how cART impacts oral microbial ecology and downstream pathologies [23, 62, 95].  
The persistence of HIV infection and periodontitis in patients on cART indicates that 
ancillary treatments specifically directed at restoring the normal oral microbiota in conjunction 
with cART may improve HIV periodontal progression and decrease systemic immune activation 
[16, 23, 24, 26].  Feline dental disease is currently managed by comprehensive dental treatment 
consisting of hand and ultrasonic scaling, identical to techniques used in humans [96, 97]. 
Probiotic supplementation has been successful in early studies as an adjuvant for treating 
periodontitis in people, and similar commercial oral probiotics products are available for 
management of feline oral conditions [98-100]. Thus, the application of comprehensive dental 
 140 
cleaning with probiotic treatments in the feline model has the potential to assess the impact of 
local therapy for restoring oral homeostasis during lentiviral infection, and may increase our 
understanding of the progression and/or resolution of FIV-induced oral lesions and oral 
microbiome in the presence and absence of cART.  Results from such studies may help to 
guide the development of potentially effective strategies for management of HIV oral infections, 
and may also provide means to match MALT related changes to chronic systemic inflammation. 
The findings presented in this chapter indicates that FIV-infection produces aberrant 
cytokine expression in saliva of infected cats.  IL-8, IFNγ, IL-1B, and IL-12 p40 are critical for 
innate and adaptive immunity against viral and bacterial infections, neutrophil function, and 
lymphocyte proliferation and differentiation. Deficiencies in these cytokines could facilitate oral 
dysbiosis through reduced immunocyte function and inability to maintain normal oral flora [101-
103].  IL-2 promotes proliferation of both CD4+ and CD8+ T cells, and local increases in IL-2 
may therefore promote lymphocyte activation and inflammation as a result of bacterial 
overgrowth [104]. KC (CXCL1) is secreted by macrophages, neutrophils, and epithelial cells at 
sites of inflammation, and functions as a major neutrophilic chemoattractant [105, 106]. 
Increases in this pro-inflammatory cytokine may likely represent a consequence of innate 
immune stimulation in response to opportunistic bacterial overgrowth. Collectively, these 
preliminary results suggest that FIV mediated immune dysfunction may result in oral dysbiosis, 
perpetuating FIV associated oral disease through secondary immune activation and lymphocyte 
proliferation. Most importantly, these findings represent an opportunity to investigate the role of 
immune dysfunction in the development of lentiviral induced oral disease, and highlight the 
potential for immunomodulatory therapy to attenuate systemic and local immune activation 
through restoration of oral homeostasis by chronic inflammation during FIV and HIV infection.  
Type I interferons (IFN-α, IFN-β, and IFN-ω) are expressed during viral infection and 
exhibit antiviral and anti-proliferative properties [107, 108]. The mechanism for Type 1 IFN 
inhibition of HIV (and other viruses) has been linked to changes in expression of Interferon-
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stimulated genes which are activated soon after IFN exposure [109, 110]. While IFN-α has been 
shown to inhibit HIV infection in vitro, its therapeutic use in vivo has been associated with 
disease progression during late infection and limited treatment effect on HIV-induced oral 
disease [111, 112]. IFN-ω is a monomeric glycoprotein secreted by virus-infected leukocytes 
structurally related to IFN-α and IFN-β [107]. In contrast to other Type I Interferons, IFN-ω 
exerts strong immunomodulatory effects by stimulating Natural Killer cell activity, enhancing 
expression of MHC-I, and inhibiting lymphocyte proliferation [107].  IFN-ω has also been 
reported to be a potent inhibitor of HIV infection in vitro, but in vivo therapeutic potential in 
human patients has not been evaluated [108].  Alternatively, recombinant feline interferon 
omega (rFeIFN-w) has been shown in vivo to decrease the severity of oral disease in FIV-
infected cats and influence innate immunity to reduce pro-inflammatory stimuli [113-115].  
Therefore, studies aimed at assessing the outcomes of IFN-ω therapy on FIV oral disease in the 
presence and absence of cART have great potential to elucidate anti-inflammatory mechanisms 
and potential for adoption as an agent for HIV-associated oral disease.  
In summary, the results of pilot study demonstrate that similar to HIV, FIV infection of 
domestic cats is associated with (1) oral microbiota dysbiosis with marked loss of microbial 
diversity during lentiviral-associated periodontitis; (2) changes in salivary cytokine levels, even 
in the absence of FIV clinical oral disease; and, (3) systemic markers of immune stimulation, 
signaling local and peripheral immune activation, and suggesting bacterial translocation.  These 
findings identify key pathways leading to changes in oral homeostasis during HIV infection using 
an analogous animal model, and highlight the potential of the FIV model to guide approaches to 
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 Over the course of my graduate studies and as presented in this dissertation, I have 
investigated several aspects of feline immunodeficiency virus (FIV) with a focus on its 
applications as a model to study HIV.  Because FIV produces progressive immune depletion 
that eventually results in an acquired immunodeficiency syndrome (AIDS) similar to HIV 
infection in humans, and because the occupational risks of working with cats and FIV are 
considerably less than non-human primates with SIV or SHIV, the feline model of AIDS has 
great potential as a safer and more economical alternative to NHP studies. In Chapter 1 of this 
dissertation, I characterized FIV salivary viral kinetics and antibody secretions to more fully 
document oral viral pathogenesis. The results of this research demonstrate that (i) oral lymphoid 
tissues serve as a site for enhanced FIV replication, resulting in accumulation of FIV particles 
and FIV-infected cells in saliva, and (ii) failure to induce a virus-specific oral mucosal antibody 
response, and/or viral capability to overcome inhibitory components in saliva may perpetuate 
chronic oral cavity infection.  While it is accepted that FIV is primarily transmitted by biting, few 
studies have evaluated FIV oral infection kinetics and transmission mechanisms, and such 
modern quantitative analyses applied to natural FIV oral infection help to further our 
understanding of lentiviral oral disease and transmission. Most importantly, these results 
provide a model of oral FIV pathogenesis and suggest alternative diagnostic modalities and 
translational approaches to study HIV pathogenesis, particularly oral manifestations of HIV 
infection. 
In Chapter 2 of this dissertation, I immunized cats with soluble CD134, recombinant FIV-
SU protein, and/or CD134+SU complexes prior to challenge with FIV to determine if vaccination 
with CD134-SU complexes could induce protection against FIV infection.  Immunization induced 
production of anti-CD134 and anti-SU antibodies in vaccinated cats, and purified anti-CD134 
and anti-SU antibodies significantly inhibited FIV infection in vitro.  However, no vaccine 
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combination protected cats from FIV infection in vivo and vaccination induced high titers of 
antibodies directed at vaccine by-products relative to target antigens.  Because FIV and HIV 
utilize parallel modes of receptor-mediated entry, and because autoantibodies to FIV-SU and 
the CD134 binding receptor are able to block FIV infection ex vivo, it was optimistic that 
vaccination with anti-receptor antibodies could provide a novel immunotherapy to block viral 
infection in vivo, and that this innovative vaccine modality might be adapted to preventative 
strategies in HIV. However, due to the failure of this vaccine strategy to induce protection from 
infection in vivo, the results presented in Chapter 2 of this dissertation reinforce the need to 
monitor components of vaccine preparations, and emphasize that vaccination may induce 
proliferation of susceptible target cells and enhancement of heat-labile serum components that 
counteract neutralizing antibodies. 
In Chapter 3 of this dissertation, I administered immunosuppressive doses of 
prednisolone or CsA to cats chronically infected with FIV and monitored alterations in 
hematological parameters and FIV viral/proviral loads in response to therapy. Similar to HIV, 
FIV-infected cats frequently develop secondary or opportunistic infections as a consequence of 
viral-induced immune dysfunction, including anterior uveitis, chronic rhinitis, gingivostomatitis 
and periodontitis, encephalitis and neurologic dysfunction, and lymphoma. Both prednisolone 
and cyclosporine A (CsA) are commonly used clinically to treat lymphoproliferative and immune-
mediated diseases in these patients, but the impact of these compounds on infection has not 
been well documented, and their understanding immunomodulatory effects on viral replication 
and persistence is critical to guide safe and effective use of these therapies. In this study, both 
prednisolone and CsA treatments caused (i) acute increases in CD4+ lymphocytes, (ii) 
increased FIV viremia, and (iii) significant alterations in cytokine expression that favored a shift 
toward a Th2 response.  These results highlight the potential for immunosuppressive drug-
induced perturbation of FIV replication and underscores the need for consideration of chronic 
viral infection status when prescribing immunomodulatory medications. 
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In Chapter 4, I presented the findings of a pilot study in which I investigated changes in 
the oral microbiota and oral immune system during FIV infection. Because gingivitis and 
periodontitis are primary clinical signs associated with untreated natural and experimental FIV-
infection, these principal attributes have great potential to elucidate pathogenic mechanisms 
involved in the perturbation of the oral immune system and microbial environment. Since other 
commonly used animal models for studying HIV pathogenesis, such as SIV/SHIV infections in 
NHPs or HIV infections in humanized mice, do not reliably incite oral lesions, the FIV model of 
lentiviral-induced oral disease presents a unique opportunity to investigate the development of 
this disease syndrome and to test the efficacy of novel immunomodulatory therapies that may 
have translational applications during HIV infection. Such studies aimed at evaluating FIV-
associated changes in the oral microbiota, local and systemic virologic parameters, and immune 
dysfunction under novel treatment protocols may provide an innovative approach in the future  
to expand our understanding of the complex interactions between HIV infection, oral immune 
dysfunction, and the perturbations to the oral microbiota that occur in the context of HIV 
infection. 
 
